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Abbreviations 
Standard nomenclature is used to distinguish between protein and RNA expression, e.g. 
Arg1 denotes the murine arginase 1 mRNA or gene, ARG1 the human mRNA or gene, 
and ARG1 both the human and murine protein. When referring to both mRNA and 
protein simultaneously, the full name arginase 1 is used.  
ARG1   arginase 1  
CAT2B  cationic amino acid transporter 2b a.k.a. solute carrier family 7a2b 
(SLC7A2B) 
CHI3L3 chitinase3-like protein3, a.k.a YM1 
DFMO difluoromethylornithine 
GCN2 general control non-derepressible kinase 2, a.k.a eukaryotic translation 
initiation factor 2-alpha kinase 4, EIF2AK4 
IFNγ   interferon gamma 
IL   interleukin 
IL4R   interleukin receptor 
MRC1  mannose receptor, C type 1 
NOS2  nitric oxide synthase 2, a.k.a inducible nitric oxide synthase 
ODC  ornithine decarboxylase 
PBMC  peripheral blood mononuclear cells 
PEG  polyethylene glycol 
RETNLB  resistin-like β, a.k.a FIZZ1 
SSAT  Spermidine/spermine N1-acetyltransferase 
SMO  spermine oxidase 
TNFα   tumor necrosis factor alpha 
VSMC  vascular smooth muscle cells 
 
Keywords  
arginine metabolism, alternative activation, polyamines, arginine transport, 
inflammatory disease 
 
Keypoints 
x Macrophage classification in vivo should be based on function 
x Arginine metabolism and transport in macrophages serves to control ambient 
arginine 
x Control of local arginine availability is a mechanism to limit inflammation and 
fibrosis 
x Macrophage arginase 1 does not play a role in polyamine synthesis 
x Macrophage arginase 1 does not play a significant role for proline synthesis to 
support collagen deposition 
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Role of arginine in macrophage function 
Macrophages 
Macrophages are gluttons with daily garbage clearance and recycling among their major 
functions in the body. They phagocytose up to 2x1011 erythrocytes per day in the spleen, 
preserving the iron from hemoglobin for reuse, and they remove cellular debris and 
apoptotic cells everywhere else. The enormous importance of this task is reflected by the 
huge numbers of macrophages (10-15% of all cells) that are found in almost every tissue 
(1). If one assumes the recently published estimate of 3,72x1013 cells in a human body 
(2), this amounts to ~5x1012 macrophages. Although the phagocytic function clearly was 
the inspiration for their name, macrophages are usually associated with their role in 
innate and adaptive immune defense. Accordingly, a Pubmed inquiry with the search 
terms “macrophages” and “immunity” results in ~37,800 hits, whereas “macrophages 
AND phagocytosis NOT immunity” delivers only ~3460 references (August 2014).  
 
Macrophages are a heterogeneous cell population and are classified according to their 
tissue distribution, their activation status and their expressed surface markers, depending 
on the interests of the researcher or the methods applied. None of these criteria is 
permanent, since tissue distribution, activation status and surface markers can change 
rapidly in response to environmental triggers, such as cytokines, infectious agents, and 
foreign substances. Nevertheless, the activation status is the most relevant characteristic 
for the function of macrophages in innate and acquired immunity. In accordance with 
the TH1/TH2 nomenclature, macrophages have been classified as M1 and M2, or 
classically and alternatively activated macrophages, respectively (3). M1 macrophages 
show enhanced microbiocidal and tumoricidal capacity, and are induced by IFNγ and 
LPS or TNFα, whereas M2 macrophages are often activated by IL4 and IL13 and 
support TH2-associated effector functions, play a role in wound healing, and in parasite 
killing. The M2 label has been further subdivided into M2a, M2b and M2c 
subpopulations (4,5) based on the stimuli that are required for their activation:  
- M2a: IL4/IL13-elicited alternatively activated macrophages;  
- M2b: induced by immune complexes, Toll-like receptor (TLR) agonists or IL1R 
agonists; and 
- M2c: activated by IL10 and glucocorticoid hormones. 
Macrophage subsets 2a-2c share some common functional properties, such as low IL12 
expression and involvement in TH2 responses and are, therefore, often collectively 
named M2 macrophages. According to some references, all M2 subpopulations show 
increased IL10 expression (5,6), but others assign high IL10 expression only to 
subpopulations 2b and 2c (7,8). The evolving view is that M1 and M2 polarization are 
the extremes of a continuum, that macrophages can switch activation states, and 
intermediate forms exist (3,8,9). Pure M1- or M2-polarized macrophages probably only 
exist in culture where well-defined triggers are used but not in vivo where the cells are 
exposed to a multitude of triggers in combinations and concentrations which differ in 
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every tissue and with every type of infection. In addition, the often described plasticity 
of macrophages allows them to change from one activation status to another provided 
the appropriate triggers are delivered by the environment as has been demonstrated in 
vitro (10,11) and in vivo (12-14), and reviewed extensively (15,16). 
In addition to their highly desirable protective immunological and repair functions, all 
macrophage populations named above also aggravate pathological situations by 
supporting excessive inflammation (M1), or tumor growth, tissue fibrosis and allergy 
(M2). 
 
Since macrophages grouped under M2 include cells with remarkable differences with 
respect to gene expression and physiologic function on the one hand, and since 
macrophages with similar expression profiles of marker genes can be elicited by quite 
diverse stimuli on the other hand (see below), a classification based on fundamental 
functions has also been suggested (8). This classification distinguishes:  
- macrophages involved in host defense, which are identical to the classically 
activated or M1 macrophages,  
- wound-healing macrophages that are important in repair processes and, finally,  
- regulatory macrophages that suppress or down-regulate immune responses. 
The regulatory macrophages include tumor-associated macrophages (TAM) and a 
subgroup of the related myeloid-derived suppressor cells (MDSC). Both play an 
important role in tumor progression and will be discussed later. 
As for the classification by activation triggers, the authors of the classification by 
fundamental function also stress that hybrid and transition states exist between all 
populations. The classification by function, however, matches better with recent 
observations discussed below.  
 
A case in point is the metabolism of the amino acid arginine by macrophages. It is often 
stated that the macrophage populations named above differ in their usage of the amino 
acid arginine, which is a substrate for both nitric oxide synthases (NOS) and arginases 
(ARG) (Figure 1). Expression of Nos2 is characteristic for classically activated 
macrophages (or M1), whereas STAT6-dependent expression of Arg1 (17) has always 
been associated with alternatively activated and regulatory macrophages (subpopulations 
2a & 2c), but not macrophages activated via immune complexes and TLRs 
(subpopulation 2b). However, STAT6-independent induction of host Arg1 gene 
expression by TLR stimulation has been demonstrated in classically activated 
macrophages infected with intracellular pathogens (18), such as Mycobacterium bovis or 
bacillus Calmette-Guérin (BCG). In addition, characterization of wound macrophages in 
a polyvinylalcohol (PVA) sponge wound model in mice has surprisingly revealed that 
wound macrophages express several markers of the alternative phenotype, including 
ARG1, but that neither IL4, IL13 nor STAT6 phosphorylation plays a role in the 
activation of those macrophages (19). We, therefore, strongly support the suggestion (8) 
that a classification of macrophages based on their function in vivo is more useful than a 
classification based on stimuli required for eliciting a specific macrophage subtype in 
vitro. 

Chapter I  
 
 
 
Arginine metabolism is not a simple marker for macrophage activation status, but has a 
strong effect on the outcome of many diseases. This review will, therefore, investigate 
macrophage arginine metabolism and its role in chronic diseases. 
 
 
 
Figure 1. Fates of Arginine. Arginine is one of the 20 basic amino acids and as such a precursor for 
protein synthesis. Arg-tRNA also serves to arginylate proteins, an important pathway in protein 
degradation and protein modification during development (167). Arginine is the precursor for signaling 
molecules, namely agmatine, which seems to be an important neuromodulator (168) and, more 
importantly, the radical nitric oxide, which is generated by nitric oxide synthases and is amongst other 
things a relaxing agent for smooth muscle cells and a bactericidal agent in the immune defense. Arginine 
is also a precursor for creatine production. Arginases break down arginine to yield ornithine and urea. 
Ornithine is a precursor for polyamines and proline. This review focuses on two aspects of macrophage 
arginine metabolism that is NO formation and arginine degradation, and their consequences for health and 
disease. 
Macrophage subpopulations 
Macrophages can respond to external stimuli with dramatic changes in gene expression. 
Dependent on the kind of stimulus, different gene expression programs are induced 
resulting in macrophages with very different immunological properties. Understanding 
these properties and being able to modify them could lead to very promising new 
therapeutic approaches. A recent review suggests the use of epigenetic interventions 
such as targeting histone deacetylases to modulate macrophage polarization and to 
thereby treat inflammatory diseases (20). 
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Macrophages involved in host defense, or classically activated macrophages 
IFNγ, together with TNFD or stimuli that induce TNFD, will result in macrophages that 
play a role in host defense, the so-called classically activated macrophages. These 
macrophages are characterized by a high capacity to present antigen, are immune 
effector cells that kill intracellular pathogens through NO and oxygen radical production, 
and secrete pro-inflammatory cytokines, such as IL1, IL6, IL12 and IL23 to induce and 
amplify TH1 and TH17-dependent immune responses (8). TH17-cells are a group of 
recently identified T-helper cells associated with chronic inflammation in autoimmune 
diseases and host defense in bacterial and fungal infections (21) (22). In analogy with 
the TH1 nomenclature, these macrophages are often called M1. They are important in 
host defense, but are also potent mediators in inflammatory diseases, such as 
inflammatory bowel disease (IBD) (23) (24) and atherosclerosis (25). If not properly 
controlled, they may also play a role in cancer development through persistent 
inflammation (26). Classical activation in murine macrophages leads to the induction of 
NOS2 and cationic amino-acid transporter 2B (Cat2b or Slc7a2b) expression (27,28), 
which results in increased arginine uptake and NO production.  
 
Alternatively activated macrophages or wound healing macrophages 
Alternatively activated macrophages, a subgroup of the M2 macrophages, are induced in 
vitro by IL4 and IL13 with enhancing roles suggested for IL21 (29), IL33 (30,31) and 
galectin-3 (32). The cytokines IL4 and IL13 signal via STAT 6 and this results in the 
expression of typical marker genes, such as Arg1, the macrophage mannose receptor 
(mannose receptor, C type 1 (Mrc1)), resistin-like β (Retnlb, also known as Fizz1), and 
chitinase3-like protein3 (Chi3l3, also known as Ym1), and, at least in culture, Cat2b 
(Slc7a2b) (28). Note that Cat2b is also a marker for classically activated macrophages. 
These macrophages are thought to promote wound healing through extracellular matrix 
reorganization and stimulation of fibroblasts to increase collagen production. This is 
reflected in their expression of growth factors that promote fibroblast proliferation and 
proteins that interact with, or support extracellular matrix deposition. It is often 
suggested that the role of arginase 1 in this scenario is the production of ornithine, which 
can serve as a precursor for either proline or polyamines, relevant molecules in collagen 
production and cell proliferation, respectively (8).   
 
A more detailed in vivo characterization of wound macrophages in a murine PVA 
sponge model now challenges, however, the concept that the alternatively activated 
macrophages of the Petri dish are the wound-healing macrophages encountered in vivo 
(19). Wound macrophages isolated on days 1, 3 and 7 from sponges implanted 
subcutaneously in mice indeed express arginase 1, CHI3L3, mannose receptor and 
TGFE proteins, but they also produce TNFD, a marker for classically activated 
macrophages. More importantly, neither IL4/IL13 nor STAT6 phosphorylation seem to 
be involved in eliciting the expression of these marker genes. IL4 or IL13 were not 
found in wound fluid, wound macrophages showed no STAT6 phosphorylation and, 
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most compellingly, Il4ra-/- macrophages, which lack functional IL4 and IL13 receptors, 
are indistinguishable from wild type wound macrophages in this model. The lack of IL4 
in wound fluids was previously demonstrated in rodents in a burn wound model (33) and 
in foreign body-response models (34,35), lending extra credibility to the findings of 
Daley et al. (19,36). The absence of IL4/STAT6 signaling has recently also been 
confirmed in wound-healing macrophages in a laser-injury wound model of choroidal 
neovascularization in the eye (37). 
 
From these data, we conclude that wound-healing macrophages express the markers 
described for alternatively activated markers, but can obviously be induced by stimuli 
other than IL4 and IL13. Depending on the type of wound, the same macrophage 
function can be elicited by different triggers. In helminth infections, IL4 and IL13 are 
abundant and expression of wound healing markers is STAT6 dependent (38).  Other 
types of wounds, such as sterile foreign body-induced wounds or burn wounds, may 
depend on other triggers to activate the desired macrophage phenotype. Again, this 
argues for a classification of macrophages by function rather than by external stimuli. 
The question that remains, however, is – what is the trigger for the wound healing 
phenotype in sterile wounds? One good candidate for such an alternative trigger is TGFβ 
that is found in abundance in certain wound fluids and capable of inducing arginase 1 
protein expression (39) in fibroblasts (40) and microglia (41), and increasing arginase 
activity in macrophages (42). 
 
Regulatory macrophages or all other macrophages?  
The term regulatory macrophages was introduced by David Mosser and Justin Edwards 
(8) to distinguish macrophages with strong anti-inflammatory activity from wound-
healing macrophages. These regulatory macrophages are characterized by high IL10/low 
IL12 expression and are elicited by various stimuli including immune complexes that 
bind to TLRs, prostaglandins, G-protein coupled receptor (GPCR) ligands, 
glucocorticoids, apoptotic cells or by IL10 stimulation. They also express arginase 1 
mRNA (43), although ARGINASE 1 protein expression has been described as limited 
(44) or is not mentioned at all (45). In addition, they produce the chemokines 
CCL17, -18 and -22, and also TGFβ (4,5). IL10 production is high in TLR-stimulated 
macrophages, whereas stimulation by IL4 and/or IL13 alone (definition of alternatively 
activated macrophages) does not seem to result in significant IL10 expression (8), 
although conflicting reports exist (5,46). Unfortunately, high IL10/low IL12 expression 
is also named as a characteristic of tumor-associated macrophages and myeloid-derived 
suppressor cells (discussed below in “Arginase as a controller of arginine availability” 
and “Arginase and Cancer”), but often also simply for M2 macrophages (47) to 
distinguish them from M1 macrophages (5,48), which renders this characteristic useless 
for a meaningful distinction of macrophage populations. In agreement, a recent article 
on the nomenclature of macrophages started with the encouraging sentence: 
“Description of macrophage activation is currently contentious and confusing” (22). The 
authors strongly advise a coherent nomenclature based on macrophage origin, activators 
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used and a consensus set of markers for characterization. As stated above, however, a 
nomenclature based on these criteria is most useful for in vitro experiments, where the 
activators can be controlled.  
 
It is very obvious that macrophages can be activated by a wide variety of triggers on the 
one hand and can respond with an equally wide range of activation profiles on the other 
hand: the more markers are measured, the more different populations are found. The 
usefulness of these distinctions is mostly descriptive and depends on the experimental 
circumstances. The distinction of regulatory and wound-healing macrophages is based 
on the assumption that wound-healing macrophages participate, in addition to exerting 
their immunosuppressive activities, also in matrix deposition and possibly tissue 
healing/proliferation through ornithine production by arginase 1. Ornithine can serve as 
a precursor for both proline and polyamines (Figure 1). Recent research, however, seems 
to indicate that there are only two main functions of macrophages, namely immune 
activation and immune suppression and that the arginase activity of wound-healing 
macrophages is more important in immune suppression than in matrix deposition or 
proliferation. This will be discussed below. 
 
Arginine metabolism of macrophages 
Arginine transport in murine macrophages 
Murine macrophages take up arginine via the y+L or y+ system of transporters. The y+L 
system is well characterized (49) and consists of a light chain (SLC7A6, a.k.a y+LAT2, 
or SLC7A7, a.k.a y+LAT1; SLC stands for solute carrier family) that associates with a 
heavy chain (SLC3A2, a.k.a 4F2hc or CD98) for surface expression. These 
heterodimeric transporters are exchangers, which are subject to "trans-stimulation". 
Trans-stimulation occurs when a compound on one side of a membrane stimulates 
transport on the other side of the membrane (50). y+L transporters preferably import a 
large neutral amino acid (such as leucine) plus Na+ in exchange for the export of a 
cationic amino acid. y+LAT2 can mediate an efficient influx of large neutral and cationic 
amino acids, but the efflux is clearly biased towards cationic amino acids. The uptake of 
arginine into cells is, therefore, often inhibited with leucine plus sodium, which actually 
stimulates arginine efflux. In the absence of extracellular leucine, measurable arginine 
y+LAT2-mediated influx occurs, as was shown in erythroid cells (51). 
 
The y+ system is encoded by the cationic amino-acid transporter (Cat) genes Slc7A1 
(Cat1), Slc7A2 (splice variants Cat2a and Cat2b) and Slc7A3 (Cat3). These transporters 
all mediate Na+-independent transport of the cationic amino acids arginine, lysine and 
ornithine (52,53), but CAT1 shows a strong trans-stimulation, which is lacking in CAT2. 
The three transporters differ in spatial and temporal expression patterns. CAT3 is 
important in embryogenesis and is found in central neurons in the adult. Cat1 mRNA is 
often constitutively expressed, but its translation (54) and activity (55) are strictly 
regulated by nutrient status, cytokines and hormones. CAT2 exists in 2 splice-variants. 
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The constitutively expressed, low-affinity CAT2A variant is expressed in liver, pancreas, 
skeletal muscle, cardiomyocytes and vascular smooth muscle, while the high-affinity 
CAT2B is inducible by inflammatory cytokines.  
 
Under basal, i.e. non-stimulated conditions, macrophages take up most of the arginine 
via the y+L system. Once they are stimulated with M-CSF to proliferate, increased 
arginine import via CAT1 is observed (28). Stimulation of macrophages with either the 
TH1 cytokine IFNγ plus LPS or the TH2 cytokines IL4 and IL10 leads to upregulation of 
Slc7a2b (Cat2b) (28). Cat2b expression stimulated by TH1 cytokines is often induced 
together Nos2 expression. Accordingly, sustained NO production by peritoneal 
macrophages from Cat2-/- mice is virtually abolished (56). Intracellular arginine 
concentration and Nos2 expression, however, are unchanged in these macrophages. This 
has been interpreted as a strong indication for the presence of different arginine pools in 
macrophages that are not freely exchangeable (49). Another study in experimental 
asthma showed upregulation of Cat2 together with Arg1, but not Nos2; unfortunately, 
the Cat2 isoform that was expressed (A or B) was not identified (57). 
Based on a study on murine bone marrow-derived macrophages with 14C-labeled 
arginine (28), the following model was suggested: quiescent macrophages import 
arginine via the y+L system, incorporate a small amount thereof into proteins and return 
the rest to the medium. Proliferating macrophages, stimulated by M-CSF, probably take 
up arginine through CAT1. 50% of this arginine goes into protein synthesis, 5% into 
polyamine synthesis and the rest is returned to the medium. Classically or alternatively 
activated macrophages both import arginine via CAT2B and use it for NO production 
via NOS2 or for ornithine/urea production via arginase 1, respectively (28). However, 
data from Cat2-/- mice support those findings only partially. Infection of such mice with 
Toxoplasma gondii, which elicits a TH1-type response, indeed results in a much higher 
susceptibility to the infection due to decreased NO production. Infection of the same 
mice with Schistosoma mansoni, which results in a pronounced TH2 response, also led to 
the development of more severe disease-related pathologies. However, bone marrow-
derived macrophages from these mice show higher urea production, a measure of 
arginase activity, in culture, when stimulated with TH2 cytokines. In the same study, 
higher arginase 1 mRNA expression was found in lung tissue of infected mice (58). 
These observations strongly suggest that arginase 1 also has access to a CAT2-
independent arginine pool, but the experiments performed do not allow the distinction 
between an extracellular or intracellular source of arginine. Again, it is obvious that the 
association of specific stimuli with specific transporters found in vitro cannot be directly 
translated into the in vivo situation.  
A recent study (24) demonstrated that the different susceptibility of C57BL/6 and 
Balb/C mice to Leishmania infections is due to a mutation in the Cat2 promoter of 
C57BL/6 mice, which results in diminished arginine uptake into macrophages when 
stimulated with IL4 (but not IFNγ). Increased CAT2 activity provides arginine for 
polyamine synthesis for the intracellular pathogen in Balb/C, but not in C57BL/6 mice. 
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Neither Cat1 (y+) mRNA expression nor basal y+L-mediated arginine transport are 
affected by macrophage activation (28). Since CAT1 protein expression is regulated at 
the translational rather than the transcriptional level in mice (54) and men (59), protein 
expression may still be increased and serve as a source of arginine in TH2-cytokine-
stimulated macrophages. The lack of a specific antibody has been hampering a detailed 
investigation of the regulation of Cat1 under these circumstances. Unfortunately, 
Cat1fl/fl/Tie2Cre mice on a 129Sv/OlaHsd background do not survive after birth due to 
severe anemia, similar to the phenotype of constitutive Cat1-/- mice [our own 
unpublished observations: CC de Theije, SE Köhler, WH Lamers]. Hopefully, 
Cat1fl/fl/LysMCre mice will enable us to address the role of CAT1 in substrate delivery 
to macrophages under type II inflammatory conditions. Intriguingly, backcrossing the 
Cat1fl/fl/Tie2Cre from a129Sv/Ola background to C57BL/6J increases the life 
expectancy of these mice to adult age and even allows the breeding of homozygous mice. 
They remain, however, fragile with a higher than normal mortality and smaller than their 
wild-type littermates as adults, which hampered vessel cannulation for blood-pressure 
measurements [our own unpublished observations: CC de Theije, SE Köhler, WH 
Lamers, R. Chennupati]. 
 
Arginine transport in human macrophages 
Arginine transport in human monocytes and macrophages is less well characterized than 
in mice. System y+L is reportedly mainly responsible for basal transport in human 
alveolar macrophages. These cells do not respond with increased arginine import or NO 
production to LPS stimulation, although they upregulate CAT2B mRNA expression (60). 
In contrast, an increased y+-dependent transport activity and NO production was 
reported in PBMCs from septic patients (61). The authors assigned the increased 
transport to CAT2 expression, since they found CAT2 mRNA in 5 of 7 PBMC samples 
from septic patients, but not in controls, and no change in CAT1 mRNA levels in the two 
groups. It is possible, however, that translation of CAT1 mRNA was also upregulated in 
these patients. This hypothesis is supported by an increased NO production without 
concomitant CAT2 mRNA expression in 2 of the 7 septic patients. Increased CAT2 
expression and y+-dependent arginine transport have also been reported in PBMCs of 
pregnant women, but no clear correlations between arginine transport, CAT2 expression 
and NO production were found (62). Stimulation of freshly isolated human monocytes 
with IFNγ resulted in increased arginine import attributable to system y+L and was 
accompanied by an increased expression of SLC7A7 (y+LAT1) (63), whereas mRNA 
expression of other cationic amino-acid transporters such as CAT1 (SLC7A1) and 
CAT2B (SLC7A2) was unaffected. A more rigorous analysis of arginine transport in 
human macrophages is highly desirable. 
 
In summary, data from murine macrophage cultures suggest that activation of 
macrophages leads to stimulation of arginine transport through gene and protein 
expression and that the same transporter, CAT2B, is used in both the classical and 
alternative activation state (28,58). In vivo data with macrophage-specific gene deletion 

Chapter I  
 
 
confirmed the role of CAT2 under TH1 conditions, but were less convincing for TH2 
conditions. The question whether the same intracellular arginine pool is accessible for 
NOS2 and arginase 1 is, therefore, still not fully answered. The fact that Cat2-/- mice are 
viable and fertile suggests that there is redundancy in arginine transporters in C57BL/6J, 
but probably not in 129Sv/Ola mice. Moreover, the metabolic activity and intracellular 
arginine content of Cat2-/- macrophages is not affected in the basal, unchallenged state 
(56), a finding that fits with the observation that the system y+L is the major arginine 
transporter under those conditions (28).  
 
It is tempting to speculate that the different degrees of trans-stimulation observed for 
CAT1, CAT2A and CAT2B add an extra level of control. In such a scenario, CAT1 
would serve as the ideal transporter in an arginase 1-expressing cell to deplete the 
environment of arginine, CAT2B would be best for arginine uptake in a cell that rapidly 
metabolizes arginine, and CAT2A would allow arginine uptake and accumulation 
without (excessive) export of another cationic amino acid in exchange. The expression 
of CAT2A in liver cells and CAT2B in activated macrophages fits with this suggestion, 
but the role of CAT1 as the transporter of choice in proliferating macrophages is 
difficult to combine with its pronounced exchanger profile.  
 
Control of arginase expression in murine macrophages 
Arginase 1 expression is constitutive in periportal hepatocytes, but inducible by 
cytokines in other cell types, such as macrophages and fibroblasts. The majority of 
extra-hepatic arginase 1-expressing cells are macrophages and dendritic cells as shown 
by a reporter mouse that carries an IRES-YFP knock-in allele into the 3’-end of the 
arginase 1 gene (64). In macrophages and dendritic cells, arginase 1 expression is 
associated with TH2-type cytokines, such as IL4, IL10, IL13 and TGFβ, which are all 
strong inducers of arginase 1 expression in vitro. This induction is STAT6- and C/EBPβ-
dependent (65). Remarkably, in classically activated macrophages, STAT6-independent, 
MyD88- and C/EBPβ-dependent expression of arginase 1 has been demonstrated after 
infection with intracellular pathogens (18).  
 
Mouse models, deficient for IL4, IL10, IL13 or combinations thereof indicate that IL4 
and IL13 are the major inducers of arginase 1 expression in vivo. IL10 (66) shows 
significant synergistic effects with IL4 on arginase 1 induction, probably due to the 
upregulation of Il4ra expression (67). On its own, IL10 is only able to induce a low level 
arginase 1 expression.  
 
Control of arginase 1 expression in human macrophages or myeloid cells 
The expression of arginase 1 in human macrophages is still controversial. Several 
studies have shown that in human monocytes/macrophages in vitro alternative activation 
by either IL4, IL10 or IL13 does not lead to induction of arginase 1 (and other murine 
markers of alternative activation) (68-72). Other studies, however, have shown that 
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human macrophages can and do express arginase 1 during filarial infection in vivo (73) 
and after infection with Coxiella burnetti in vitro (74). The same authors demonstrated 
that uptake of apoptotic cells induced an alternative phenotype in human macrophages 
characterized by high expression of mannose receptor and secretion of TGFβ and IL10. 
Neutralization of IL10 or TGFβ prevented persistent Coxiella infection (75). 
Interestingly, both types of infection also result in alternative macrophage activation in 
susceptible mouse strains (76,77). In addition, weak arginase 1 gene expression has been 
shown in human adipose-tissue macrophages (78). Again, this provides an argument for 
classification of macrophages by function (i.e. the protein expression profiles) rather 
than activation trigger in vivo. For in vitro studies, the recently proposed, more complex 
nomenclature framework for macrophages, which is based on the source of the 
macrophages, the activators and a consensus selection of markers, will be useful for 
comparison of different cell populations and cell populations of different research 
groups (22). 
 
Immune functions that are covered by macrophages in mice may be performed by other 
immune cells in humans. Constitutive ARG1 expression is found in human circulating 
PMNs or granulocytes, which sequester arginase 1 in intracellular granules. Upon 
certain triggers, these granules are released into plasma and decrease arginine 
concentration there (69,79,80).  
 
Control of arginase expression in other cell types 
TGFβ-dependent induction of arginase 1 has also been shown in vascular smooth muscle 
cells and resulted in measurable increases of putrescine and proline production in vitro 
(81). TGFβ also seems to be an important inducer of arginase 1 in fibroblasts (82,83). In 
addition, arginase 1 expression was shown in endothelial and vascular smooth-muscle 
cells of aged rats (84,85) and in human intestinal microvascular-endothelial cells after 
stimulation of with the inflammatory triggers LPS and TNFα (86). Wound fibroblasts 
express high levels of arginase. Interestingly, deletion of CAT2 leads to increased 
arginase activity in both cultured macrophages and fibroblasts as determined by urea 
production (58). The authors suggest that CAT2 suppresses arginase activity, but the 
mechanism is unclear. The role of CAT2B upregulation by type II cytokines would then 
be limitation of arginase activity rather than provision of substrate, thereby limiting the 
extent of type II response-associated inflammation. 
 
Arginase as a controller of arginine availability  
Intracellular arginase 1 expression can control local extracellular arginine levels and, 
thus, reduce arginine availability for neighboring cells that do not express arginase. The 
suggested mechanism involves rapid uptake of arginine by a cationic amino-acid 
transporter (CAT) and degradation by cytosolic arginase 1. The formed ornithine, in turn, 
stimulates arginine import via CAT-mediated ornithine-arginine exchange. This 
mechanism seems highly relevant in immunosuppression, where alternatively activated 
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macrophages or related cells, such as dendritic cells or granulocytes, can suppress T-cell 
activation by local arginine depletion. T-cells are very sensitive to arginine deficiency, 
as has been demonstrated both in vitro in murine (87,88) and human cells (89,90), and in 
vivo in mouse tumor models (91,92).  
 
The so-called myeloid-derived suppressor cells (MDSC), a collective name for cells that 
support tumor growth in murine models and in human cancers, and includes precursors 
of granulocytes, macrophages, dendritic cells, or early myeloid progenitors. MDSCs 
express arginase 1 intracellularly (93) and use CAT1-mediated ornithine-arginine 
exchange to locally deplete the extracellular fluid of arginine through uptake and 
subsequent degradation to ornithine and urea (88,94). Ornithine may be further 
metabolized to polyamines or exported. As a consequence of arginine deficiency, T-cells 
become anergic through the activation of GCN2 kinase (95), which results in 
suppression of general protein translation. In vitro, this process of T-cell inhibition can 
be reversed through the addition of arginine.  
 
It has been suggested, that cells expressing the cationic amino-acid transporter CAT1 
may even be depleted of their intracellular arginine, when the cells are in contact with 
extracellular arginase or an arginase-expressing cell (96). This depletion results from 
trans-stimulation of CAT1-mediated arginine export from the cell by another 
extracellular cationic amino acid, because CAT1 functions much more efficiently as an 
amino-acid exchanger than as a unidirectional transporter (see section on "Arginine 
transport"). High extracellular concentrations of ornithine provided by arginase activity 
in another cell, i.e. a MDSC, or by extracellular arginase activity could thus induce 
increased ornithine import in exchange for arginine export from neighboring cells, such 
as T-cells, thereby rapidly depleting those cells of arginine and making them anergic 
(95,97). Once depleted, CAT1-expressing cells take up arginine only very slowly. 
Although this sounds like a very elegant and plausible mechanism, CAT1 expression in 
lymphocytes has, as far as we know, not yet been demonstrated. 
 
Arginine – Proline 
Arginine can also serve as a precursor for proline or glutamate, provided ornithine 
aminotransferase (OAT) is co-expressed with arginase. In this case, ornithine produced 
by arginase is converted by OAT to glutamic γ-semialdehyde, which cyclizes non-
enzymatically to pyrroline-5-carboxylate, which is then reduced by NADPH-dependent 
pyrroline-5-carboxylate reductase to proline. It has been repeatedly suggested that 
arginase expression acerbates fibrosis due to excessive collagen production from proline 
(98-100) or supports wound healing through the same mechanism (101). M2 
macrophages of the “wound-healing” type have in particular been associated with 
increased production of proline in fibrotic disease (102). Arginase 1-overexpressing 
mice, however, show no fibrosis in any tissue and certainly not in the gut where the 
enzyme is overexpressed (103,104). Few papers show actual experimental data linking 
arginase expression to proline formation or collagen deposition. Dependence of collagen 
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deposition on arginase activity was shown in murine fibroblasts in vitro and in the same 
paper increased arginase 1 expression was demonstrated in myofibroblasts in 
bleomycin-induced pulmonary lesions in mouse lung (40). Arginase-dependent proline 
production has also been shown in VSMC stimulated by either cyclic stretch or TGFβ1 
(81,105). Proline production from arginine was demonstrated in vivo, but the amount of 
arginine-derived proline incorporated into protein-bound proline was only 5% of total 
that of direct proline incorporation (106), indicating that this metabolic route is hardly 
relevant. The in vivo finding that proline is abundant in wound fluid and arginine scarce 
(in rodents) further supports the notion that arginine is not an important precursor for 
collagen synthesis, even though both arginine and ornithine have positive effects on 
hydroxyproline production and scar strength in mice (107). Interestingly, the stimulatory 
effect of arginine (108), but not that of ornithine (109) on hydroxyproline production 
and scar strength are abolished in NOS2-/- mice, suggesting that the NOS2 pathway 
plays a role in mediating the effects of arginine on wound healing. In cell culture, 
inhibition of arginase reduces collagen synthesis in rat, but not in human fibroblasts (82). 
Since inhibitor studies may be hampered by undesired inhibition of enzymes other than 
the intended target, results from arginase knockout mice can hopefully further clarify the 
issue. A recent study by Campbell et al. (37) indeed showed that arginase 1 is required 
to accelerate wound healing, since absence of arginase 1 from macrophages resulted in 
delayed wound closure and a more inflammatory wound environment. The absence of 
arginase 1 in this model resulted in increased numbers of NO-producing cells, but did 
not diminish collagen expression. This however did not result in increased matrix 
deposition, since the expression of gelatinases (matrix metalloproteinases) was also 
increased in this pro-inflammatory environment. Again, the main effect of arginase 
seems not to lie in the provision of precursors for proline and hence collagen synthesis, 
but rather in the control and suppression of excess inflammatory cells. 
 
Lessons from Schistosoma infections 
Mice deficient in M2 macrophages due to a macrophage-specific disruption of the 
IL4RDgene (Interleukin-4 receptor alpha chain) show no change of fibrotic lesion size 
after Schistosoma mansoni infection. These mice do, however, succumb to the disease 
much faster than their wild-type littermates due to excessive TH1 cytokine responses and 
increased NOS2 activity (110). In a less drastic mouse model with macrophage-specific 
deletion of arginase 1 (Arg1fl/fl/Tie2-Cre and Arg1fl/fl/LysM-Cre mice with arginase 1 
deletion in all hematopoietic and endothelial cells, or in granulocytes and macrophages, 
respectively), infection with Schistosoma mansoni resulted in even larger fibrotic lesions 
in the knockout animals than their arginase 1-expressing litter mates (92). These 
findings suggest that macrophage arginase 1 protects against rather than sensitizes to 
fibrosis. Furthermore, the local depletion of arginine by alternatively activated 
macrophages suppressed proliferation of T-cells in this model. A consequence of this 
suppression was a reduction of excessive macrophage accumulation in granulomatous 
lesions. This suggests that the major role of macrophage arginase 1 is suppression of T-
cell proliferation by local arginine depletion. The observed increased fibrosis in the 
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arginase-deficient model is probably a consequence of increased stimulation of collagen 
deposition by myofibroblasts through inflammatory cells. A very recent review by 
Wynn & Barron (111) also emphasizes the role of macrophages as regulators of fibrosis 
controlling the collagen-depositing activity of myofibroblasts. These authors also 
interpret the role of macrophage arginase as a controller of arginine availability, 
depriving both CD4+ T-cells and myofibroblasts of a metabolite that is essential for their 
survival. Supportive evidence for this claim comes from Schistosoma-infected Cat2-/- 
mice that show increased arginase 1 expression in myofibroblasts in granulomatous 
lesions with concomitant collagen deposition and increased lesion size (58). The 
ornithine produced by alternatively activated macrophages obviously played no 
significant role in stimulating collagen deposition, whereas the depletion of arginine by 
macrophages reduced arginine availability to myofibroblasts. There are two possible 
explanations for these seemingly contradictory findings. Firstly, extracellularly produced 
ornithine is not a precursor for collagen, whereas intracellularly produced ornithine is, or 
secondly, ornithine in general is not a relevant precursor for collagen-incorporated 
proline. Two studies that investigated the role of arginine in wound healing come to a 
similar conclusion, namely, that it remains to be proven that ornithine is an important 
precursor of collagen-incorporated proline (106,107).  
 
Arginine – Polyamines 
Polyamine function 
Polyamines, such as putrescine, spermine and spermidine, are aliphatic cationic 
molecules that consist of, respectively, 1, 2, and 3 putrescine moieties. Due to their 
highly positive charge, polyamines bind and stabilize RNA and DNA. Moreover, they 
seem to be able to regulate local histone acetylation via upregulation of histone 
acetylases (HATs) and histone deacetylases (HDACs) (112). They can increase the 
accessibility of promoters and facilitate transcription and translation of specific genes 
(for a review see (113)). Polyamines are also thought to play an important role in cell 
cycle regulation and proliferation (114). Liver regeneration after partial hepatectomy is, 
for example, absolutely dependent on the presence of spermidine (115,116). 
Furthermore, polyamine metabolism is frequently deregulated in cancer (117). 
Accordingly, polyamine levels are tightly controlled by feedback mechanisms that 
regulate synthesis, breakdown and transport. These feedback mechanisms result in 
adaption of the expression of polyamine-synthesizing or -degrading enzymes (118,119) 
to keep free polyamine concentrations stable (Figure 2).  
 
Polyamines are either taken up from the diet or synthesized by decarboxylation of 
ornithine by ornithine decarboxylase (ODC), which catalyzes the first, rate-determining 
step. Decarboxylation of arginine to agmatine can also, via agmatinase, yield putrescine. 
Agmatinase is structurally related to arginase. Both arginine decarboxylase and 
agmatinase are expressed in RAW 264.7 macrophages and this expression is regulated 
by LPS, TGFβ, IL4 and IL10 (120). However, there is some doubt about the 
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functionality of murine agmatinase (121)  Most of the evidence for the requirement of 
polyamines for cell function comes from experiments using the inhibitor α-
difluoromethylornithine (DMFO or eflornithine), and knockout or overexpression 
studies of ODC (117).  
 
Figure 2. Polyamine Synthesis and Degradation. Synthesis and degradation of the three polyamines 
putrescine, spermidine and spermine and the most important enzymes and precursors or degradation 
products in shown. APA: acetamidoproprionaldehyde, dAdoMet: decarboxylated S-adenosylmethionine, 
MTA: methylthioadenosine, PAO: polyamine oxidase, SMO: inducible spermine oxidase, SSAT: 
Spermidine/spermine-N1-acetyltransferase 
 
Arginase and polyamine synthesis 
Since arginine is a precursor for ornithine, arginase activity can exert control over 
polyamine synthesis when ornithine is limiting, as has been shown in experiments where 
arginase 1 was either overexpressed (122) or induced by TGFβ in vascular smooth 
muscle cells (VSMC) (81); see also (123) for references). Since polyamine production 
and ODC expression are elevated in many tumors (118) and in wound healing (124), and 
since arginase 1 expression has also been associated with tumor growth and metastasis 
(125), and wound healing (126), the logical conclusion seems that arginase 1-expressing 
macrophages may increase polyamine production to support tissue regeneration in 
wounds (127) and vascularization of tumors (128). Experimental evidence for this 
particular hypothesis is, however, scarce. Thus far, few papers have investigated changes 

Chapter I  
 
 
in expression and /or activity of both ODC and arginase simultaneously. A study on 
arginine- and ornithine-metabolizing enzymes in the kidney after testosterone treatment 
(129) showed a 1.5-fold increase in arginase activity and a 450-fold increase in ODC 
activity. Since incorporation of the carbon backbone of arginine into polyamines was not 
determined, it is precarious to deduce a functional relation. A similar critique can be 
raised against a recent study (130), in which the stimulatory effects of smoking in 
asthmatics on arginase and ODC expression were reported. In this study, enzyme 
activities did, for instance, not correlate with polyamine concentrations or levels of 
polyamine-degrading enzymes. Similarly, a recently claimed positive correlation of 
polyamine concentrations and arginase activity in sputum was not convincing, see below 
(16). 
Another compelling example arguing against a direct relation between arginase levels 
and polyamine synthesis is that arginase 1 and arginase 2 single- and double-knockout 
mice show hardly any changes in polyamine levels in liver, kidney, small intestine or 
brain, even though the animals were only 2 weeks old (131). Similarly, polyamine levels 
(putrescine, spermine and spermidine) in the small intestines of mice overexpressing 
arginase 1 in their enterocytes were not increased, despite a 30% increase in ornithine in 
the same tissue (103). Finally, IL4 induced polyamine production is not impaired in 
arginase 1-deficient macrophages (15). On the contrary, Arg1-deficient macrophages 
even showed increased polyamine production upon IL4 stimulation when compared to 
their wild-type counterparts. A possible explanation for this surprising finding is that, 
instead of providing ornithine as a substrate, arginase 1 activity, together with a cationic 
amino-acid exchanger, depletes the cell of ornithine (for each molecule of arginine 
imported, one molecule of ornithine is exported), thereby efficiently preventing 
polyamine synthesis. In the absence of arginase, ornithine is no longer exported and 
available for ODC. Together, these findings suggest that arginase 1 suppresses 
polyamine synthesis in the expressing cell, i.e. the macrophage. In support, a recent 
study in mice on the effects of polyamines on asthma showed virtually no correlation 
between increased concentrations of polyamines and arginase activity in sputum (16). 
Polyamine concentration was 1.5-fold increased (with very little variation) in this model. 
Arginase 1 activity was, as expected, not detectable in non-asthmatic sputum and 
elevated in asthmatic sputum, but the variation in arginase 1 activity was no less than 6-
fold. 
 
Polyamine flux  
It was recently shown that even though tissue polyamine concentrations do not change 
when ODC or SSAT are overexpressed or inhibited/knocked-out, polyamine turnover 
and thus metabolic flux may change considerably. Increased polyamine flux can lead to 
the depletion of important metabolites, such as cytosolic acetyl-CoA and malonyl-CoA 
(132) (see Figure 2), and to an increase in toxic by-products such as H2O2. It is, therefore, 
possible that unchanged polyamine levels mask an increased polyamine flux, in 
particular when substrate levels are high. Some of the phenotypic abnormalities 
observed in arginine-deficient mice, such as hair loss in arginase1-overexpressing F/A2 
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mice and ornithine transcarbamoylase-deficient Spf/Ash mice (133) are comparable to 
those of spermidine/spermine N1-acetyltransferase (SSAT)-overexpressing mice. 
Overexpression of SSAT results in an increased polyamine flux, but is also characterized 
by an accumulation of putrescine, which was not found in F\A2 mice. Circumstantial 
evidence in the SSAT mice points to putrescine accumulation as the culprit of the hair 
loss (see Minireview (115)), whereas in F/A2 mice, tissue polyamine levels were not 
changed. Instead, the arginine deficiency had activated the integrated stress response 
kinase GCN2 in many tissues (134). A recent review (135) presents evidence that 
polyamines can induce stress responses resulting amongst other things in inhibition of 
general protein synthesis, similar to the effects of GCN2-mediated eIF2α 
phosphorylation in mammals. Whether hair loss in transgenic SSAT, Spf/Ash, and F\A2 
mice is the consequence of activation of the integrated stress response is intriguing and 
warrants further investigation. 
 
Polyamine synthesis in macrophages 
The increased polyamine synthesis in VSMC cells that overexpress arginase 1 (see 
section on "Arginase and polyamine synthesis") could not be reproduced in the murine 
macrophage cell line RAW 264.7, suggesting that arginase-derived ornithine is only 
rate-limiting for polyamine production when no other ornithine source such as proline or 
glutamate (and the necessary enzymes) is available (136). An arginase-dependent 
increase in polyamine synthesis in RAW 264.7 cells could, nevertheless, be 
demonstrated after LPS- or 8-Bromo-cAMP-stimulated ODC expression. After 6 hours 
of treatment with LPS or 8-Bromo-cAMP stimulation, arginase 1-overexpressing 
macrophages showed marked increases in the levels of putrescine (3-fold) and 
spermidine (1.5-fold) compared to lacZ-transfected or untransfected control cells. The 
higher increase in putrescine than in spermidine is in line with increased polyamine flux 
(115) in these cells to maintain stable polyamine levels and is not accompanied by 
increased cell growth (136).  
The experiment described above mimics the situation in pathogen-infected macrophages. 
Indeed, increased polyamine production in macrophages is observed in vivo after 
infection with different pathogens, and this increased production has disastrous effects 
on the macrophages themselves. The opportunistic pathogen Pneumocystis induces 
upregulation of AZI, the antizyme inhibitor of ODC antizyme, which results in increased 
cellular ODC protein and polyamine levels. This, in turn, results in increased polyamine 
oxidase expression and activity. A by-product of polyamine oxidation is H2O2, which 
leads to macrophage apoptosis (137). Helicobacter pylori infection has a similar effect 
via a different mechanism. Helicobacter activates c-Myc in gastric macrophages, which 
upregulates ODC expression and spermine production. Spermine suppresses NOS2 
transcription, which prevents an effective immune response against the pathogen. In 
addition, Helicobacter infection results in increased SMO expression (a spermine-
specific polyamine oxidase; see Figure Polyamine Metabolism) and H2O2 production in 
the macrophages and concomitant macrophage apoptosis.  
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Susceptible (“non-healer”) strains of mice, such as BALB/c, respond to Leishmania 
major infection with a polarized TH2 response with increased arginase 1 expression and 
a concomitant increase in polyamines (138). Inhibition of arginase reduces polyamine 
production and parasite growth. The authors conclude that the pathogens exploit 
ornithine and polyamine production by the host for their own multiplication. 
Accordingly, non-susceptible (“healer”) strains, such as the TH1-biased C57Bl/6 mice, 
do not express arginase in their macrophages at the onset of infection and are therefore 
able to resolve it (139). Interestingly, when a healer strain is treated with a daily dose of 
ornithine or putrescine during Leishmania infection, the lesion size increased, lending 
further support to the conclusion that the pathogen uses host ornithine for growth 
(140,141). In the first two cases, this leads to macrophage apoptosis thereby supporting 
the infection, whereas in the latter case, the accelerated growth of the pathogen is 
supported through host polyamines. ODC inhibitors such as DMFO are already 
successfully used against Trypanosoma infections and other ODC inhibitors seem 
promising in treating Leishmaniasis (142).   
 
In conclusion, macrophage arginase 1 can support increased polyamine synthesis in 
disease or infection if ODC levels are also upregulated, but this results in either host-cell 
apoptosis or increased pathogen growth rather than host tissue proliferation. There is 
evidence that fibroblast or smooth-muscle arginase 1, on the other hand, does support 
host cell proliferation (122,143) and tissue remodeling and that this may become 
excessive when not controlled by macrophage arginase 1.  
 
Arginase and Cancer 
Tumor-associated macrophages (TAMs) or myeloid-derived suppressor cells (MDSCs) 
Increased expression of arginase 1 in MDSCs (93) (for a recent review see (144)) has 
been demonstrated in mouse models (145-147) and human MDSCs isolated from 
melanoma, small cell lung cancer and renal carcinoma patients (97,148,149). The effect 
of arginase expression, however, can either be immunosuppressive and thus tumor-
promoting, or tumor-inhibiting, depending on tumor properties and arginase 
concentration.  
Arginase 1 expression can result in local arginine depletion, which negatively affects T-
cell proliferation and activation (see Arginase as a controller of arginine availability), 
and thereby promotes tumor growth through immunosuppression, or cancer cells 
themselves and thereby inhibits tumor growth. Cancer cell lines that are sensitive to 
arginine deprivation lack argininosuccinate synthetase (ASS), the enzyme that catalyzes 
the rate-limiting step in arginine synthesis from citrulline (150). Immunohistological 
characterization of tumors is, therefore, necessary to identify tumors that may be 
targeted by arginine deprivation (151,152). Interestingly, reduced ASS expression in 
osteosarcoma is associated with a higher risk of pulmonary metastasis after surgery 
(153).  
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Arginase expression in MDSC is, therefore, presumable only beneficial for the host 
when the tumor in question is susceptible to arginine deprivation, a hypothesis that can 
be tested in murine tumor models with arginase 1-deficient MDSC. On the other hand, 
increased tumorigenesis has been associated with disturbed polyamine metabolism due 
to elevated ODC levels and concomitantly increased polyamine concentrations 
(112,117), but also with increased expression of the polyamine-degrading enzyme 
spermidine/spermine N1-acetyltransferase (SSAT) (154). Both observations together 
have led to the often cited hypothesis that arginase 1-derived ornithine serves as a 
precursor for polyamines, which, in turn, are essential for rapidly growing tumor cells. 
Inhibition of arginase by N-hydroxy-L-arginine (NOHA) in susceptible tumor cells 
reduced spermine content and subsequently caused apoptosis (155). The same authors 
demonstrated later, however, that apoptosis was not a consequence of polyamine 
depletion but an effect of NOHA that was independent of polyamine depletion (156).  
Attempts to modulate polyamine concentrations often result in increased polyamine flux 
due to compensatory overexpression of polyamine-catabolizing enzymes (157,158). 
Accelerated flux leads to the depletion of acetyl-CoA and ATP and the generation of 
harmful compounds such as H2O2 that may lead to tissue damage and inflammation, and 
subsequently to tumor formation. Whether arginase-dependent production of ornithine is 
relevant for the increased polyamine metabolism in tumors has not been demonstrated to 
our knowledge.  
 
Therapeutic arginine deprivation 
New therapeutic approaches make use of the sensitivity of certain tumors to arginine 
deprivation by treating patients with PEGylated arginine deiminase (L-arginine 
iminohydrolase), a stabilized form of the enzyme that rapidly reduces plasma arginine 
concentrations by hydrolyzing arginine to citrulline. The therapy was well tolerated in 
patients with unresectable hepatocellular carcinoma, even when plasma arginine levels 
were below the detection limit for 3 months (159). Another approach is the combination 
of arginine deprivation followed by canavanine treatment (160), an arginine analogue 
that is incorporated into proteins and causes misfolding. Cancer cells in vitro were more 
susceptible than healthy cells.  
 
Effects of arginine availability on TH1 and TH2 responses  
Schistosomiasis 
Schistosomiasis is a chronic helminthic infection that causes a TH2-type inflammation in 
response to the eggs deposited in the intestines and liver, and results in hepatic fibrosis 
and portal hypertension. TH2-type cytokines, such as IL4 and IL13, induce alternative 
activation of macrophages, including arginase 1 expression.  
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As mentioned above, arginase 1 ablation in hematopoietic cells aggravates schistosoma 
pathology (92) and comparable results were found for Mesocestoides corti infections in 
IL4-deficient mice, where arginase expression in macrophages is diminished (161). The 
decreased TGFβ and increased IL12/IL23p40 production of peritoneal exudate cells in 
mice with arginase 1-deficient macrophages appear to account for the observed 
excessive pathology, as blocking IL12/IL23p40 production ameliorated the disease-
associated pathology considerably and improved survival (162). Collectively, the data 
therefore support the hypothesis that the immunoregulatory function, i.e. suppression of 
TH17 and TH1 responses, is the main function of arginase 1 in macrophages.  
 
Interestingly, a greatly enhanced fibrosis in lung and liver, portal hypertension, 
increased granuloma size, a significant increase in mast cells and eosinophils, and an 
unchanged schistosoma burden were found in Cat2-/- mice (58). Despite the increased 
pathological response, inflammatory cytokine production of both TH1 cytokines (IFNγ) 
and TH2 cytokines (IL4, IL13) was reduced in these mice. Since both macrophages and 
granuloma-derived fibroblasts of Cat2-/- mice show elevated arginase activity, the 
authors attribute the reduced T-cell proliferation to local arginine deprivation and 
suggest that CAT2 both supports NO production and suppresses arginase activity. One 
possible mechanism that might explain this observation is the reduced production of Nω-
hydroxy-nor-L-arginine (nor-NOHA) in Cat2-/- deficient mice. Macrophages that can no 
longer sustain high NO production by NOS-2 also produce less nor-NOHA, an efficient 
suppressor of arginase activity. In any case, the data on arginase 1- and CAT2B-
deficient mice strongly support the notion that arginase 1 overexpression inhibits T-cell 
proliferation and does not provide substrates for proline and polyamines production. 
 
Asthma 
A pronounced increase of arginase 1 expression in asthma has been demonstrated in 
both mice (163) and men (57), and a link with disease severity has been suggested. The 
precise location of the expressed arginase has however not yet been demonstrated 
convincingly. Weak arginase 1 protein expression was shown in bronchiolar-epithelium 
of healthy rats (164) and mock-immunized BALB/c mice. In OVA-sensitized and -
challenged mice a modest increase of this expression was observed (163). In our murine 
model and in another study with experimental asthma in mice (57), however, arginase 1-
staining by immunohistochemical techniques was only detected in macrophages of 
asthmatic animals and never in their bronchial epithelium. Animals, which were not 
sensitized to OVA, did not show any arginase 1-positive macrophages in their lungs as 
tested by immunohistochemistry on lung tissue or Western blotting of lung protein 
extracts (165). Ablation of Arg1 in macrophages (Arg1fl/fl/Tie2Cretg/-) led to an 
improvement of peripheral lung function in OVA -treated mice, without altering air 
hyperreactivity and lung inflammation (165).  
In another series of experiments with arginine- rather than Arg1-deficient mice 
(manuscript in preparation: (166)), we found that circulating arginine concentrations 
primarily affected airway resistance in the larger airways. We, therefore, hypothesized 
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that ablation of Arg1 in lung macrophages increases the parenchymal arginine 
concentration, which, in turn, facilitates NO production and smooth-muscle relaxation in 
the peripheral airways, but not the larger conducting airways. 
 
Conclusion 
Macrophage arginase 1 can in cooperation with cationic amino acid transporters control 
ambient arginine availability by efficiently depleting arginine locally. In infectious 
diseases, this suppresses not only proliferation of inflammatory T-cells, but also 
decreases collagen deposition by fibroblasts. The often cited causal link between 
arginase activity and increased collagen production does not seem to play a role in 
wound healing or infectious diseases characterized by excess fibrosis. The same holds 
true for the claim that increased arginase activity is sufficient for increased polyamine 
production in disease. Alternatively activated macrophages rather limit both processes 
by controlling local arginine concentrations. 
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SYNOPSIS AND SCOPE OF THE THESIS 
L-arginine is a basic amino acid in physiological fluids. Arginine is a precursor for proteins, for 
creatine and for the signaling molecules agmatine and nitric oxide. Arginine is also a 
secretagogue for growth hormone, insulin, glucagon and prolactin. Its content is relatively high 
in seafood, watermelon juice; nuts, seeds, algae, meats, rice protein concentrate, and soy protein 
isolate (1,2) but low in the milk of most mammals (including cows, humans, and pigs)(3,4). In 
addition, preterm infants who represent 10-12% of newborns, exhibit arginine deficiency (5), 
resulting in hyperammonemia and multiorgan dysfunction (6). It has also been shown that 
arginine supplied in current diets is inadequate for maximal growth of milk-fed piglets (7) or 
maximal reproductive performance of swine (8). Thus, arginine nutrition remains a significant 
concern in both human and animal health. This thesis aims at characterizing the role of arginine 
in growth and chronic inflammatory diseases through manipulation of local or systemic arginine 
concentration using conditional knockout and other transgenic mouse models.  
Macrophages are phagocytic cells involved in daily garbage clearance on the one hand and play 
an important role in innate and adaptive immunity on the other hand. Immunologically active 
macrophages are a heterogeneous cell population with two outer extremes, classified as M1 and 
M2 macrophages, or classically and alternatively activated macrophages (9), respectively. M1 
macrophages (also described as inflammatory macrophages) use arginine for the generation of 
nitric oxide by inducible nitric oxide synthase (NOS2), whereas the immunosuppressive M2 
macrophages deplete arginine through catabolism by arginases (ARG). 
This raises the interesting question whether and to which extent arginine metabolism determines 
macrophage function. Arginine metabolism is not a simple marker for the activation status of 
macrophages, but also has a strong effect on the outcome of many diseases. The Chapter I of 
this thesis reviews the arginine metabolism of macrophage and its role in chronic diseases. 
To further study the role of arginine – several knockout (KO) models were generated that 
allowed us to investigate arginine metabolism or to manipulate arginine availability. The models 
that were used affect arginine synthesis (conditional KO of arginine-synthetase, Ass), transport 
(conditional KO of cationic amino acid transporter 1, Cat1) or degradation (conditional KO of 
arginase 1, Arg1) or resulted in excessive arginine degradation (intestinal overexpression of rat 
arginase 1, F/A2). Chapter II of this thesis describes the chosen strategy for the generation of 
conditional knockout mice, and its advantages and limitations. The development of optimal 
screening and selection protocols for embryonic stem cells after transfection is described. We 
demonstrate that a PCR-based approach to amplify the homologous arms of a targeting construct 
is not very efficient due to the error rate of the heat-stable DNA polymerase. This chapter is a 
trouble-shooting guide for the generation of a conditional KO mouse.  
To elucidate the role of arginase 1 in chronic diseases, a tissue-specific KO mouse of arginase 1 
was created using Cre/loxP recombination. Arg1fl/fl mice were crossed with Tie2Cre or LysMCre 
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mice to eliminate ARG1 expression from all hematopoietic and endothelial cells or from 
granulocytes and macrophages, respectively. Chapter III shows that ablation of Arg1 in 
hematopoietic and endothelial cells did not affect OVA sensitization and flow resistance but 
attenuated tissue elastance (H) and tissue resistance (G) in a murine model of asthma, indicating 
that Arg1 ablation mainly affected the lung parenchyma (10), but not the airways. 
It is also possible that the main function of macrophages (and possibly other arginase-expressing 
cells) is the control of arginine availability. Interestingly, there is a limited period of perinatal 
intestinal arginine synthesis in rodents and pigs – which is later abolished by arginase 
expression. Mammalian milk contains too little arginine for normal growth, but its precursors 
proline and glutamine are abundant; but the small intestine of rodents and piglets produces 
arginine from proline during the suckling period. Parenterally fed, premature human neonates 
frequently suffer from hypoargininemia. These findings raised the question whether the human 
small intestine also expresses the enzymes that enable the synthesis of arginine from proline 
and/or glutamine.  Chapter IV is a histological study which shows that the human intestine 
indeed has the capacity to synthesize arginine, and that this capacity is strongest in the first three 
years after birth. However, the function of the arginine thus produced is not clear (11). 
It is believed that perinatal intestinal arginine synthesis compensates for insufficient arginine 
concentrations in maternal milk to ensure appropriate development. To test this hypothesis, we 
inactivated arginine synthesis in the gut by specifically inactivating ASS expression in the 
enterocytes of the small intestine. In contrast to mice overexpressing arginase 1 in the 
enterocytes (F/A2 mice), which showed severe retardation in general growth, reduced hair 
growth and impaired B cell maturation, mice deficient for ASS in their enterocytes showed no 
major phenotype. In Chapter V we characterized the mice with intestinal ASS deficiency.  
Absence of intestinal arginine biosynthesis in ASS deficient mice resulted in an increased 
production of citrulline by the gut and an increased hepatic absorption of arginine. Furthermore, 
arginine synthesis in the kidneys was increased (12). The question remained what might be the 
reason for the dramatic phenotype of F/A2 mice (clearly not the lack of intestinal arginine 
synthesis, but rather the excessive breakdown of not only intestinal arginine but also arginine 
from the diet) – in other words, what are the mechanisms underlying these dramatic effects of 
arginine deficiency? 
The phenotype of F/A2 mice is reminiscent of the phenotype of IGF-1 deficient mice, which are 
also growth retarded. We hypothesized that the syndrome results from an interaction of the 
growth-hormone/IGF-1 axis and the amino acid-sensing GCN2 stress-kinase pathway. In 
Chapter VI we characterized this mouse model in vivo in combination with several in vitro cell 
culture models. We show that arginine deficiency inhibits the release of growth hormone from 
the pituitary gland and ubiquitously activates the stress kinase GCN2 leading to a general shut-
down of protein synthesis. Our findings demonstrate the signaling properties of arginine on the 
growth hormone axis and on the protein synthesizing machinery (13).  

 

In the general discussion, we review known or claimed beneficial effects of arginine 
supplementation and analyze the available evidence from our own studies and those of others. 
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Construction of conditional knockout mice 
 
 
Introduction 
The development of techniques that allow the modification of the DNA sequence of an allele of a 
gene in embryonic stem cells enables us, in combination with microinjection techniques, to 
deliberately modify the expression of genes in a living organism, usually the mouse. The deletion 
(knockout) or replacement (knock-in) of specific genes has proven to be a powerful tool. In this 
chapter, we comment on our experience with the generation of conditional knockout mice of the 
genes that code for argininosuccinate synthetase (Ass; VM), arginase 1 (Arg1; SS) and cationic 
amino-acid transporter 1 (Cat1; CCdT).  
 
Conventional knockout mice (deletion of a specific gene in every cell of the organism) are often 
not viable. This problem can be overcome by making “conditional” knockout mice that allow the 
deletion of a gene in a specific tissue or at a specific developmental stage. Deletion in specific 
tissues or at a specific time point can be achieved with just one genetic modification of the gene 
of interest, that is, the insertion of two recognition sites for an enzyme with recombinase activity. 
Mice harboring such a modified allele are crossed with mice expressing the recombinase under 
control of a promoter that determines the spatiotemporal expression of the recombinase and 
thereby the spatiotemporal deletion of the DNA fragment surrounded by the recombinase 
recognition sites. Two systems are most widely used and discussed in this chapter, viz, the 
cre/loxP system and the flp/frt systems. LoxP and frt refer to the recombinase recognition sites, 
and CRE and FLP to the respective recombinases (1-4). There are now more than 100 cre mice 
available (see http://www.mshri.on.ca/nagy/), permitting deletion of genes in specific cell types 
(macrophages, B-cells, enterocytes, hepatocytes, endothelial cells to name a few) or at specific 
times using a recombinase that is modified to contain the ligand-binding domain of a member of 
the steroid-hormone receptor family. Most often, this ligand-binding domain is modified itself to 
respond only to a ligand that is not endogenously produced. In practice, the combination of a 
modification of the estrogen-receptor ligand-binding domain and the ligand tamoxifen is most 
often used. 
 
The first step in the generation of a conditional knockout mouse is the design and construction of 
an appropriate vector that is then introduced into embryonic stem cells by transfection. This paper 
describes a PCR-based method for vector construction and specifies screening protocols for the 
embryonic stem cells after transfection. The approach is summarized in Figure 1. 
 
The Targeting Plasmid  
A targeting plasmid consists of two regions with target homology (hereafter called flanking 
regions; Figure 2), the region of the gene to be deleted, and genes that are used as selection tool. 
The flanking regions are placed at either end of the sequence to be deleted and are identical to the 

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Figure 1: Overview of the design and construction of the targeting plasmid, the selection and characterization of 
the targeted ES cells, and the procedure to modify the germline of mice. 
 
sequences surrounding the target sequence. The flanking regions are required for homologous re-
combination, that is, for the site-specific insertion of the construct into genomic DNA. In our 
strategy, the exon(s) or gene to be deleted are flanked by loxP sites, whereas the selection tools 
(neomycin phosphotransferase (“neo”) and viral thymidine kinase (“tk”)) are surrounded by frt 
sites.  
 
Figure 2: Structure of a targeting construct. The fragment to be deleted is surrounded by “loxP” sequences 
(“floxed”). Adjacent to the floxed sequence, a selection cassette is inserted, which itself is surrounded by “frt” 
sequences for later removal. The target sequence and the selection cassette are located in between the “flanking 
regions”, which are identical to the sequences surrounding the part of the gene that is to be deleted. At both ends of 
the construct, fragments of the vector can be left behind to facilitate selection. See text for details. 
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 Vector construction has been greatly facilitated by the availability of the complete mouse 
genome (http://www.ncbi.nlm.nih.gov, http://www.onderzoekinformatie.nl) and additional 
information on SNPs and strain differences. This made it possible to use a PCR-based approach 
for vector construction, which also facilitates the introduction of additional restriction sites 
necessary for later cloning steps. The advantages and pitfalls of this approach will be discussed. 
 
Selection of target region to be excised 
One can delete one or more crucial exons or the entire coding sequence to inactivate the gene of 
interest. Deletion of one or a few exons is often preferable, since the efficiency of the CRE 
recombinase seems to be at least partially dependent on the distance between the loxP sites (5).  
The region chosen for deletion should either code for domains that are important for the function 
of the gene product (eg. the active site of an enzyme) or should result in a frame shift with 
premature stop codons. One should nevertheless be aware of alternative splicing which could 
result in a partially functional gene product excision (e.g. (6)). Literature data on lethal mutations 
in man and mouse should be consulted, because they can be very valuable for the development of 
the knockout strategy. Examples are: natural mutants (in the case of the arginosuccinate 
synthetase gene, we selected exon 13 for deletion, because the deletion results in a frame shift 
and natural mutations in this exon led to undetectable levels of enzyme activity (7) or results 
known from conventional knockout mice (in the case of the arginase-1 gene, we selected exon 4 
for deletion, because the conventional arginase I knockout mouse was made by deleting this exon 
and died between 10-14 days after birth (8)).   
 
Prerequisites for homologous recombination: length of the homologous 
regions 
Between 2 and 10 kb, the relationship between the length of the homologous region and the 
frequency of targeting events is exponential and shows saturation at 14 kb of homology (9). 
Therefore, a minimum length of 2 kb is recommended for the flanking region to support optimal 
homologous recombination. However, 1.5 kb of homologous region at one end and 5 kb at the 
other end proved sufficient for efficient recombination of the Glutamine Synthetase gene (Y. HE, 
AMC Liver Center, Amsterdam). In our case, we used approximately 4.5 kb of homologous 
region on either side of the construct. Although this was thought to be advantageous for 
homologous recombination, long flanking regions as e.g. found in pROSA26 (10) make 
screening of clones by Southern or PCR more difficult. For this reason, many constructs contain 
a long and a short flanking region.   
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Comment 
An important parameter that is often neglected when selecting a target region for vector 
construction is the presence of repeats in the sequence to be amplified. Such repeats should be 
avoided since they are troublesome during amplification by PCR.  
 
Recombinase systems 
Cre-loxP system 
The P1 bacteriophage cyclization recombination (cre) recombinase recognizes a pair of loxP sites 
flanking a DNA sequence. LoxP sites are 34 bp long and composed of an 8bp core, which 
determines directionality, flanked by 13 bp of palindromic sequence on either side (Figure 3A). 
The natural occurrence of this exact sequence is unlikely in any eukaryotic genome. Sequences 
flanked by loxP sites are said to be "floxed". The cre enzyme brings the two loxP sites into 
juxtaposition. If the loxP sites flank a DNA segment in a cis arrangement and are oriented in the 
same direction, CRE recombinase mediates excision and circularization of the flanked segment 
(Figure 3B). If the loxP sites flank the DNA segment in a cis arrangement and are oriented in 
opposite directions, CRE recombinase mediates the inversion of the segment (Figure 3C). If the 
loxP sites are located on different strands of the DNA and are oriented in the same direction, 
CRE recombinase can mediate translocation of the segment (not shown). 
 
 
 
Figure 3: LoxP sites. Panel A: The nucleotide sequence of loxP sites. Note the inverted repeat surrounding the 
asymmetric core sequence. Due to their asymmetric core, the orientation and position of the loxP sites determines the 
outcome of the recombination event. In conditional knockout strategies, the aim is excision of the fragment which is 
achieved by placing 2 loxP sites on each side of the sequence of interest in the same orientation (B). With an 
opposite orientation of the loxP sites, an inversion of the floxed region is obtained in presence of CRE (C).  
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Flp-frt system 
The yeast flp recombinase (4, 11) recognizes target sites called frt (12, 13). A full-length frt site is 
48 bps long and, similar to a loxP site, consists of an asymmetric central 8bp spacer sequence, 
flanked by 13bp inverted repeats (Figure 4). However, in contrast to loxP sites, it contains a third 
13bp direct repeat at one side (14). Because the Flp/frt system is derived from S. cerevisiae, its 
optimal working temperature is 25-30˚C. At 37˚C, the activity of the enzyme is dramatically 
reduced (15, 16), so that Flp is less suitable and less frequently used to engineer genome 
modifications in mammals. Attempts to overcome this limitation have led to the development of 
an “enhanced” mutant FLP (FLPe) by cycling mutagenesis. FLPe is said to have a better 
thermostability and activity (16, 17) and a more efficient function in mammalian cells (16, 18). 
  
 
 
Figure 4: The nucleotide sequence of frt sites. Note inverted repeat surrounding asymmetric core sequence, which 
contains a convenient XbaI restriction site. Also note that the left-sided repeat needs to be present as 2 copies for 
higher efficiency. 
 
Selection tools 
A homologous recombination is a very rare event compared to random integration. Based on our 
experience, homologous recombination occurs in ~50% (ROSA locus; M. Konings) to 0.05% of 
all integration events (arginase I locus). Selection is therefore necessary to identify the clones in 
which homologous recombination has occurred and to distinguish these clones from the clones in 
which the modified sequence is randomly integrated into the genomic DNA. To achieve this, a 
positive-negative selection protocol is commonly used (19). The positive selection tool is used to 
identify ES cells with the targeting sequence integrated into their DNA. Neomycin 
phosphotransferase (neo) is often used as a positive selection marker to select for ES clones in 
which the construct is integrated. Only clones that have integrated the construct will be able to 
grow in G418-containing medium as neomycin phosphotransferase will detoxify the compound.  
 
The negative marker can be used to select for homologous recombination of the targeting 
construct (Figure 5A) or to select for successful removal of the positive selection marker in the 
ES cells prior to blastocyst injection (Figure 5B). As a tool to select for homologous 
recombination, the negative selection marker has to be placed at the outer end of one of the 
flanking regions, whereas the positive selection marker is placed in the middle of the construct. 
Positioning the negative selection marker at one extremity of the targeting construct (Figure 5A) 
will lead to elimination of this marker during homologous recombination. Addition of the 
selection compound to the medium will then kill all cells that still express the negative selection 
marker due to random integration, whereas clones with homologous recombination will not be 
affected. Viral thymidine kinase (tk) is a commonly used negative selection marker, as it confers 
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sensitivity to ganciclovir in the ES cells. Phosphorylated ganciclovir is a toxic substance, so that 
cells can only grow if thymidine kinase is not or no longer present.  
 
Figure 5: The two applications of a negative selection marker. In panel A, a negative selection marker is placed at 
either end of the construct to select against random integration. In panel B, the negative marker is placed in the 
middle of the construct and surrounded by recombinase recognition sites for removal after recombination.  
 
Removal of selection markers  
To select for successful removal of the positive selection marker, both positive and negative 
selection tools have to be present in between the two flanking regions (Figure 2). There are 2 
strategies to remove the selection markers. One approach uses three loxP sites that surround the 
target sequence and the selection marker. In the other approach, the target sequence and the 
selection markers are surrounded by loxP and frt sites, respectively. After selection for the 
positive selection marker and identification of a correct clone by the appropriate screening 
protocols, the selection tools are removed by transient transfection with either a cre- or flpe-
expressing plasmid, depending on whether the selection tools are surrounded by loxP (Figure 6) 
or frt sites (Figure 2). In vivo, loxP sites are preferable over frt sites as recognition sites for a 
recombinase, because CRE is a more efficient recombinase than FLP and because there are many 
more mouse strains harboring tissue-specific expression of cre than flp. Therefore, the gene 
fragment to be excised in vivo is usually surrounded by loxP sites.  
 
Figure 6 shows the use of 3 loxP sites for gene targeting. Transient transfection of ES cells with a 
cre-expressing plasmid will ideally yield three products: cell clones, in which only the selection 
tool is deleted, cell clones in which only the target sequence is deleted, and cell clones with 
excision of both the selection tools and the target sequence. The first type of clones is the desired 
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outcome, whereas the second and third type of clones will generate conventional knockouts. It is 
unfortunately not yet possible to predict if the desired type of clones can be obtained. We, 
therefore, chose for an approach in which the targeted gene fragment is placed between loxP sites 
and both positive and negative selection tools are present in the middle of the construct in 
between frt sites (Figure 2). This allowed us to first select for integration of our constructs into 
the genomic DNA and then to select for deletion of the positive-negative selection tool before the 
injection of ES cells into blastocysts. 
 
 Figure 6: Gene targeting using loxP sites. Gene targeting using solely loxP sites can be used to inactivate a specific 
gene in a desired cell type.  In the standard homolous recombination protocol, three loxP sites are introduced along 
with a selection tool “M” at the target locus “A”. Subsequent transient transfection of a cre recombinase-expression 
plasmid or breeding a chimeric mouse with a deleter-Cre mouse results in recombination between the three loxP 
sites. In the desired Type I recombination, only the selection tool is removed. Both other recombinations generate 
convential unconditional knockouts.  
 
Comments 
1. An alternative to “select” against random integration by including a negative selection marker 
at the outer end of the targeting construct is the use of a high throughput screening protocol, 
e.g. a PCR-based screening for the presence of remaining vector sequence. This strategy will 
be discussed in section III A. 
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2. Multiple copies of loxP can lead to chromosomal instability during expression of cre (20).  
3. An alternative to plasmid transient transfection with cre or flp to remove the selection tools is 
to cross mice carrying the properly recombined targeting construct that still contains the 
selection marker with a mouse expressing cre or flp in early development, i.e., before the 
germline is set apart. An example of a cre-expressing mice is the II2a-Cre mouse  (21), while 
the “flipper” mouse is an example of an often used flpe-expressing mouse (22). The 
availability of the efficient flipper mouse (~50% frt excision (22) ) has made the use of a 
negative selection marker like thymidine kinase obsolete, because the positive selection 
marker can now be removed in vivo. The use of solely the neo selection tool and its removal 
in vivo has 3 additional advantages:  
x one round of in vitro selection can be avoided (see section IV B), which decreases the 
chance that pluripotency of the ES cell is lost;  
x crossing the mice with a flpe-deleter mouse on a pure background spares one round of 
breeding towards a new background; 
x a targeted allele containing neo is available. Such alleles are often cripple (19, 23-26), 
allowing one to obtain not only animals with 0, 50% and 100% gene expression of the 
gene of interest, but also animals with intermediate expression levels (0-50% and 50-
100%).   
 
Cloning the target and flanking regions 
PCR 
Homologous recombination requires a 1.5 kb - 5 kb stretch of DNA on either side of the 
construct that is identical to the sequence to the wild type DNA (27). The efficiency of 
homologous recombination depends on the degree of sequence similarity. When the construct is 
generated by PCR, the use of a high fidelity of the DNA polymerase for the amplification of the 
flanking regions from genomic DNA is therefore a prerequisite.  
 
The different commercially available thermostable DNA polymerases show a ~20-fold difference 
in error rates (28, 29). The DNA polymerases from thermophilic bacteria (e.g. Thermus 
aquaticus) miss proof-reading 3’-5’- exonuclease activity and lack the ability to synthesize 
products larger than 5 Kb. DNA polymerases from hyperthermophilic archaea (e.g. 
Thermococcus fumiculans (“Tfu”) and litoralis (“Vent”) and especially Pyrococcus furiosus 
(“Pfu”) and abyssi) have low error rates, but the stronger the proofreading activity, the lower the 
product yield of long DNA fragments. Therefore, blends of the non-proofreading Taq and a 
proof-reading enzyme are often used: “LA” (long and accurate (30) ) PCR. According to the 
manufacturer, the Accutaq LA DNA Polymerase (Sigma), which we used for amplifying the 
homologous arms, has a 6.5-fold greater fidelity than Taq polymerase. However, in 3 different 
targetings, we observed 27 differences with published sequences in 6.9 kb of DNA (0.4%). Some 
of these differences may reflect strain differences (published sequences are often C57BL/6 or 
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BALB/c, whereas the ES cell line came from 129P2/OlaHsd mice). In the case of arginase I 
construct, we found 5 mismatches in the exonic sequences, which did not lead to a change in 
amino-acid coding. We did not correct sequences, if they did not affect a consensus splice site or 
a coding sequence. However, when a coding sequence was affected (e.g. (GCG (Ala) to GTG 
(Val) in exon 6 of the arginase-1 gene), we did correct the mismatch.  
 
Another problem of the PCR approach that we encountered was the presence of highly repetitive 
sequences in the region to be amplified. In the 5’-flanking region of the ASS targeting construct, 
for instance, a 36 bp TA repeat was present in the middle of the 4.2 kb fragment. To amplify this 
sequence, we tried several high-fidelity Taq enzymes (Pfu “Ultra High” Fidelity and “Herculase” 
DNA Polymerases (Stratagene); AccuTaq Polymerase (Sigma)), but none of them was able to 
amplify the sequence. Eventually, we had to break up this flanking region into 4 fragments of 
approx. 1 kb each. 
 
Comments 
Our choice to amplify the flanking regions using genomic rather than plasmid- (BAC-) derived 
DNA was based on the limited availability of BAC clones when we designed our approach. 
However, since BAC-derived DNA is ~30,000-fold purified per weight unit for a particular 100 
kb fragment relative to primary genomic DNA, the number of PCR cycles necessary to amplifly 
the DNA is reduced by ~17, which strongly reduces the fidelity issue. 
 
Electroporation of the targeting construct 
Purification of the targeting construct 
Prior to electroporation in the ES cells, the construct is either linearized by restriction enzymes 
cutting in the vector backbone or digested with two restriction enzymes to remove the vector 
backbone. Complete removal of the backbone of the vector has the advantage of working with a 
“clean” construct without additional sequences that might interfere with homologous 
recombination in the cell. On the other hand, linearization avoids extra steps of purification of the 
targeting construct. Furthermore, the additional vector sequences can be used for a PCR 
screening strategy to eliminate clones with random integration quickly. This approach is 
described in section III.a (Elimination of randomly integrated clones).  
 
There are several methods to purify large DNA fragments by electrophoresis (purification with 
commercial kits, electrophoresis in low melting point agarose followed by acid-phenol extraction 
or electro-elution). We used electroelution, using a bridging system to concentrate the DNA on a 
dialysis membrane (Figure 7A). The purified DNA was then precipitated in ethanol for 
electroporation.  
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Figure 7: Electroelution. Panel A: Schematic representation of the electro-elution system used to purify the 
targeting vector prior to electroporation. The two cylindrical reservoirs communicate through a buffer compartment 
on top. DNA migrates in an electric field (open arrow) from the agarose slices (in large reservoir, left) onto the 
dialysis membrane (in small reservoir, right). Panel B: after electroelution, the DNA concentrates on the dialysis 
membrane. The left picture shows an efficient transfer of DNA to the dialysis membrane, whereas the right picture 
shows an inefficient transfer (a high proportion of DNA remained in the agarose).  
 
Comments 
1. DNA that is to be used to generate transgenic animals should be protected as much as 
possible from UV light (i.e. day light, UV light box). Long-wave UV light or a Dark Reader® 
using visible light (Clare chemicals), is recommended to visualize DNA. We are aware of a 
case in which undue exposure to UV light caused mutations in the majority of otherwise 
successfully targeted ES cells.  
2. Residual ethidium bromide will interfere the efficiency of homologous recombination. Traces 
of ethidium bromide in a DNA preparation can be easily detected on an agarose gel from 
which ethidium bromide has been omitted. If DNA is detectable under UV light, the 
preparation should be re-extracted. For the same reason, working surfaces and equipment 
(UV tray; scalpels) have to be clean, when isolating fragments from agarose gels. 
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3. During electroelution of DNA, the agarose blocks should be stacked properly to ensure 
efficient transfer (Figure 7B, left picture). Floating pieces of agarose result in inefficient 
transfer of DNA (Figure 7B, right picture) and are a major source of DNA loss.  
 
Choice of ES cell line 
The choice of ES cell line is an important factor to achieve high success rates. The 
129P2/OlaHsd-derived IB10 ES cells (a subclone from (male) E14 ES cells (31)) was used 
successfully by our group for the generation of 4 conditional knockout and 3 knock-in mice. 
 
Figure 8: The phenotype of ES cells cultured in vitro. Picture A: 
a colony of undifferentiated ES cells cultured on mouse embryonic 
fibroblasts (MEFs). The cells are spherical and show no boundary 
at the circumference of the colony. Picture B: a colony of 
differentiated ES cell with part of the cells exhibiting a high degree 
of differentiation (arrow). The cells are no longer spherical. Picture 
C: a colony of ES cells grown in BRL-conditioned medium. 
Although still undifferentiated, this ES colony is very different in 
appearance from one grown on MEFs.      
Electroporation of IB10 ES cells 
ES cells from an 80% confluent 25cm2 culture flask 
were electroporated with 25 μg DNA in a final volume 
of 200 μL sterile PBS. At a setting of the capacitance at 
1 μF, the time constant should not exceed 0.1. After 
electroporation, the ES cells were seeded in two 10 cm 
dishes, containing medium without selection compound.  
The exposure of the electroporated ES cells to the 
selection medium (200 μg/mL G418) was started 24 
hours after electroporation. Five days later, resistant 
colonies become visible, with individual colonies 
becoming visible after 6 to 8 days. The colonies should not be left to grow too big, since this 
induces differentiation of the ES cells. Figure 8A shows an undifferentiated ES colony with cells 
retaining their spherical shape. On the other hand, when the ES cells become differentiated, they 
acquire a rectangular shape (Figure 8B) and should be disgarded. Series of 16 undifferentiated 
colonies were picked and transferred to 96-well plates containing neomycin-resistant mouse 
embryonic fibroblasts (neo-MEF). After 2-3 days, when the cultures are around 60% confluent, 
they are split onto two plates, one containing neo-MEFs and the other 150 μL of BRL (Buffalo 
Rat Liver) conditioned medium. The cultures on neo-MEFs were grown to semiconfluence (2-3 
days) and frozen. The colonies on BRL medium were expanded for isolation of genomic DNA. 
Note that these ES cells look different from MEF-supported ES cells (Figure 8C). 
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Comment 
Recombinant ES cells should be grown under selection pressure until the selection tool has been 
excised to suppress the growth of wild-type cells. The requirement for a “deep split” (see section 
IV.a.) shows that selection pressure should be a standard part of the procedure. 
 
Screening for Homologously Recombined Clones 
Once neomycin-resistant clones originating from single cells have been picked, they need to be 
screened for proper integration of the construct into the targeted gene. The picked clones are 
seeded individually in 96-well plates. It was common to observe differences in the growth rate 
among the recombinant cells. Therefore, care was taken not to allow cells to grow too confluent, 
thereby avoiding differentiation. Because screening is a tedious and time-consuming procedure, it 
is recommended to temporarily freeze an aliquot of promising ES colonies, while going through 
the selection with the remaining portion of the clone. Two ways of freezing down the cells were 
used. A computer-assisted cooling device, in which the cryotubes were placed, in a temperature-
controlled chamber with a reduction in temperature of 1ºC per minute to -80ºC, before 
transferring the tubes to liquid nitrogen. When this machine was not available, we cooled the 
cryotubes in a foam box containing liquid isopropanol based on the same principle as the Mr 
Frosty labware (Nalgene) in a -80ºC freezer before transferring them to liquid nitrogen.  
 
Elimination of randomly integrated clones 
After electropration of the targeting vector, the vector either integrates randomly in the genomic 
DNA (RI) or recombines homologously with the gene of interest (HR). An interesting difference 
between these two ways of insertion is that the extremities of the vector are kept during randing 
integration, but lost during homologous recombination (Figure 9A). We used this difference for a 
preliminary test to remove clones with randomly integrated DNA. We left the multiple cloning 
region (MCR) on either end of the linearized fragment or only linearized targeting construct. A 
MCR- or vector-specific primer and a construct-specific primer were used. Since the outer ends 
of the construct are lost during homologous recombination, only randomly integrated clones still 
have the MCR- or vector-specific sequence necessary for primer binding (Figure 9B). This 
“short” PCR approach worked well for some targeting vectors, e.g. ASS, that is, ~70% of the 
clones that were randomly integrated could be eliminated. We therefore suggest linearizing the 
targeting construct near the shortest flanking sequence. When the construct was restricted at the 
outer side of the MCRs before electroporation, leaving no backbone, this short PCR did not work 
efficiently. Probably, the extremities of the construct are nibbled off by nuclease activity before 
integration. Clones yielding a PCR product were discarded; clones negative for this PCR were 
treated as potential candidates for proper homologous integration and investigated further.  
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Selection of homologously recombined clones 
Long PCR  
Clones negative for the “short PCR” were subjected to a “long PCR”. To discriminate the 
recombined allele from the wild-type allele, the primers for the long PCR were chosen to be 
specific for the recombined allele. The target-specific primer sequences were chosen in the 
selection markers, the lox P sites, or the frt sites in the center of the construct and in the genomic 
sequence outside that present in the targeting vector sequence (Figure 9C). This PCR yields a 
specific PCR product with a known size, when homologous recombination has taken place. The 
PCR product is then restricted with appropriate enzymes and sequenced to confirm the exact 
insertion of the targeting vector. The long PCR yields very detailed information on the 
integration of the DNA. We, therefore, recommend to perform this long PCR on both sides of the 
integrated vector, if this is possible. Finally, all crucial sequences are sequenced to check for any 
mutation.  
 
Figure 9: PCR-Screening for homologous recombination. Panel A: Configuration of a targeting construct after 
random integration or after homologous recombination. The vector-specific sequences at the ends of the targeting 
construct (black) remain only present if the construct is randomly integrated. Panel B: This structural feature allows a 
negative selection for properly integrated clones by “short” PCR. Primers are designed specifically for these 
sequences, which will only give a band for randomly integrated clones.  It is obvious that PCR at the right side (long 
vector sequence left) is less sensitive to “nuclease nibbling” than PCR at the left side. Panel C: Screening for 
homologous recombination by “long” PCR. By using primers in the endogenous DNA outside the targeting construct 
and in the selection marker or recombination sites, a PCR product that is unique for the recombined allele is 
produced. This PCR product can then be used to sequence crucial parts of the modified allele without interference 
from the wild-type allele. 
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Southern blot  
Clones positive for the long PCR on both sides were further tested by Southern blot to check for 
clonality, that is, checked for the presence of an equal number of copies of the recombined and 
the unmodified endogenous allele to test for the presence of wild-type ES cells that were not 
removed during the positive selection procedure. This Southern-blot does also reveal the presence 
or absence of additional random integrations.   
 
The DNA sequence used to probe such a Southern blot should be localized external to the 
flanking regions of the construct. The quality of the probe determines the quality of the result. 
We found that a relatively short probe that is specific and contains no repetitive elements is more 
efficient than longer probes containing such repetitive elements. Also, it should be close to the 
boundaries of the construct to avoid excessively long sequences. Exons are preferable to introns 
because introns more often contain repetitive sequences and, therefore, bind non-specifically to 
sequences elsewhere, resulting in smears as depicted in Figure 10, left panel. However, 
sometimes the next exon is so far away that intronic sequences have to be used as probe. Any 
candidate probe should be checked for its specificity by blasting for the occurrence of relatively 
short sequences (>12 bp) that are shared with other regions (comparison with the mouse genomic 
database) and then tested on a Southern. There is no golden rule to select a sequence for a 
Southern probe, in the sense that intronic probes can be as good as exonic probes as shown in 
Figure 10, right panel, where we used an intronic sequence of 300 bp for the Southern probe and 
obtained high specificity.  
 
 
Figure 10: Southern blotting as tool to identify 
homologous recombination. Panel A: ES-cell 
DNA was digested with Xmn-I, blotted, and 
hybridized with an external intronic ASS probe 
(1.17kb). The probe generated the same staining 
pattern as ethidium bromide, demonstrating non-
specific hybridization. Panel B: ES-cell DNA was 
digested with Blb-1, blotted, and hybridized with a 
short 300bp intronic arginase-1 probe. The wild-
type allele is 6.1 kb long and the recombined allele 
8.5 kb. Note the difference in intensity of the wild-
type and recombined allele. The excess of wild-type 
DNA suggests that wild-type cells had escaped 
removal during neomycin selection.  
R: Recombinant DNA fragment; E: Endogenous 
DNA fragment.  
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Comment 
DNA isolated for genotyping may be difficult to dissolve. If the centrifugational force is limited, 
a more homogenous solution is usually obtained. Prolonged centrifugation during precipitation 
should, therefore, be avoided.  
 
Removal of Selection Tools 
Clonality of the recombined clone (“deep split”)  
The picked ES colonies are often contaminated with WT ES cells. These contaminant cells need 
to be removed before blastocyst injection. The clonality test, a Southern blot-based technique, 
allows us to visualize the intensity (that is, the prevalence in the population) of both the 
endogenous and recombinant alleles and to compare them. If the ES cells used on the blot 
originate from a pure recombinant clone, the intensities of the two bands should be equal. On the 
other hand, if the intensity of the endogenous band is stronger than the recombinant one, there is 
most likely a contamination with wild-type ES cells (Figure 10B). We observed contamination 
with wild-type ES cells in many cases as long as we stopped the G418 selection after picking the 
clones. It is therefore highly recommended to continue the drug selection throughout the whole 
procedure.  To remove the remaining wild-type cells, a deep split has to be done and the resulting 
“single-cell” ES cultures have to be subjected to a new round of G418 selection. 
 
Removal of the neo-tk cassette 
The presence of a selection cassette can interfere with the expression of a nearby gene (19, 23-
26). Furthermore, ES cells that express tk are less likely to be incorporated into the male germ 
line (23, 32). It is therefore recommended to remove the neo-tk cassette or any other selection 
cassette in the selected ES-cell clones prior to blastocyst injection. The excision of the cassette 
can be achieved by transient expression of either flpe or cre recombinase through electroporation 
of either a flpe- or cre-expressing plasmid. In our constructs, we use the Cre-LoxP system to 
achieve specific gene inactivation, so that the Flp-Frt system remained to remove our selection 
cassette.   
 
Comments 
1. The flpe-expression plasmid (Figure 11A) is a fastidious plasmid. After electroporation into 
e.g DH5-α bacteria according to the Biorad standard electroporation protocol, the incubation 
temperature of the bacteria should not exceed 30˚C. At 37˚C, the apparent size of the plasmid 
doubled (Figure 11B). Forty-eight hours after transformation, colonies were picked for 
inoculation of 5 mL cultures. When incubated at 30˚C with a constant agitation of 180 rpm 
(instead of 270 rpm), these cultures yielded the proper-sized plasmids (Figure 11C). Large-
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scale cultures were grown under the same conditions. 25μg aliquots of the plasmid were 
stored in sterile PBS at -20˚C until electroporation.  
2. The thymidine kinase protein that is encoded in the neo-tk cassette is as stable as cellular bulk 
protein with an estimated long half-life of around 40 hours (33), meaning that the deletion of 
the gene does not make the cell insensitive to ganciclovir for several days. In order to make 
sure that no tk is left in the cells, they were grown in selection-free medium for 5 days before 
ganciclovir was added. Due to this long time period, the cultures have to be split between 
transfection and selection. Care should therefore be taken that independent clones are 
generated. After the deep split, a pure ES cell clone was expanded to 25 cm2, trypsininzed, 
and electroporated with 25μg FLPe plasmid. One tenth of the cells were seeded onto the wells 
of a 6-well plate containing wild-type mouse embryonic fibroblasts (wtMEFs). Two-three 
days after electroporation, the cells of each 6-well were split onto two 6-well plates at a 
dilution of 1:30 and 1:100. After another 2-3 days, ganciclovir selection was started.  
3. Ganciclovir is a nucleotide analogue that may cause mutations. We therefore resequenced 
crucial sections of the recombined alleles. In the ASS allele, we did indeed find a mutation in 
the targeted exon that resulted in a frameshift (ATC to TTT – Ala to Val). This mutation was 
not present before FLPe-mediated excision and ganciclovir selection, and would have 
inactivated the enzymatic activity (34). 
4. Flpe-deleter (“flipper”) mice (22) are available and have already shown their usefulness in 
excising selection cassettes (see II.d.1, comment 3). 
 
 
Figure 11: Flpe plasmid. Panel A: Schematic representation of the pCAGGS- expression vector. Flpe expression is 
driven by the chimeric chicken actin/CMV promoter-enhancer (18). The ampicillin (amp) and puromycin resistance 
genes are present for selection in bacteria and eukaryotic cells, respectively. The flpe sequence harbours four amino-
acid changes (P2S, L33S, Y108N, S294P) that collectively improve the in vitro recombination activity 4-fold at 37ºC 
compared with wild-type flpe (16). Panel B: The plasmid was electroporated into XL-1 Blue bacteria, using a 
standard mini-preparation. The observed size of the supercoiled form of the 7.7 kb plasmid appeared to exceed 12 kb 
(arrow). M: Size marker. Panel C: Under optimized bacterial culture conditions (180rpm; 30˚C), the linearized (lin) 
plasmid was 7.7kb long (arrow) and the uncut (unc), supercoiled form ~5.5kb.  
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Injection of ES Cells into Blastocysts   
A clone that passed all tests was karyotyped before injection into the blastocyst. Despite all 
quality checks, ES cells may incur damage during transfection, freezing, selection, and 
culture procedures, that is not detected. Therefore, the karyotype of the ES cells of each ES 
line was routinely tested. At least 15 metaphase spreads were counted, of which at least 80% 
should have the proper karyotype (40 chromosomes).  
 
To exclude artifacts due to DNA modifications in the ES cells, germ-line chimeras of at least two 
independent modified clones should be generated. To eliminate DNA mutations outside the locus 
of interest that have accumulated during many generations of in vitro culture of the ES cells, 
newly generated genetically modified mice should be bred into wild-type mice for several 
generations.  
 
Comment 
Prior to blastocyst injection, the ES cells should pass the following checklist:  
1. Correct DNA stoichiometry by Southern hybridization (1:1 ratio between wild-type and 
recombinant allele). 
2. Morphology check (undifferentiated status, Figure  8B) 
3. Karyotyping  
 
Breeding Schemes  
Chimeras 
A rule of the thumb is that the best – in the sense of germline transmission - chimeras should be 
moderately chimeric. However, we do not know in advance whether the genetically modified ES 
cells that we produced are still sufficiently pluripotent. In the case of arginase I, the best chimeras 
gave 5 floxed animals out of 20-25 offspring. Since the percentage of ES cells that populates the 
germline is always relatively small and since an ES cell can populate the germline without 
carrying the modified allele, it can be very reassuring to identify a germline transmission of a 
modified ES cell that, as a result of meiosis, does not carry the floxed allele. This is possible 
based on the coat colour of the offspring. 
 
The 129P2/HsdOla line carries the coat colour alleles A/A and cch/cch, whereas the important 
colour alleles of the C57Bl/6 donors of the blastocysts are a/a and C/C. A stands for agouti and is 
the normal brown wild-type colour of mice, whereas “a” stands for non-agouti, making the mice 
black. In addition, however, the c or C alleles influence the development of the colour determined 
by the a/A alleles. C stands for albino, meaning a c/c mouse will be white, whereas C will 
support whatever colour is determined by A. The allele cch stands for chinchilla and will result in 
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dilution of the colour determined by the A-allele, yielding beige or grey mice. An a/a, C/C mouse 
is a black mouse, such as the C57Bl6. An A/A, cch/cch mouse (donor of the stem cells) shows a 
beige coat (and red eyes). In the chimera, those cells originating from the donor blastocyst are a/a 
C/C, whereas those cells originating from the modified ES cells are A/A cch/cch. The fur coat 
therefore reveals whether offspring is chimeric.  
 
When chimeric males are bred with C57Bl6 or 129P2/HsdOla females, the beige coat colour of 
the offspring will indicate that there was germline transmission of the ES cells injected into the 
blastocysts, independent of the demonstration of the recombinant gene. This is because the male 
chimera can donate either a/C (wild type) or A/cch (derived from the ES cells) sperm cells, while 
a C57Bl6 mother has a/C eggs. After fertilization, the offspring will either be a/a C/C (pure 
C57Bl6), yielding a black and therefore wild-type animal. If the offspring is A/a C/cch, resulting 
in a brown (agouti-coloured) animal, germ line transmission of the ES cell line has taken place.  
 
Coat-colour can be used in a similar way to check for germline transmission in a crossing of male 
chimeras with 129P2/HsdOla mice. Again the male chimera provides sperm cells that are either 
a/C or A/cch, while the female 129P2/HsdOla has A/cch egg cells. Two types of offspring colour 
can be expected: a brown (agouti) animal with the genotype A/a C/cch, showing that the chimera 
donated a wild-type allele, or a cream-coloured, red-eyed animal (like the mother), meaning that 
the chimera donated the colour alleles from the injected ES-cells. Therefore, cream-coloured 
animals are evidence for germline transmission.  
 
Animals with a proper coat colour still need to be genotyped for genetic modification, because 
crossing over may segregate the floxed allele from those conferring coat colours. Nevertheless, 
an animal with a proper coat colour shows that the chimeric male that sired, is a promising 
candidate for offspring carrying the floxed allele. A chimeric mouse that only yields black 
offspring (>20 pubs) should not be used for further breedings. Furthermore, even when brown or 
light-brown offspring are obtained, one might have to analyze several nests before ever getting a 
positive offspring showing germline transmission. For the ASS project, a chimeric male breeding 
with Ola females gave 10 nests with a total of 61 offspring. Although the offspring were 
predominantly brown, the first 52 offspring (first 9 nests) gave no positive animals for the ASS 
construct. We had to wait for the 10th nest to get one mouse positive for the ASS construct.  
 
There are actually more alleles determining coat colour, that these alleles do not play a role here. 
Depending on the ES cell line used, it may be worthwhile to check the genetics beforehand and 
use this information to decide on crossings that yield a 2-fold higher rate of ES-cell derived 
offspring. A comprehensive review of coat colour alleles and their interaction can be found on 
www.jax.org by Willys K. Silvers (1979), The coat Colors of Mice; a model for mammalian gene 
action and interaction. 
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Breeding tissue-specific knockout mice 
The ES cells injected into the blastocysts have one floxed allele and one wild-type allele. The 
chimeras obtained are bred to find offspring that carry the floxed genotype in their germline. This 
mouse is then bred to increase the number of floxed offspring.  It is also crossed with a Cre 
mouse, in which Cre is expressed under control of the EIIa promoter. This promoter is expressed 
at the zygotic stage, i.e. before the germline is set aside, so that we obtain a hemizygous knockout 
mouse (35). This hemizygous knockout will be crossed with hemizygous floxed mice.  
 
It takes at least three generations of mice from the chimera to the genetically modified animal 
(Figure 12). If we first work with a floxed allele and a tissue-specific cre, we will go for a safe 
breeding protocol, meaning that Xflox/flox  mice are crossed with X+/-/Cre+/- mice. The advantage of 
this approach is that Cre has to inactivate only one allele in the tissue of interest, doubling the 
chance that the cells in the tissue of interest do not express the gene X. The disadvantage of this 
approach is that all cells in the body only contain 1 functional allele of gene X and, hence, 
usually only 50% of the normal protein content. If excision proves efficient, we prefer matings 
between Xflox/flox  and Xflox/flox/Cre+/- mice, because all cells in these mice, where Cre is not active, 
contain 2 functional copies of gene X. 
 
Figure 12: Breeding scheme to generate tissue-
specific knockout mice. Chimeras are bred with wild-
type mice to obtain mice with 100% germline 
transmission and with “del-Cre” mice to obtain mice, 
which are heterozygous for the target gene. The 
resulting X+/flox mice (left arm of scheme) are 
interbred to obtain Xflox/flox mice, which can be 
produced with a high efficiency. The heterozygous 
X+/- mice (right arm of scheme) are bred with the 
desired tissue-specific Cre mice to generate X+/-/Cre+/- 
mice. These mice are then crossed with the Xflox/flox 
mice to obtain X-/flox/Cre+/- mice, which have gene X 
deleted in a tissue-specific manner. This scheme is advisable if Cre is suspected to remove the floxed fragment 
inefficiently. However, all cells in the organism have the X+/- genotype. If Cre efficiently removes floxed fragments, 
one can better use mice with a Xflox/flox/Cre+/- genotype, because then the targeted sequence is deleted in the tissue of 
interest only. 
 
Conclusions 
The following are the important factors to be considered from our experience. 
1. Constructing the targeting vector: If using the PCR-based approach to amplify the 
homologous arms from genomic DNA, BAC clones should be used to decrease the 
number of amplications. Furthermore, repeats in the regions to be amplified should be 
avoided as they are very difficult to amplify by PCR. Finally, sequence differences 
between strains should be taken into account when selecting the homologous sequences: 
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they may interfere with the efficiency of the homologous recombination and should not 
be interpreted as mutations.   
2. Selection of the recombinant ES clone: The clone to be injected into blastocysts should 
contain only homologously recombined cells. To achieve this, selected colonies should be 
continuously cultured in presence of the appropriate selection drug to avoid the growth of 
wild-type cells. 
3. Screening against random integration: The “short” PCR method to eliminate the 
randomly integrated clones described in III.a. is an easy, fast and reliable method to 
eliminate randomly integrated clones, if the target DNA is not be located totally at the end 
of the constructs.   
4. Screening for homologous recombination: The “long” PCR procedure to identify and 
characterize recombination events is faster and more informative than Southern blots. A 
draw back is that the primer pair cannot be tested and optimized before the recombinant 
clone is available.    
5. Selection of probes for Southern blotting: Intronic probes have to be checked for the 
presence of repeats. A 300bp probe can suffice for sensitive and specific detection.   
6. Selection with ganciclovir: Ganciclovir causes mutations. It is therefore necessary to 
resequence the clone after the excision of the selection cassette. 
7. Coat colour as a marker for germline transmission: Coat colour as a marker doubles 
the chance to identify a male with proper germline transmission of the floxed allele.     
8. Breeding set-up: The best genotypes to study physiological effects of gene knock out are 
flox/flox and flox/flox-Cre. In all our modified mice (ASS, Arg-1 and CAT-1), we 
obtained very good excision efficiency in vivo of both alleles with cre. It is therefore 
recommended to set up breeding schemes that yield these genotypes.   
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Cloots RH, Sankaranarayanan S, de Theije CC, Poynter ME, Ter-
windt E, van Dijk P, Hakvoort TB, Lamers WH, Köhler SE. Ablation of
Arg1 in hematopoietic cells improves respiratory function of lung paren-
chyma, but not that of larger airways or inflammation in asthmatic mice. Am
J Physiol Lung Cell Mol Physiol 305: L364–L376, 2013. First published July
5, 2013; doi:10.1152/ajplung.00341.2012.—Asthma is a chronic inflam-
matory disease of the small airways, with airway hyperresponsiveness
(AHR) and inflammation as hallmarks. Recent studies suggest a role
for arginase in asthma pathogenesis, possibly because arginine is the
substrate for both arginase and NO synthase and because NO modu-
lates bronchial tone and inflammation. Our objective was to investi-
gate the importance of increased pulmonary arginase 1 expression on
methacholine-induced AHR and lung inflammation in a mouse model
of allergic asthma. Arginase 1 expression in the lung was ablated by
crossing Arg1fl/fl with Tie2Cretg/ mice. Mice were sensitized and
then challenged with ovalbumin. Lung function was measured with
the Flexivent. Adaptive changes in gene expression, chemokine and
cytokine secretion, and lung histology were quantified with quantita-
tive PCR, ELISA, and immunohistochemistry. Arg1 deficiency did
not affect the allergic response in lungs and large-airway resistance,
but it improved peripheral lung function (tissue elastance and resis-
tance) and attenuated adaptive increases in mRNA expression of
arginine-catabolizing enzymes Arg2 and Nos2, arginine transporters
Slc7a1 and Slc7a7, chemokines Ccl2 and Ccl11, cytokines Tnfa and
Ifng, mucus-associated epithelial markers Clca3 and Muc5ac, and
lung content of IL-13 and CCL11. However, expression of Il4, Il5,
Il10, and Il13 mRNA; lung content of IL-4, IL-5, IL-10, TNF-, and
IFN- protein; and lung pathology were not affected. Correlation
analysis showed that Arg1 ablation disturbed the coordinated pulmo-
nary response to ovalbumin challenges, suggesting arginine (metab-
olite) dependence of this response. Arg1 ablation in the lung improved
peripheral lung function and affected arginine metabolism but had
little effect on airway inflammation.
airway hyperresponsiveness; arginine; inflammation
ALLERGIC ASTHMA IS A CHRONIC inflammatory disorder of the lung
that is characterized by a reversible limitation of the airflow
due to an allergic reaction in the airways with the characteris-
tics of a TH2-predominant airway inflammation. The airway
inflammation is initiated by the binding of inhaled allergens to
complementary IgEs on IgE receptor-bearing cells. Upon ac-
tivation, these cells release histamine, cytokines, and proteases,
resulting in the activation of the inflammatory cascade with
lung infiltration of eosinophils and mononuclear cells. In-
creased mucus production, mucosal edema, and a dispropor-
tionate smooth-muscle contraction lead to airway hyperrespon-
siveness (AHR). As a result of the recurring inflammation,
airway remodeling develops as a consequence of fibrosis and
airway wall thickening (2, 3, 6, 36).
Recent studies in animal models and patients revealed a poten-
tial role for the arginine-catabolizing enzyme arginase in the
pathogenesis of asthma (28, 53). Arginase exists as two isoforms,
arginase 1 and arginase 2. The expression of cytoplasmic arginase
1 and mitochondrial arginase 2 is undetectable in healthy mouse
lungs but is strongly upregulated in mouse models of allergic
asthma (50, 59). Arginase 1 is only found in cells with the
morphological characteristics of macrophages that are present in
the inflammatory infiltrates of asthmatic lungs (50, 59). Arginases
catabolize L-arginine to urea and ornithine, but arginine is also the
substrate for nitric oxide (NO) synthesis by NO synthase (NOS).
A deficient NO production represents a key feature of AHR (36),
since NO modulates bronchial and vascular tone by inducing
relaxation of smooth muscle cells. NOS enzymes have a higher
affinity for arginine (Km: 2–20M) than arginases (Km: 1–5 mM),
but the Vmax of arginase is 1,000-fold higher than that of NOS,
which confers the capability for regional substrate depletion of
arginine (56).
The role of arginases in the development and symptoms of
allergic asthma is still incompletely understood. We, therefore,
examined the effects of Arg1 deletion in the lung on methacho-
line-induced AHR and lung inflammation in a mouse model of
asthma. In rodents, extensive arginase 1 expression in the myeloid
lineage of blood cells is confined to macrophages and dendritic
cells (37). For that reason, we generated cell-specific arginase 1
knockouts by flanking exon 4 of Arg1 with loxP sites and crossing
Arg1fl/fl mice with either LysMCretg/ (9) or Tie2Cretg/ mice
(23) to delete Arg1 in myeloid cells (9), or in all hematopoietic
and endothelial cells (47), respectively. We sensitized and then
exposed these mice to ovalbumin to induce allergic asthma (26)
and measured their responsiveness to increasing doses of metha-
choline. The adaptive changes in gene expression, chemokine and
cytokine secretion, and lung histology were quantified. We report
that selective Arg1 ablation improves peripheral lung function,
without affecting lung inflammation.
MATERIALS AND METHODS
Plasmid construction and recombinant ES cell selection. The
mouse Arg1 gene is located on chromosome 10. Since deletion of
exon 4 causes a frame shift, we targeted this exon. The targeting
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vector (17.515 kb; Fig. 1A) consisted of Arg1 exons and introns 2 and
3 (4.6 kb) at the 5= end, a Neo-TK selection cassette flanked by frt
sites (10), exon 4 (160 bp) flanked by loxP sites (46), introns 4–7,
exons 5–8, and a small fragment downstream of the gene (in total 4.3
kb) at the 3= end. The targeting construct was sequence verified with
respect to exons, splice junctions, and recombinase-recognition sites;
digested with AscI (introduced by PCR for cloning purposes); and
purified by electrophoresis and electroelution. Twenty-five micro-
grams of the targeting fragment was electroporated into the mouse ES
cell line E14IB10 (129/Ola). Selection with G418 (200 g/ml) was
started 24 h after electroporation. Vector sequences that were left on
either end of the targeting construct allowed a PCR-based negative
screen against random integrations. Proper recombination of the 3=
end was demonstrated with Southern blotting after Blp1 digestion
(Fig. 1A) and probing with a 300-bp external genomic fragment, and
by long-distance PCR, using AccuTaq (Sigma), an Arg1-specific
primer 3= outside the targeting construct and a loxP-specific primer
(Fig. 1A). Proper recombination of the 5= end was demonstrated by
long-distance PCR, using AccuTaq, a 5= frt-specific primer, and an
Arg1-specific primer 5= outside the targeting construct (Fig. 1A).
Exons and junctions of candidate ES clones were sequence verified by
using those long-PCR products. After a “deep split” to ensure the
presence of recombined ES clones only (the recombined 8.5-kb band
in the initial isolate was much less intense than the endogenous 6.1 kb
band), the Neo-TK cassette was removed by transient transfection
with an FLPe recombinase expression vector (kindly provided by Dr.
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Fig. 1. Construction of Arg1fl/fl mice and validation of Arg1 elimination in lung. A: targeting construct of murine Arg1 gene. The Frt-flanked Neo-TK selection
cassette in intron 3, floxed exon 4, and the positions of relevant restriction enzymes are indicated. Blp1 was used to differentiate the recombined allele (8.5 kb)
from the wild-type allele (6.1 kb; right Southern blot); Sbf1 and SpeI, both introduced during cloning, were used to demonstrate a 1:1 ratio between the
recombined (8.3 kb) and wild-type (13.3 kb) Arg1 alleles in the blastocyst-injected ES cells (left Southern blot). The 3= 300-bp DNA fragment used as Southern
probe is shown as a white box. The products of the 5= and 3= long-distance PCRs (4.65 and 4.27 kb, respectively), used to validate the sequence of the recombined
allele, are shown in between the Southern blots. Note that in the picture of the 5= PCR 3 empty lanes were removed between the marker lane and the lane with
the 5= PCR product. B: reduced arginase 1 protein levels in the lungs of ovalbumin (OVA)/OVA-treated Arg1-KOLysM (n  9) or Arg1-KOTie2 mice (n  9),
open bars, compared with the corresponding Arg1-Con mice (solid bars). C: detail of arginase 1 expression in OVA/OVA-treated Arg1-Con lung. Note absence
of expression in arterial endothelium. A, artery; B, bronchus. Bar: 100 m. D: sections of PBS/OVA- and OVA/OVA-treated lungs of Arg1-Con mice (left 2
panels) and of OVA/OVA-treated Arg1fl/fl/LysMCretg/ (Arg1-KOLysM) and Arg1fl/fl/Tie2Cretg/ (Arg1-KOTie2) mice (right 2 panels) stained immunohisto-
chemically for the presence of arginase 1-positive cells. Note reduction of arginase 1-positive cells in Arg1-KOLysM mice and absence in Arg1-KOTie2 mice.
*P  0.05 OVA/OVA vs. PBS/OVA Arg1-ConLysM/Tie2; #P  0.05 OVA/OVA vs. PBS/OVA Arg1-KOLysM/Tie2; ‡P  0.05 OVA/OVA Arg1-ConLysM/Tie2 vs.
Arg1-KOLysM/Tie2.
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Francis Stewart, Biotechnology Center, TU Dresden, Germany). Se-
lection with ganciclovir (5 M) was started 5 days after electropora-
tion. The recombined allele was again sequence verified [ganciclovir
introduces mutations in 25% of clones (our unpublished observa-
tions)]. Two clones with 40 chromosomes and a 1:1 ratio of wild-type
and recombined Arg1 alleles [tested after digestion with Sbf1 (restric-
tion sites outside targeting construct) and Spe1 (sites present in
targeting construct only) and hybridization with the 300-bp external
genomic fragment] (Fig. 1A) were selected for blastocyst injection.
Generation of transgenic mice and husbandry. All animal experi-
ments were approved by the Committee for Animal Care and Use of
Maastricht University. Arg1-recombinant ES cells were injected into
C57BL/6J blastocysts. Chimeric male mice were bred with female
129P2/OlaHsd mice (Harlan, The Netherlands) and with deleter-Cre
females on a C57BL/6J background (48; kindly provided by Dr.
Ursula Lichtenberg, University of Cologne, Cologne, Germany) to
delete the Arg1 exon 4 in the germ line. Mice were genotyped with
primers Arg1-F1 and Arg1-R1 (Table 1), yielding a 351-bp wild-type
allele and a 384-bp floxed allele. The Cre-excised allele (298 bp) was
detected by PCR with the primers Arg1-F2 (Table 1) and Arg1-R1. To
specifically delete the floxed Arg1 allele (Arg1fl) in macrophages,
mice were crossed with LysMCretg/(9) or Tie2Cretg/ mice (23). The
Tie2Cretg/ and LysMCretg/ mice are available from Jackson Lab-
oratories as B6.Cg-Tg(TekCre)1Ywa/J and B6.129P2-Lyz2tm1(cre)Ifo/J
mice, respectively. The resulting Arg1fl/fl/LysMCretg/ (Arg1-KOLysM) mice
and their Arg1fl/fl/LysMCre/ littermates (Arg1-Con) or Arg1fl/fl/
Tie2Cretg/ (Arg1-KOTie2) mice and Arg1fl/fl/Tie2Cre/ littermates
[Arg1-Con were genotyped for the presence of LysMCre or Tie2Cre
by PCR with primers LysM-F and LysM-R or Tie2-F and Tie2-R
(Table 1)], yielding 300-bp- or 510-bp-positive bands, respectively,
for Cre-positive animals. Arg1-Con and Arg1-KOLysM were 75%
C57BL/6J and 25% 129P2OlaHsd, whereas Arg1-Con and Arg1-
KOTie2 were 50% C57BL/6J, 25% 129P2OlaHsd, and 25% FVB.
Antigen sensitization and challenge. Ten-week-old male Arg1-
KOLysM mice or Arg1-KOTie2 mice, and their Arg1-Con littermates
were injected intraperitoneally on days 0 and 14 with 10 g of
ovalbumin (OVA), grade V (Sigma-Aldrich, Zwijndrecht, The Neth-
erlands) in a total volume of 100 l PBS, containing 1 mg/ml of
AlOH3 (alum) as adjuvant (Imject Alum, Thermo Scientific, Rock-
ford, IL). On days 21–27, mice were exposed daily for 30 min to 1%
(wt/vol) aerosolized OVA in PBS in custom-made inhalation cham-
bers. The experimental groups consisted of two to three mice per
genotype and treatment and the experiments were repeated on at least
three different time points. AHR was assessed 12 h after the last
challenge (41). Lung airway resistance RN, tissue elastance H, and
tissue resistance G in response to inhaled aerosolized methacholine
were measured by use of a Flexivent apparatus (Scireq, Montreal,
Canada).
Airway hyperresponsiveness. Mice were anesthetized with pento-
barbital sodium. A total dose of 120 mg/kg was administered per
mouse. First 80 mg/kg was administered to induce anesthesia and 40
mg/kg 30 min later to maintain anesthesia. An 18-gauge blunt
needle was inserted into the trachea and connected to a mechanical
small animal ventilator (FlexiVent, Scireq, Montreal, Canada). Mice
were ventilated at 200 breaths/min with a delivered tidal volume of
0.25 ml against a positive end-expiratory pressure of 3 cmH2O applied
by a water trap for 10 min before the experiment was started.
Aerosolized methacholine (Sigma, Steinheim, Germany) challenges
were performed by delivering successively 0, 3.1, 12.5, and 50 mg/ml
methacholine in PBS. Following each methacholine challenge, venti-
lation was interrupted every 10 s to allow for 1-s passive expiration
followed by 2-s broad-band (1–19.6 Hz) volume perturbation. The
peak-to-peak excursion of the ventilator piston during delivery of
these perturbations was 0.17 ml, resulting in a delivery of 0.14 ml
after correcting for gas compression in the ventilator cylinder and
connecting tubing. Pressure and flow were recorded during applica-
tion of the perturbations and used to calculate the input impedance
(Zrs) of the respiratory system. Zrs was then fitted to the uniformly
ventilated model of the lung with constant-phase tissue impedance
(12, 16).
Zrs f RN i2fIaw
G iH
2fa
RN is the Newtonian resistance composed mostly of the flow
resistance of the conducting pulmonary airways; Iaw is the inertance of
the gas in the central airways; H, also known as elastance, reflects the
elastic energy stored in the tissues; G, also known as tissue resistance,
reflects viscous dissipation of energy in the respiratory tissues as well
as airflow heterogeneity; f is frequency; i  	1; and  couples G
and H. RN, G, and H all have units of cmH2O·s·ml1. RN and G are
shown as maximal resistance and tissue damping after application of
the methacholine challenge, whereas H is shown as the plateau value
of the elastance following the initial peak response after the metha-
choline challenge.
Plasma collection and analysis. At the end of the experiment,
blood was collected from the inferior caval vein in heparin-coated
tubes, centrifuged for 3 min at 5,000 g, snap frozen in liquid nitrogen,
and stored at 80°C. Plasma OVA-specific IgE levels were deter-
Table 1. Primers pairs used for genotyping and quantitative
PCR
Gene Primer Name Primer Sequence (5=-3=)
Excised arginase-1 Arg1-F2 TCTAGAACTAGTGGATCACCTCAG
Arg1-R1 GTGCCTTGGTCTACATTGAACATAC
Cre CRE-F GGTTCGCAAGAACCTGATGGACAT
CRE-R GCTAGAGCCTGTTTTGCACGTTCA
Tie-2-Cre Tie2-F CGCATAACCAGTGAAACAGCATTGC
Tie2-R CCCTGTGCTCAGACAGAAATGAGA
LysMCre LysM-F GGTTCGCAAGAACCTGATGGACAT
LysM-R GCTAGAGCCTGTTTTGCACGTTCA
Arginase-1 Arg1-F1 GGAGAGCCTTCCTGCACTTT
Arg1-R1 GTGCCTTGGTCTACATTGAACATAC
Arginase-2 Arg2-F CCAGCTGCCATTCGAGAAG
Arg2-R ATCATCTTGTGGGACATTAGTAAACTC
Nos-2 Nos2-F GCCACCAACAATGGCAACA
Nos2-R CGTACCGGATGAGCTGTGAATT
Scl7a1 Cat1-F CTGGTGGACCTCATGTCCATT
Cat1-R GCTCATTCTGATCTACTCGATCTAGCT
Slc7a2b Cat2b-F GATCCATTTTCCCAATGCCTC
Cat2b-R TGGAATTGATTTGAGCTAGACATTTG
Slc7a7 Lat1-F GAAGGACCCCGACCGG
Lat1-R AACAGCCACCAGGAAGATGG
Il4 IL4-F TGGAATGTACCAGGAGCCATATCC
IL4-R CTCTGTGGTGTTCTTCGTTGCTGT
Il13 IL13-F CACACAAGACCAGACTCCCCTG
IL13-R GGTTACAGAGGCCATGCAATATCC
Il5 IL5-F ATCAAACTGTCCGTGGGGGTACT
IL5-R TCTCTCCTCGCCACACTTCTCTTT
Il10 IL10-F GGACAACATACTGCTAACCGACTCCT
IL10-R CTGCTCCACTGCCTTGCTCTTATT
Ccl2 MCP1-F GCTGGAGAGCTACAAGAGGAT
MCP1-R ACAGACCTCTCTCTTGAGCTTGGT
Ccl11 Eotaxin1-F CTGCTGCTCACGGTCACTTCCT
Eotaxin1-R CAGGGTGCATCTGTTGTTGGTG
Ifng IFNG-F GGTTGCTCCTCTTACCGTCTTT
IFNG-R CGTGGCACTTTTTACCACAGA
Tnfa TNFA-F TCAATCGGCCCGACTATCTC
TNFA-R CAGGGCAATTGATCCCAAAGT
Muc5ac MUC5AC-F GATGACTTCCAGACTATCAGTG
MUC5AC-R TGGCGTTAGTCAGCAGA
Clca3 CLCA3-F CCGGCTGCCGCTAAAGAG
CLCA3-R CAGAAGCATCAACAAGACCATTG
18S 18S-F AGTTAGCATGCCAGAGTCTCG
18S-R TGCATGGCCGTTCTTAGTTG
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mined by ELISA (MD Biosciences, M036005, Zürich, Switzerland).
For the determination of plasma amino acids, 50 l of plasma was
added to 4 mg sulfosalicylic acid, vortexed, snap frozen in liquid
nitrogen, and stored at 80°C until use. Plasma amino acid concen-
trations were measured with a fully automated HPLC system (54).
Tissue isolation. Immediately following euthanasia, lungs were
isolated. The left lung was filled with 4% formaldehyde (Klinipath,
Deventer, The Netherlands) for 10 min at a pressure of 20 cmH2O and
submersed overnight in 4% formaldehyde at room temperature (RT)
prior to paraffin embedding. The right lung was snap frozen in liquid
nitrogen and pulverized in a liquid-nitrogen-chilled mortar and pestle.
Tissue powder was stored at 80°C until further use.
Histology and immunohistochemistry. Paraffin-embedded tissue
was cut into 4 m thick sections and stained with hematoxylin &
eosin (H&E), Sirius red (collagen fibers), or ammoniacal silver nitrate
(reticular fibers). For immunostaining, epitopes were retrieved by
heating the slides for 5 min in 10 mM sodium citrate (pH 6) at 95°C
and cooling to RT for 30 min before blocking endogenous peroxidases
with peroxidase block (DAKO, S2001, Enschede, the Netherlands) for
10 min at RT. This step was omitted if antibody binding was
visualized with the alkaline phosphatase (AP) system. Sections were
blocked with 10% normal goat serum for 30 min. After washing in
PBS, slides were incubated with anti-arginase 1 (Amsterdam Liver
Center, AMS40.11.13), anti-arginase 2 (sc-20151Santa Cruz Biotech-
nology, California), anti-myeloperoxidase (MPO; DAKO), or anti-
major basic protein (MBP; kindly provided by Dr. James Lee,
MT14.3.7, Mayo Clinic Scottsdale, AZ) (27). After washing, sections
were incubated with a 1:200 diluted biotinylated rabbit anti-rat sec-
ondary antibody (DAKO) for 45 min at RT. Sections were washed,
incubated with streptavidin/horseradish peroxidase (HRP; Vector) for
30 min at RT and developed with 3,3=-diaminobenzidine (Sigma,
Steinheim, Germany) for 10 min. Sections stained for arginase 1 and
2 were incubated with an AP-labeled secondary antibody (1:200,
Sigma A-3687) for 45 min, developed for 30 min with nitroblue-
tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate (Roche, Alm-
ere, The Netherlands), dissolved in 50 mM MgSO4, 100 mM Tris·HCl
(pH 9.5), and coverslipped with an aqueous mounting medium
(DAKO).
Histological assessment. The H&E-stained slides were used to
identify inflammation in general. Sirius red- and silver nitrate-stained
slides, which visualize collagen and reticular fibers, respectively, were
used to assess tissue remodeling in the lungs of OVA/OVA-treated
mice. MBP-, MPO-, and ARG2-positive cells in full-face sections of
the lung were imaged with a panoramic 3DHISTECH slide scanner
and counted with 3DHISTECH software (3DHISTECH, Budapest,
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Fig. 2. Expression of arginine-metabolizing enzymes and transporters in mouse lungs that are or are not Arg1 deficient. Arg1-Con and Arg1-KOTie2 are
represented by solid and open bars, respectively. Treatment (PBS/OVA or OVA/OVA) is indicated below the bars. The mRNA abundance (AU; number of
mRNA copies normalized for 18S rRNA expression and multiplied by 10,000) of the arginine-metabolizing enzymes Arg1, Arg2, and Nos2 and the arginine
transporters Slc7a1, Slc7a2, and Slc7a7 is shown as means 
 SE of 7–8 mice per group. Amino acid concentrations (M) of arginine, citrulline, and ornithine
are shown as means 
 SE (PBS/OVA-treated Arg1-Con: n  7; Arg1-KOTie2; n  8; OVA/OVA-treated Arg1-Con: n  10; Arg1-KOTie2; n  9). *P  0.05
PBS/OVA vs. OVA/OVA Arg1-Con; †P  0.05 PBS/OVA Arg1-KOTie2 vs. Arg1-Con, #P  0.05 OVA/OVA vs. PBS/OVA Arg1-KOTie2; ‡P  0.05
OVA/OVA Arg1-Con vs. Arg1-KOTie2.
Table 2. Amino acid concentrations in venous plasma of
8-day-old Arg1- KOdelCre
Amino Acid Arg1-Con Arg1-KOdelCre
Glu 115 
 8 210 
 49*
Asn 97 
 3 138 
 33
Ser 361 
 19 327 
 85
Gln 611 
 26 1344 
 279*
His 143 
 7 200 
 24
Gly 417 
 23 326 
 61
Thr 293 
 9 276 
 57
Cit 94 
 3 176 
 12*
Arg 251 
 13 2185 
 295*
Ala 452 
 31 303 
 120
Tyr 190 
 8 211 
 68
Tau 511 
 55 743 
 96
Val 322 
 24 300 
 69
Met 126 
 3 234 
 52
Ile 125 
 11 142 
 26
Phe 106 
 5 82 
 9*
Orn 175 
 16 112 
 30
Leu 191 
 13 206 
 46
Trp 92 
 2 68 
 10*
Lys 833 
 38 404 
 31*
Total amino acids 5,506 
 208 7,987 
 1259
Values are M 
 SE. *P  0.05 Arg1-CondelCre (Arg1/fl/delCre/) vs.
Arg1-KOdelCre (Arg1/fl/delCretg/).
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Hungary). Detection limits were set to count cells positive for di-
aminobenzidine with a diameter between 10 and 15 m. The density
of cells is expressed per mm2.
Milliplex assay. Tissue powder was homogenized in PBS, pH 7.6,
in the presence of a proteinase inhibitor cocktail (Complete, Roche).
Cytokines [CCL11 (a.k.a. eotaxin-1), IL-4, IL-5, IL-10, IL-13,
TNF-, and IFN-] were quantified by using a Luminex xMAP
multiplex platform, combined with a customized Milliplex mouse
chemokine/cytokine panel from Millipore (Billerica, MA).
RNA isolation and quantification. Tissue powder was homogenized
in Tri reagent (Sigma) with the Mini Bead-Beater (Biospec Products,
Bartlesville, OK). To remove genomic DNA, RNA was precipitated
with 2 M LiCl for at least 30 min at 20°C. RNA integrity was
checked by denaturing gel electrophoresis. RNA concentration was
determined with a NanoDrop-ND-1000 spectrophotometer at 260 nm
(Isogen Life Sciences, Wilmington, DE), and 400 ng of total RNA
was transcribed using a first-strand synthesis kit (Roche). Quantitative
PCR was performed in a Lightcycler 480 (Roche), using Lightcycler
480 SYBRgreen Master Mix (Roche) and the following settings:
denaturation 30 s at 95°C, annealing 30 s at 60°C, elongation 30 s at
72°C, 45 cycles, and a final elongation step for 5 min at 72°C. If
reverse transcriptase was omitted, no product was formed. Primary
fluorescent data were exported and analyzed with the Lin-Reg Anal-
ysis program (44). mRNA abundance was expressed relative to 18S
rRNA abundance. Primer sequences are given in Table 1.
Western blot. Tissue powder was homogenized in RIPA buffer [25
mM Tris·HCl (pH 7.6), 150 mM NaCl, 1% Nonidet P-40, 1%
Na-deoxycholate, 0.1% SDS, containing Complete cocktail (Roche)].
Protein concentration was measured with the bicinchoninic-acid assay
(Pierce, Rockford, IL). Twenty-five micrograms protein was separated
on an SDS-polyacrylamide gel, transferred onto 0.45 m nitrocellu-
lose membranes by use of a wet transfer system (Bio-Rad, Hercules,
CA), stained with Ponceau S to confirm equal loading of lanes,
washed with TBS (50 mM Tris, 150 mM NaCl, pH 7.6), and blocked
with 5% skimmed milk in TBS/0.5% Tween-2. Arginase 1 was
visualized with rabbit anti-arginase 1 antibody (1:200), followed by an
HRP-conjugated swine anti-rabbit secondary antibody (DAKO). The
signal was developed using the Super Signal West Pico Substrate
(Pierce) and quantified with the Fuji systems darkbox (Fuji Film Life
Sciences, Tokyo, Japan).
Statistical analyses. Statistical analysis of the groups was per-
formed using the Kruskal-Wallis test for PBS/OVA- vs. OVA/OVA-
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Fig. 3. Arginase 2 expression in mouse lungs
that are or are not Arg1 deficient. A: sections
of PBS/OVA- (top row) and OVA/OVA-
treated (bottom row) lungs of Arg1-Con mice
(left 2 panels) and of Arg1-KOTie2 mice (right
2 panels) stained immunohistochemically for
the presence of arginase 2-positive cells. Main
panels, 10 objective; insets, 40 objective.
Note the increase of arginase 2-positive cells
in OVA/OVA-treated mice without difference
between Arg1-Con and Arg1-KOTie2 mice.
Bar: 200 m. B: quantification of arginase
2-positive cells per mm2 lung tissue in PBS/
OVA- and OVA/OVA-treated Arg1-Con
(solid bars) and Arg1-KOTie2 mice (open
bars). Sections were stained simultaneously.
Values are shown as means 
 SE (PBS/
OVA-treated Arg1-Con: n  7; Arg1-KOTie2;
n  8; OVA/OVA-treated Arg1-Con: n  10;
Arg1-KOTie2; n 9). *P 0.05 PBS/OVA vs.
OVA/OVA Arg1-Con; #P  0.05 OVA/OVA
vs. PBS/OVA Arg1-KOTie2.
L368 ALLERGIC ASTHMA IN MICE WITH ARG1-DEFICIENT LUNGS
AJP-Lung Cell Mol Physiol • doi:10.1152/ajplung.00341.2012 • www.ajplung.org

treated, and Arg1-Con vs. Arg1-KO mice. Only if this nonparametric
test indicated the presence of a difference among experimental groups,
a multiple comparison of the groups was carried out. Values were
considered statistical significant if P  0.05, and as indicating a trend
if P  0.1.
Pearson’s bivariate two-tailed correlation coefficients between each
of the lung function parameters, mRNA and protein concentrations,
histology scores, and plasma amino-acid concentrations were deter-
mined after combining the data from the comparable PBS/OVA and
OVA/OVA groups. In Fig. 9, P values of the resulting correlation
coefficients were color coded, with red indicating a P 0.001, orange
0.01  P  0.001, and yellow 0.05  P  0.01.
RESULTS
Generation of conditionally Arg1-deficient mice. We flanked
exon 4 with loxP sites to create a conditionally Arg1-deficient
mouse. When these Arg1fl/fl mice were crossed with deleter-
Cre females (48) to delete exon 4 in the germ line, the resulting
Arg1/ mice died between postnatal days 10 and 14, as
reported for constitutive Arg1-deficient mice (20). At postnatal
day 8, plasma levels of arginine and glutamine were approxi-
mately nine- and approximately twofold higher, respectively,
whereas lysine levels were decreased to 50% in Arg1/
(Arg1-KODelCre) compared with Arg1/fl (wild-type) mice
(Table 2). Although these changes, with the exception of the
increased plasma arginine concentration, differ from those
reported for Arg1-deficient mice in the moribund phase (20),
the data show unambiguously that excision of the floxed exon
4 results in a nonfunctional Arg1 allele.
Arginase expression in the lungs of asthmatic Arg1-Con and
Arg1-KO mice. Half of the Arg1-KOLysM or Arg1-KOTie2 mice
and their Arg1-Con littermates were sensitized and then chal-
lenged with ovalbumin (OVA/OVA). The other 50% of the
mice were only challenged with ovalbumin (PBS/OVA). In
lungs of OVA/OVA-treated Arg1-Con mice, numerous peri-
bronchiolar, parenchymal, and perivenous arginase 1-positive
cells were found, whereas lungs of similarly treated Arg1-
KOLysM mice showed fewer peribronchiolar ARG1-positive
cells, while no ARG1-positive cells were found in lungs of
OVA/OVA-treated Arg1-KOTie2 mice (Fig. 1D). Arginase 1
mRNA and protein were hardly detectable in the lungs of mice
undergoing the PBS/OVA protocol, whereas a robust increase
of arginase 1 mRNA and protein was found in the lungs of
OVA/OVA-treated Arg1-Con mice (Figs. 1B and 2). The lungs
of Arg1-KOLysM OVA/OVA mice contained residual arginase
1 mRNA and protein, but the expression of arginase 1 in the
lungs of Arg1-KOTie2 OVA/OVA mice did not exceed that
seen in PBS/OVA mice (Figs. 1B and 2). Quantification
showed that arginase 1 mRNA and protein concentrations in
Arg1-KOLysM OVA/OVA lungs were reduced to 40 
 7 and
32 
 8%, respectively, of that found in Arg1-Con OVA/OVA
mice, and in Arg1-KOTie2 OVA/OVA mice to 4 
 2 and 2 

0.2%, respectively, of that found in Arg1-Con OVA/OVA
mice. Of note, we did not observe ARG1-positive endothelial
cells in PBS/OVA or OVA/OVA-treated lung arteries (Fig.
1C). Since the cell type specificity of the LysM-Cre and
Tie2-Cre overlap with respect to Arg1-expressing cells, we
conclude from these findings that the Arg1 allele was virtually
completely deleted in the lungs of Arg1-KOTie2 mice, includ-
ing their macrophages, but incompletely in Arg1-KOLysM
mice. Since the phenotype of Arg1-KOLysM mice was minimal,
we limited the description of our study to Arg1-KOTie2 mice
and their Arg1-Con littermates.
Effect of Arg1 ablation on arginine-metabolizing and -trans-
porting genes in lung and on circulating amino acids. We next
investigated to what extent Arg1 ablation caused adaptive
changes in the expression of arginine-metabolizing or -trans-
porting proteins (Fig. 2). Compared with PBS/OVA treatment,
OVA/OVA induced increases in expression of Arg1, Arg2,
Nos2, and Slc7a2 mRNA in the lungs of Arg1-Con mice,
whereas the expression of Slc7a1 and Slc7a7 was not changed.
In contrast, OVA/OVA treatment failed to induce an increase
in expression of Arg1, Arg2, Nos2, and Slc7a2, and decreased
that of Slc7a1 and Slc7a7 in Arg1-KOTie2 mice. Furthermore,
we evaluated the expression pattern of arginase 2 protein in
sections of PBS/OVA and OVA/OVA-treated Arg1-Con and
Arg1-KOTie2 mice (Fig. 3). As expected (59) arginase 2-posi-
tive cells with the morphology of macrophages accumulated in
the lungs of OVA/OVA-treated mice. Quantification revealed a
small increase in the number of ARG2-positive cells after
OVA/OVA treatment, compared with PBS/OVA treatment, but
no difference was detected between Arg1-Con and Arg1-
KOTie2 mice.
Relative to PBS/OVA, OVA/OVA treatment caused a de-
crease in the concentration of circulating arginine and citrulline
(Fig. 2), and asparagine, serine, histidine, glycine, tyrosine, and
methionine (Table 3) in Arg1-KOTie2 mice, whereas that of
glutamate increased. When OVA/OVA-treated Arg1-Con and
Arg1-KOTie2 mice were compared, the latter had lower con-
centrations of glycine, citrulline, and isoleucine (Table 3).
Arg1 ablation improves peripheral lung function in OVA/
OVA-treated mice. To determine whether Arg1 ablation has an
effect on respiratory mechanics, we measured responsiveness
Table 3. Amino-acid concentrations in venous plasma of
Arg1-Con and Arg1-KOTie2 mice
Arg1-Con Arg1-KOTie2 Arg1-Con Arg1-KOTie2
Amino Acid PBS/OVA PBS/OVA OVA/OVA OVA/OVA
Glu 15 
 2 13 
 2 28 
 1* 26 
 2†
Asn 39 
 3 38 
 3 30 
 2 26 
 2†
Ser 136 
 31 118 
 22 87 
 13 52 
 5†
Gln 834 
 48 822 
 25 823 
 46 752 
 67
His 110 
 6 107 
 5 96 
 5 84 
 3†
Gly 297 
 63 279 
 30 199 
 9 155 
 7†§
Thr 131 
 6 121 
 6 125 
 8 112 
 5
Cit 75 
 2 68 
 3 71 
 6 57 
 3§
Arg 102 
 4 95 
 5 85 
 6 76 
 6†
Ala 750 
 59 702 
 31 686 
 17 604 
 51
Tyr 174 
 5 179 
 11 161 
 10 134 
 9†
Tau 189 
 13 184 
 13 166 
 12 144 
 12
Val 262 
 13 219 
 9‡ 256 
 14 218 
 9
Met 51 
 2 50 
 2 46 
 3 40 
 2†
Ile 142 
 9 114 
 6‡ 136 
 9 111 
 5§
Phe 32 
 3 28 
 2 31 
 1 25 
 2
Orn 49 
 9 34 
 6 49 
 5 38 
 5
Leu 184 
 11 154 
 8 178 
 12 153 
 7
Trp 235 
 10 229 
 10 219 
 10 214 
 9
Lys 417 
 14 397 
 16 383 
 21 347 
 26
Total amino acids 4,233 
 264 3,959 
 154 3,865 
 107 3,379 
 169
Values are M 
 SE. Arg1-KOTie2, Arg1fl/fl/Tie2Cretg/ mice; Arg1-Con,
their Arg1fl/fl/Tie2Cre/ littermates. *P  0.05 PBS/OVA vs. OVA/OVA
Arg1-Con; †P  0.05 PBS/OVA vs. OVA/OVA Arg1- KOTie2; ‡P  0.05
Arg1-Con vs. Arg1-ConTie2 PBS/OVA; §P  0.05 Arg1-Con vs. Arg1-
ConTie2 OVA/OVA.
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to inhaled methacholine (Fig. 4). Compared with PBS/OVA,
OVA/OVA treatment of Arg1-KOTie2 and Arg1-Con mice
resulted in an increase in RN upon exposure to methacholine
(P  0.04), albeit without difference between the Arg1-KOTie2
and Arg1-Con mice. H, which was higher in OVA/OVA- than
in PBS/OVA-treated Arg1-Con mice, was attenuated in OVA/
OVA-treated Arg1-KOTie2 mice (P 0.0009). Compared with
PBS/OVA, OVA/OVA treatment also increased G in Arg1-
Con and Arg1-KOTie2 mice upon exposure to methacholine,
but the response in Arg1-KOTie2 mice was significantly
lower (P  0.001) than in Arg1-Con mice. In aggregate,
these findings show that the absence of arginase 1 in the
lung does not affect RN but does affect H and G, which
reflect properties of the lung parenchyma rather than of the
larger airways (12, 16).
Arg1 ablation affects levels of mRNA and selected proteins
of inflammatory genes in lung. We next investigated whether
Arg1 ablation in the lung had an effect on the expression of
asthma-associated cytokines (Fig. 5). As expected, OVA/OVA
treatment resulted in an increased abundance of Il4, Il13, Il5,
Ccl11, Ccl2, and Il10 mRNAs in Arg1-Con mice. The OVA/
OVA-induced increase in Ccl11 expression was markedly
reduced in Arg1-KOTie2 mice. Furthermore, the expression of
the inflammatory markers Tnfa and Ifng was strongly sup-
pressed. The expression of the respiratory epithelium-specific
Muc5ac and Clca3 genes was increased upon OVA/OVA
treatment in both Arg1-Con and Arg1-KO animals, but the
response was markedly attenuated in Arg1-KOTie2 mice, in
particular with respect to Clca3.
To investigate whether Arg1 deletion in the lung also af-
fected the pulmonary protein concentration of cytokines and
chemokines, we performed ELISAs for IL-4, IL-13, IL-5,
CCL11 (eotaxin-1), IL-10, TNF-, and IFN- on whole lung
extracts (Fig. 6). Except for IL-10 and IFN-, the pulmonary
concentration of these proteins increased after OVA/OVA
treatment, but the increase in IL-13 and CCL11 concentration
was significantly lower in Arg1-KOTie2 than in Arg1-Con
mice. These data show that the production of most asthma-
associated cytokines proceeded independently of Arg1 defi-
ciency in the lung.
Effect of Arg1 deletion on the production of OVA-specific
IgE. OVA-specific IgE was undetectable in plasma of PBS/
OVA-treated mice but increased to easily detectable concen-
trations after OVA/OVA treatment in both wild-type and
knockout mice, without significant differences between ani-
mals with or without Arg1 ablation (Fig. 6). Apparently,
ablation of Arg1 in Arg1-KOTie2 mice did not affect the
adaptive immune response to ovalbumin.
Effects of Arg1 deletion on tissue inflammation. Finally, we
investigated whether Arg1 ablation in the lung modified the
allergic asthma-induced inflammatory response of the lung
(Fig. 7). We did not observe any inflammatory cells in H&E-
or ARG1-stained lung sections of PBS/OVA-treated mice (Fig.
7A, top row, and Fig. 1D). Furthermore, there were no cells
that contained MBP and MPO, which are markers for eosino-
phils and neutrophils, respectively (Fig. 7A, middle and bottom
rows). In lungs of OVA/OVA-treated mice, on the other hand,
many inflammatory cells were present, without discernible
differences between Arg1-KOTie2 mice and their Arg1-Con
littermates. In lung sections stained for Sirius red and reticulin
we found no differences between the OVA/OVA-treated Arg1-
Con and Arg1-KOTie2 mice in the amount of stained fibers
(Fig. 8). We quantified the number of MBP- and MPO-positive
cells, and did not find differences between Arg1-KOTie2 mice
and their Arg1-Con littermates either (Fig. 7B). Furthermore,
lung sections stained for the presence of collagen and reticular
fibers showed a similar degree of remodeling upon OVA/OVA
treatment between Arg1-Con and Arg1-KOTie2 mice (Fig. 8).
Apparently, Arg1 ablation in the lung does not affect the
infiltration of inflammatory cells or tissue remodeling in re-
sponse to experimental asthma, nor does it induce or reduce
remodeling effects.
Comparison of the adaptive responses of Arg1-Con and
Arg1-KOTie2 mice. To answer the question whether arginase 1
activity exerted a coherent influence on the adaptive responses
to asthma, we also investigated the correlation coefficients
between each of the lung-function parameters, mRNA and
protein concentrations, histology scores and plasma amino-
acid concentrations (Fig. 9). In Arg1-Con mice, lung function
parameters H and G corresponded well mutually and with IL-5,
IL-13, and CCL11. Except for Slc7a7, Slc7a1, Tnfa, and Ifng
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mRNAs, mRNA concentrations correlated very well mutually
and with the corresponding proteins (including ARG1). Tissue
concentrations of IL-4, IL-13, IL-5, CCL11, and TNF- cor-
related mutually. Finally, it should be mentioned that IL-10,
IFN-, and OVA-specific IgE did not correlate tightly with any
of the other markers investigated. In aggregate, these data show
that H, Slc7a2b, Arg1, Nos2, Il4, Il13, Il5, Ccl11, Il10, Ccl2,
Muc5ac, and Clc3a mRNA, ARG1, IL-4, IL-13, IL-5, CCL11,
and TNF- protein are sensitive parameters to assess quanti-
tative differences in the allergic pulmonary response to OVA.
The best overall cross-correspondence was seen for H, Il4,
Il13, and Il5 mRNA, IL-13, IL-5, CCL11, and TNF- protein.
Striking were the weak cross-correspondences of these param-
eters with RN and mRNAs coding for arginine-metabolizing
and transporting proteins, Furthermore, only the density of
MBP-positive cells in the lung correlated weakly with lung
function and gene expression, whereas virtually no correlation
was found for MPO-positive cells.
Relative to Arg1-Con mice, Arg1-KOTie2 mice showed a
pronounced general loss of correspondence of OVA/OVA-
sensitive parameters (Fig. 9). A few correlations became stron-
ger, such as that of H with Nos2 mRNA, IL-4 protein, and
plasma citrulline concentrations and that of Arg1 mRNA with
IL-4, IL-5, CCL11, and TNF- protein concentrations. In
aggregate, the data show that the near complete elimination of
Arg1 expression from the lung disturbed the coordinated pul-
monary response to OVA/OVA treatment, that is, showed that
some aspect of arginine metabolism coordinated this response.
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DISCUSSION
We generated mice in which exon 4 of the Arg1 gene was
floxed and effectively ablated arginase 1 expression in the lung
by crossing them with Tie2Cre mice. Ablation of Arg1 in
hematopoietic and endothelial cells did not affect OVA sensi-
tization, as reflected in a similar increase in OVA-specific IgE
in plasma of Arg1-Con and Arg1-KO mice. OVA sensitization
and challenge of Arg1-KO mice did not affect RN but attenu-
ated H and G, indicating that Arg1 ablation mainly affected the
lung parenchyma. Furthermore, it reduced the mRNA abun-
dance of Arg2, Slc7a1, Slc7a7, Ccl11, Tnfa and Clca3 in
OVA/OVA-treated mice. Correlation analysis revealed that
Arg1 ablation in the lung disturbed the coordinated pulmonary
response to OVA/OVA treatment and made it more dependent
on adaptive changes in arginine metabolism.
All our experiments were carried out in mice constructed in
the 129Sv strain and backcrossed to the C57BL/6J strain. Since
allergic asthma is considered a TH2-dominated immune disor-
der, it is sometimes argued that the TH1-responsive C57BL/6J
mouse strain is less suitable to OVA sensitization and challenges
than e.g., the TH2-responsive BALB/c mouse strain. However,
(nearly) all genetically modified mice are bred in the C57BL/6J
strain. To avoid undue influence of the genetic background of the
mice, we used Arg1fl/fl/Tie2Cre/ littermates of Arg1fl/fl/
Tie2Cretg/ mice as reference throughout the study.
Macrophages are the main myeloid-derived cells that express
arginase upon induction by TH2 cytokines in rodents (37). Be-
cause no macrophage-selective Cre line exists, we used both
LysMCre (9) and Tie2Cre (23) mice to bring about Arg1 ablation
in macrophages. Whereas the expression of LysMCre is confined
to macrophages and granulocytes (9), that of Tie2Cre includes all
hematopoietic and endothelial cells (47). However, we found that
the endothelium of lung arteries does not contain arginase 1,
whereas, to the best of our knowledge, murine lymphocytes also
do not express arginase. Furthermore, Tie2Cre-mediated ablation
is usually complete (15, 23, 25, 47), whereas LysMCre-mediated
ablation is notably less effective, with target excision in 50–80%
of the target cells (9, 14, 21, 58). In agreement with these earlier
findings, we observed a much smaller reduction of arginase 1
protein in the lungs of OVA/OVA-treated Arg1-KOLysM mice (to
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30%) than in the lungs of similarly treated Arg1-KOTie2 mice or
in thioglycollate-elicited peritoneal macrophages of these mice
(53) (to 2%). Of interest, a recent study (9a) identified the
ARG1-positive macrophages as CD11bGr1F4/80Ly-
6CLy-6G myeloid-derived suppressor cells and ascribed to
them, together with the CD11bGr1F4/80Ly-6CLy-6G
monocytoid cells, which mainly produce NO, a key coordinating
role in the manifestation of allergic asthma. The expression of
arginase 1 in cells that resemble lung macrophages and the
near-complete elimination of Arg1 expression from the lung and
from peritoneal macrophages in Arg1-KOTie2 mice, therefore,
shows that we did target arginase 1 expression in macrophages
and that the present study allows conclusions with respect to the
role of arginase 1 in allergic asthma of mice. Since the described
phenotype was only observed in the Tie2 line, Arg1 deletion in
macrophages apparently had to be near complete to mediate
pronounced effects.
Arg1 ablation affects the expression of genes coding for
arginine-metabolizing and -transporting proteins. The genetic
elimination of Arg1 in macrophages of OVA/OVA-treated mice
decreased the expression of Arg2, Slc7a1 (Cat1), and Slc7a7
(Lat1) mRNAs. These effects point to an arginase 1-dependent,
and, hence, probably an arginine concentration-dependent decline
in expression of genes involved in arginine transport and metab-
olism. The OVA/OVA-mediated increase in pulmonary arginase
activity is reported to reduce parenchymal arginine content ap-
proximately twofold (22), but did not prevent an approximately
twofold increase in NO production (4).
Effect of Arg1 ablation on lung mechanics. RN in the large
airways of OVA/OVA-treated Arg1-deficient mice was not
different from that in similarly treated animals without the
deletion, but H and G were markedly lower in the Arg-KOTie2
mice. H and G primarily reflect peripheral lung function (1)
and may, in allergic asthma, reflect “closure” of peripheral
airways by mucous bridges (30, 31, 55). In agreement, the
mRNA abundance of Clca3 (Gob5), which regulates mucus
production, and the mucin Muc5ac were lower in OVA/OVA-
treated Arg1-KOTie2 than Arg1-Con mice. Overexpression of
Clca3 exacerbates AHR in OVA/OVA-treated mice, whereas
downregulation attenuates peak airway pressure (resistance)
after methacholine (29, 38), strongly suggesting a role for this
gene in the development of peripheral responsiveness. On the
basis of our observations in sections stained for the presence of
collagen and reticular fibers, the improved peripheral lung func-
tion could not be caused by less remodeling in OVA/OVA-treated
Arg1-KOTie2 mice compared with Arg1-Con mice.
The effects of arginase 1 activity on the biomechanics of
asthmatic lungs were also studied pharmacologically. Inhibitors of
arginase activity decreased airway resistance in OVA/OVA-
treated guinea pigs (33, 34) and mice, but did not change (19, 40)
or even increased (7) H and G in mice. These pharmacological
findings differ from the present findings in a genetic model and
suggest that systemic and, in our case, macrophage-specific sup-
pression of arginase activity has different effects. In fact, the
presence or absence of arginase 1 in lung macrophages seems to
be more important than its concentration, because the strong
increase in Arg1 and Arg2 expression that was observed in
OVA/OVA-treated Nos2-deficient mice compared with control
(C57BL/6) mice (4) did not affect AHR (and eosinophil influx)
(42). On the basis of our findings in an OVA/OVA-treated
arginine-deficient mouse model (our unpublished observations),
we speculate that changes in the circulating concentration of
arginine primarily affect the function of the larger airways,
whereas the local presence or absence of arginase 1 primarily
affects the function of the peripheral airways. This explanation
Fig. 8. Lung sections of OVA/OVA-treated
mice stained for the presence of reticular and
collagen fibers, and NOS2. Serial sections of
Arg1-KO (A–C) and Arg1-Con mice (D–F)
were stained with silver nitrate (reticular
fibers; A and D), Sirius red (collagen fibers;
B and E), or NOS2 (C and F). Note presence
of additional reticular and collagen fibers in
the cuff around main bronchi (b1) and arter-
ies of OVA/OVA-treated mice, but the ab-
sence of such fibers around these structures
in the parenchyma (b2). NOS2 was only
found in the epithelium of bronchi that were
not enveloped in connective-tissue sheaths.
ap, Pulmonary artery; v, pulmonary vein.
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would accommodate the observed differences between the phar-
macological and genetic interventions.
Effect of Arg1 ablation in the lung on pulmonary inflammation.
The allergic response to OVA challenge is at least partly
mediated by OVA-specific IgE (49). Unexpectedly, therefore,
circulating anti-OVA IgE concentrations did not correlate with
any other parameter of allergic asthma (Fig. 9). OVA/OVA
treatment resulted in a pan-pulmonary cellular inflammation in
all mice, with participation of both eosinophils (MBP) and
neutrophils (MPO). The relatively low number neutrophils
relative to eosinophils in the lung of OVA/OVA-treated mice
can be ascribed to our treatment protocol, as neutrophils
preferentially infiltrate the lung shortly after a challenge (24
h) and eosinophils later (43). For the same reason, our rela-
tively extended challenge protocol (6 consecutive days) prob-
ably accounts for the observation that only the number of
eosinophils corresponded with the functional and biochemical
sequels of OVA/OVA treatment (Fig. 9). One or more of the
inflammatory cell types produced and induced an increased
expression of mRNAs of cytokines and chemokines that are
involved in TH2 responses (Il4, Il13, Il5, Ccl11), macrophage
function (Ccl2, Il10), and mucus production in the respiratory
epithelium (Muc5ac, Clca3). The expression of Muc5ac and
Clca3 correlated well with the expression of genes coding for
arginine-metabolizing and -transporting proteins in Arg1-Con
mice, but this coordination was largely lost in Arg1-KOTie2
mice, implying that cellular arginine concentration plays a role in
their expression. In contrast, the abundance of Il4, Il13, Il5, Ccl2,
and Ccl11 mRNA remained coordinated irrespective of the pres-
ence or absence of Arg1, implying no or a limited role of arginase
1. Arg1 deficiency in OVA/OVA-treated mice led to reduced
Ccl11, Tnfa and Clca3 expression and CCL11 protein accumula-
tion. The lower CCL11 (eotaxin-1) content, however, did not
result in the recruitment (13) of fewer eosinophils to the lungs.
Furthermore, the pulmonary content of IL-13, a cytokine associ-
ated with AHR induction (35), was reduced.
Posttranscriptional regulation of genes in OVA/OVA-treated
mice. For arginase 1, IL-4, IL-13, IL-5, IL-10, CCL11, TNF-,
and IFN-, we measured both mRNA and protein concentra-
tions in lung homogenates. Correlations varying from reason-
able (P  0.05) to good (P  0.01) were found between
mRNA and protein levels in Arg1-Con animals for IL-4, IL-13,
IL-5, and CCL11 (Fig. 9), but in Arg1-KOTie2 mice, only
mRNA and protein concentrations of IL-5 and CCL11 still
correlated. Posttranscriptional control is well established for
the expression of cytokines (8), but we were not aware of such
extensive posttranscriptional regulation of Arg1 expression.
Because we wanted to study the coordinated pulmonary re-
sponse to ovalbumin sensitization and challenges in the pres-
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IL10 .552 .471 .124 .192 .162 .199 .234 .243 .122 -.346 -.294 -.014 -.174 -.112 .041 .352 -.037 .320 .091 .059 -.095 .008 .668 .080 -.114 -.184 .372 -.186 -.585 .670 .647 -.034 .245 .561 1 .458 -.398 .259 .435 -.110 -.213 -.181 -.004
IFNγ -.006 .429 .148 -.032 -.356 -.397 -.253 -.259 -.511 -.227 -.064 -.005 -.272 .197 -.396 -.172 -.392 -.322 -.189 -.157 -.304 -.240 .158 -.091 .078 .125 .542 -.005 -.478 -.042 .229 -.098 -.005 .010 .294 1 -.305 -.010 .317 .118 -.032 .352 .188
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MBP .713 .744 .731 .743 .523 .645 .617 .728 .282 .545 .622 .663 -.193 .140 .507 .578 .507 .631 .555 .559 .453 .534 .029 .722 .523 .580 -.489 -.392 .797 .497 .625 .551 .657 .753 .138 .039 -.445 1 .760 -.439 .047 .297 -.141
MPO .593 .789 .583 .490 .043 .028 .079 .136 -.140 .188 .288 .057 -.516 -.427 -.430 -.131 -.377 -.222 -.121 -.179 -.375 -.321 -.237 -.033 -.097 .162 -.385 -.514 .087 .119 .540 -.169 .033 .299 .422 .526 .050 .623 1 -.405 .050 .173 -.182
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[Cit] -.587 -.780 -.697 -.689 -.568 -.531 -.688 -.683 -.291 -.260 -.526 -.584 -.157 -.501 -.257 -.440 -.389 -.522 -.147 -.238 -.109 -.271 -.381 -.296 -.144 -.123 -.047 -.191 -.195 -.583 -.164 -.184 -.445 -.580 -.383 -.550 -.420 -.759 -.531 .648 1 -.015 .187
[Orn] -.054 -.180 .180 -.036 -.357 -.169 -.191 -.081 -.174 .015 .069 .056 -.371 -.521 -.289 -.256 -.345 -.077 -.127 -.193 -.307 -.285 -.362 -.013 -.364 -.199 -.327 -.452 .768 -.266 -.050 -.191 -.161 -.158 -.300 -.239 -.488 .416 .268 .032 .313 1 .661
Σ[AA] -.651 -.586 -.632 -.734 -.628 -.691 -.755 -.735 -.414 -.209 -.487 -.469 -.161 -.224 -.259 -.574 -.315 -.677 -.349 -.393 -.299 -.425 -.534 -.509 -.416 -.316 -.060 -.059 .016 -.657 -.435 -.340 -.581 -.749 -.529 -.310 -.403 -.623 -.503 .492 .807 .342 1
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Fig. 9. Correlation of lung function, abundance of pulmonary mRNAs and proteins, pulmonary histopathology, and concentrations of plasma amino acids in mice
with lungs that are or are not Arg1 deficient. Top right triangle refers to data obtained in Arg1-Con mice and bottom left triangle to data from Arg1-KOTie2 mice.
Numbers show the correlation coefficients between parameters indicated above and to the left of the columns and rows, respectively, as measured in all 15 or
16 mice of the Arg1-Con or Arg1-KOTie2 genotype studied, that is, both the PBS/OVA- and the OVA/OVA-treated groups. The significance of the correlations
is color coded according to the P value of the correlation coefficient: yellow 0.05  P  0.01, orange 0.01  P  0.001, and red P  0.001. Note the decline
of the number or degree of significant correlations in Arg1-KOTie2 compared with Arg1-Con mice, in particular with respect to lung function and abundance of
pulmonary mRNAs and proteins.
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ence or absence of arginase 1 enzyme activity, we have only
determined changes in mRNA levels.
Comparison with other animal models with macrophage-
specific Arg1 deletion. Recently, the effects of macrophage-
specific Arg1 deficiency on lung function and inflammation
were studied in OVA/OVA-treated wild-type mice after bone
marrow transplantation with constitutively Arg1-deficient cells
(39), a procedure that also involves Arg1 elimination in all
bone marrow-derived cells. Comparable to our results, infil-
tration of the lungs with eosinophils and neutrophils was
similar in mice with or without Arg1 ablation in hematopoietic
cells. Lung function was assessed with the airway pressure-
time index, which is less sensitive to changes in peripheral lung
function (45) and may explain why no differences in lung
function were found in that study (39).
The effects of arginase 1 activity on the biomechanics of
asthmatic lungs were also studied with RNA interference and
administration of arginase inhibitors. Inhibition of Arg1 expres-
sion by instilling anti-Arg1 shRNA in the trachea of mice atten-
uated IL-13-induced airway resistance (Raw) (57), whereas we
found that genetic ablation did not have this effect. The discrep-
ancy may be caused by the amount of rIL13 instilled into the lung
(10 g), which exceeds the content of IL-13 in OVA/OVA-
treated lungs (100 pg/mg lung protein) by three orders of
magnitude. Pharmacological inhibition of arginase activity de-
creased RN in OVA/OVA-treated guinea pigs (32, 34) and mice
(19, 40) but did not change H or G, although one mouse study
found no change RN and an increase in H and G (7).
Both Nos1- and Nos3-deficient mice suffer from a more pro-
nounced AHR than wild-type mice (17, 18), whereas in Nos3-
overexpressing mice, allergen-induced AHR to methacholine is
completely abolished (11, 51), indicating a prime role for NO in
airway relaxation. In agreement, inhibition of arginase activity in
OVA/OVA-treated Nos2/ mice did not induce AHR, suggest-
ing that NOS1 and -3 used the increased tissue arginine levels to
produce more NO and relax the smooth muscles of the larger
airways (42). Similarly, inhibition of NOS2 almost completely
abolished OVA/OVA-induced AHR in BALB/c mice (24). Since
Nos2 overexpression also decreases airway resistance (Raw)
(17a), the source of NO is apparently less important.
The use of strong arginase inhibitors like nor-NOHA in-
crease tissue arginine levels and corresponding decreases in
AHR and eosinophil influx in C57BL/6 mice (5, 39). In another
series of experiments with arginine- rather than Arg1-deficient
mice (our unpublished observations), we found that circulating
arginine concentrations primarily affected RN in the larger
airways. We, therefore, hypothesize that ablation of Arg1 in
lung macrophages increases the parenchymal arginine concen-
tration, which, in turn, facilitates NO production and smooth-
muscle relaxation in the peripheral airways, but not the larger
conducting airways.
Conclusion. Ablation of Arg1 in macrophages leads to an
improvement of peripheral lung function in OVA/OVA-treated
Arg1-KOTie2 mice, without altering air hyperreactivity and
lung inflammation.
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Abstract
Background: Milk contains too little arginine for normal growth, but its precursors proline and
glutamine are abundant; the small intestine of rodents and piglets produces arginine from proline
during the suckling period; and parenterally fed premature human neonates frequently suffer from
hypoargininemia. These findings raise the question whether the neonatal human small intestine also
expresses the enzymes that enable the synthesis of arginine from proline and/or glutamine.
Carbamoylphosphate synthetase (CPS), ornithine aminotransferase (OAT), argininosuccinate synthetase
(ASS), arginase-1 (ARG1), arginase-2 (ARG2), and nitric-oxide synthase (NOS) were visualized by
semiquantitative immunohistochemistry in 89 small-intestinal specimens.
Results: Between 23 weeks of gestation and 3 years after birth, CPS- and ASS-protein content in
enterocytes was high and then declined to reach adult levels at 5 years. OAT levels declined more
gradually, whereas ARG-1 was not expressed. ARG-2 expression increased neonatally to adult
levels. Neurons in the enteric plexus strongly expressed ASS, OAT, NOS1 and ARG2, while
varicose nerve fibers in the circular layer of the muscularis propria stained for ASS and NOS1 only.
The endothelium of small arterioles expressed ASS and NOS3, while their smooth-muscle layer
expressed OAT and ARG2.
Conclusion: The human small intestine acquires the potential to produce arginine well before
fetuses become viable outside the uterus. The perinatal human intestine therefore resembles that
of rodents and pigs. Enteral ASS behaves as a typical suckling enzyme because its expression all but
disappears in the putative weaning period of human infants.
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Background
Arginine is a precursor for the synthesis of proteins, creat-
ine, agmatine, and nitric oxide (NO). It further plays an
essential role in ammonia and bicarbonate detoxification,
and stimulates the secretion of growth hormone, prolac-
tin, insulin, and glucagon. Arginine is also a 'condition-
ally essential' amino acid, meaning that endogenous
arginine production covers metabolic requirements in
healthy, unstressed individuals, but becomes an essential
amino acid under conditions of increased need, e.g.
growth or tissue repair, or in catabolic states such as sepsis
and starvation.
In the adult, endogenous arginine biosynthesis is an inter-
organ 'affair': the net production of citrulline occurs
almost exclusively in the enterocytes of the small intestine
[1], also in man [2], but absorption of citrulline from the
circulation and subsequent biosynthesis of arginine can
take place in many tissues [3]. Of these, the cortex of the
kidney provides approximately 20% of whole-body
requirements [4]. In perinatal mice [5,6] and piglets [7-9],
however, all enzymes necessary for arginine biosynthesis
from proline and glutamine (Figure 1) are expressed in
the enterocytes of the small intestine, while ARG1, the
main cytosolic arginine-catabolizing enzyme, is not
detectable prior to weaning [5,6,10]. In agreement, the
small intestine plays a prominent role in net arginine pro-
duction in suckling piglets [11-14]. In rodents, intestinal
expression of the enzymes that synthesize arginine from
citrulline, ASS and argininosuccinate lyase, ceases com-
pletely after weaning [6,15]. In pigs, on the other hand,
net synthesis of arginine declines more gradually and is
still present at 7 weeks of age [16]. It has been speculated
that enteric arginine synthesis is necessary to cover neona-
tal requirements, because mammalian milk is a relatively
poor source of arginine, whereas its precursors proline
and glutamine are abundant [17].
Arginine synthesis from proline or glutamine in the mammalian neonatal gutFigure 1
Arginine synthesis from proline or glutamine in the mammalian neonatal gut. Since arginase-1 is not expressed, 
arginine can either be secreted or metabolized to NO and citrulline. Names of enzymes investigated in this study are indicated 
in italics. P-5-C = pyrroline5-carboxylate synthetase.
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In prematurely born human neonates, hypoargininemia
is frequently observed [18] and hypothesized to predis-
pose such infants to the development of necrotizing ente-
rocolitis [19-21]. Although hypoargininemia in
premature human neonates has been associated with fail-
ing intestinal arginine biosynthesis as found in suckling
rodents and piglets [22], no evidence to support this asso-
ciation exists thus far. To confirm or reject the hypothesis
that the perinatal human gastrointestinal tract resembles
that of rodents or pigs with respect to arginine production,
we studied the developmental changes in the expression
of CPS, OAT and ASS, three key enzymes with a high con-
trol of de novo intestinal synthesis of citrulline and
arginine, and ARG1 and ARG2, the main arginine-cat-
abolizing enzymes in full-thickness and mucosal biopsies
of the human small intestine. The findings demonstrate
that the epithelium of the fetal and neonatal small intes-
tine abundantly expresses CPS (as we reported earlier
[23,24]), OAT and ASS, whereas cytosolic ARG1 is not
detectable. These data show that the perinatal human
intestine resembles that of rodents and, in particular, pigs
with respect to its capacity to produce arginine. We also
show that the expression of the controlling enzyme, ASS,
all but disappears between 3 and 5 years of age, that is, the
putative weaning age of human infants [25]. Finally, we
show that the enteric ganglia and arteriolar endothelium
co-express ASS and the constitutive NO-synthases NOS1
and NOS3, respectively, which both use arginine as sub-
strate for NO synthesis.
Methods
Tissue
A total of 89 samples were included in the study (Table 1).
Formalin-fixed, paraffin-embedded samples originated
from the archives of the Institute of Pathology, University
Hospital Basel, Switzerland, and the Department of
Pathology, AMC, Amsterdam, the Netherlands. Full-thick-
ness duodenal, jejunal and ileal samples were from
infants, who presented with gastroschisis, atresia, meco-
nium ileus or Meckel's diverticulum, whereas the samples
from adults were from patients who underwent surgery
for tumors. Duodenal mucosal biopsies were collected
from patients who underwent endoscopy for various gas-
trointestinal complaints. Furthermore, full-thickness
intestinal samples of 9 fetuses between 14 and 40 gesta-
tional weeks were examined. For each sample, age, gender
and diagnosis were available, but in all other respects, the
samples had been anonymized to avoid patient identifica-
tion. Under this condition, residual tissue could be used
for the research reported here [26]. In addition, approval
has been obtained from the Ethikkommission beider
Basel EKbB, Switzerland, reference number EK 135/08 for
the samples obtained from the Institute of Pathology in
Basel.
Immunohistochemistry
Tissue was fixed in 4% formaldehyde and embedded in
paraffin following standard protocols. 5–7 Pm-thick sec-
tions were used. Section thickness does not affect immu-
nohistological staining intensity, since antibodies only
bind to the surface of the sections [27]. As an additional
cautionary measure to avoid staining differences due to
differences in fixation, we used neuronal staining as an
internal reference. Sections were deparaffinized, hydrated
in graded ethanols, and heated in 10 mM sodium citrate
(pH 6.0) to 98°C for 10 minutes followed by 90 minutes
cool-down to room-temperature to retrieve antigens. After
this treatment, endogenous alkaline phosphatases are
denatured and no longer active. Remaining activity of
endogenous peroxidases (catalase) was inactivated where
appropriate by exposing the sections for 30 min to 3%
H2O2 in PBS. After blocking with TENG-T (10 mM Tris pH
7.4, 5 mM EDTA, 150 mM NaCl, 0.25% gelatin, 0.05%
Tween-20) plus 10% goat serum, sections were incubated
overnight at room temperature with the first antibody,
washed in 0.5 M Na-acetate and incubated with an alka-
line phosphatase- or peroxidase-coupled secondary anti-
body for 60 to 90 minutes. Sections were developed with
Table 1: Human gut samples
Group Age # of samples Sample origin Resections Biopsies
SI D J I
1 -182/-3 days 9 7 2 9 0
2 1 – 11 days 14 1 4 3 6 14 0
3 6 wks – 1 yr 10 4 1 5 9 1
4 1,5 – 3 yrs 12 2 7 3 5 7
5 3 – 5 yrs 16* 15 3 0 16
6 5 – 7 yrs 18* 16 5 2 16
7 14 – 22 yrs 5 1 4 4 1
8 50 – 80 yrs 5 4 1 5 0
The table shows the number of samples that were analyzed per age group, the topographic location of the samples (SI = small intestine, D = 
duodenum, J = jejunum, I = ileum), and whether they were mucosal biopsies and full-thickness resections. For age groups 5 and 6, parallel samples 
were available from two different regions of the small intestine. These were used to check for the effect of location on enzyme expression, but only 
one sample per patient was taken into account for the statistical analysis. This is the reason for the discrepancy between "# of samples" (marked by 
an asterisk) and the sum of all samples listed under "Sample origin".
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NBT/BCIP (alkaline phosphatase; Roche) or DAB (perox-
idase; Sigma). An incubation without primary antibody
served as negative control for all incubations [see Addi-
tional file 1]. This protocol allows semi-quantitative
assessment on sections [28].
The following rabbit primary antibodies were used: ASS
(1:10,000) [15]; ARG1 and ARG2 (1:500, sc-20150 and
1:400, sc-20151, respectively, Santa Cruz Biotechnology,
California); CPS (1:500) [29]; OAT (1:1,500) [30]. Anti-
body binding was visualized with alkaline phosphatase-
coupled goat anti-rabbit IgG (1:200, Sigma A-3687).
NOS1 and NOS3 were detected with mouse monoclonal
antibodies (NOS1 1:400, IgG2a clone #16; NOS3 1:200,
IgG1 clone #3, BD Transduction Laboratories) and visual-
ized with an alkaline phosphatase-coupled goat anti-
mouse secondary antibody (1:200, Sigma A3562) and a
peroxidase-coupled rabbit anti-mouse secondary anti-
body (1:200, Sigma A3682), respectively. Single NOS1
positive cells in the lamina propria were further character-
ized by staining for the presence of CD68 (monocytes/
macrophages 1:200, Dako M0876), CD3 (T-lymphocytes
1:600, Dako A0452), CD20 (B-cells 1:500, Dako M0755
clone L26), CD1A (dendritic cells 1:10, Neomarkers MS-
1856-P1), and CD138 (plasma cells 1:100, Dako M7228
clone MI15).
Western Blotting
Villus epithelium was scraped off fresh duodenal resec-
tion material and lysed in SDS-PAGE sample buffer. After
separation of samples on 10% SDS-polyacrylamide gels
and blotting to PVDF membranes, proteins were visual-
ized with antisera to ARG1 (1:200); ARG2 (1:500); NOS1
(1:2500); NOS3 (1:2500); D-SMA, (1:1000). The appro-
priate secondary horse-radish peroxidase-coupled anti-
bodies were used at a dilution of 1:10,000. The signal was
amplified using the chemiluminescent Super Signal West
Pico reagent (Pierce, Perbio Science, The Netherlands)
and pictures were taken with a LAS3000 imaging system
(Fujifilm). D-smooth muscle actin was used to determine
the contribution of the submucosa to the scrapings.
Evaluation of samples
Sections were scored for staining intensity in random
sequence by 3 investigators with the readers of the slides
blinded. Villi and crypts were scored separately. The inten-
sity of ASS, OAT and ARG2 staining in enterocytes was
expressed on a scale of 0–3 (0: absent; 1: weak; 2: interme-
diate; and 3: strong expression) relative to their expression
in the ganglia of the myenteric plexus, which always con-
tained both strongly and weakly positive neurons for ASS,
OAT, and ARG2. Expression in the strongly staining neu-
rons was set at 3. Samples without ganglia (mucosal biop-
sies from the duodenum) were compared to
simultaneously stained samples that did contain ganglia
to assign an intensity score from 0 to 3. Because CPS
expression in the small intestine is restricted to entero-
cytes, all samples were stained simultaneously and then
compared to each other using the same scale of 0–3 as
described above. There was never more than one scoring
unit difference between the 3 investigators.
Statistics
We used box-plots to visualize distribution and develop-
mental changes of enzyme expression in enterocytes.
Two-way analysis of variance (ANOVA) on rank-trans-
formed data showed age-group and structure (crypt or vil-
lus) differences as well as age and structure interactions
per enzyme. Sex (male or female) was not a factor associ-
ated with differences in enzyme expression. To pin-point
which age-groups and crypts or villi differed, non-para-
metric one-way ANOVA (Kruskal-Wallis) tests were per-
formed between age-groups per structure. Multiple
comparison (Mann-Whitney) tests between structures per
age-group were performed, when the null hypothesis was
rejected. P values were considered significant if < 0.05.
Results
The earliest sample studied was a small intestine of a 14-
week-old fetus, whereas the oldest sample was from a 79
year-old patient. Most of the samples examined were from
patients younger than 7 years. At 14 weeks of gestation, all
structural components of the epithelium, enteric nerves,
and smooth muscle layers have formed [31,32]. Speci-
mens were from the duodenum, jejunum, or ileum, with
the majority of samples originating from the duodenum
and ileum (Table 1). From 4 patients (age groups 5 and 6;
3–7 years), parallel samples of duodenum and ileum were
available. In these samples, no differences in staining
intensities of the enzymes investigated were observed
between the proximal and distal small intestine or
between males and females. For these 2 reasons, we felt
justified to pool the samples of one age group. Of neces-
sity, the studied specimens included both mucosal biop-
sies and full-thickness specimens, were all obtained to
diagnose gastrointestinal conditions, and were contrib-
uted by different institutions. Because the gastrointestinal
conditions were diverse in nature and the observed
changes in enzyme levels concordant, our conclusions
reflect developmental biology rather than pathology.
Based on the staining patterns in these samples, we
describe the developmental changes in the expression of
arginine-synthesizing enzymes CPS, ASS and OAT, and
the arginine-metabolizing enzymes ARG1, ARG2, NOS1
and NOS3 in the enterocytes of the small intestine.
Expression of CPS, ASS, OAT, ARG, NOS1 and NOS3 in 
enterocytes
Carbamoylphosphate synthetase (Figures 2A and 3; [see also 
Additional files 2 and 3])
CPS protein was exclusively found in the enterocytes.
Prior to birth (group 1), CPS expression was uniformly
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high in the enterocytes of both crypts and villi (Figure 3A).
Between birth and 3 years of age (groups 2–4), CPS
expression did not change significantly in the enterocytes
on the villi, but declined thereafter to reach adult levels by
5 years of age (difference in villous expression between
groups 1–4 vs. groups 5–8: P d 0.0001). Between birth
and 1 year of age, expression was higher in the villus than
in the crypt enterocytes (P < 0.005; Figure 3B [see Addi-
tional file 2]). Thereafter, staining differences between
villi and crypts disappeared again (Figure 3C–F). No
expression of CPS was found in the epithelium of Brun-
ner's glands [see Additional file 3].
Ornithine aminotransferase (Figures 2B and 4; [see also Additional 
files 2 and 3])
OAT expression in the epithelium was uniform prior to
birth. The youngest samples that could be investigated
were from gestational week 23 (Figure 4A). Fetal expres-
sion was significantly higher in both crypts and villi than
in the other age groups (P d 0.004). Directly after birth,
OAT expression remained strong in the epithelium cover-
ing the villi, but declined in the crypts (P d 0.017), with
the exception of age group 4 (1, 5-3 years). In some prep-
arations, expression was stronger at the base of the villi,
just above the crypts (Figure 4B, D). Above 40 years of age,
OAT expression again resembled the fetal pattern, with
crypt and villus enterocytes expressing OAT almost evenly
albeit at a lower level (Figure 4E). The epithelium of Brun-
ner's glands did not express OAT [see Additional file 3].
Argininosuccinate synthetase (Figures 2C and 5; [see also Additional 
files 2 and 3])
With the exception of the age groups 5 and 6 (3–7 years),
ASS protein accumulated to a much higher concentration
in the enterocytes on the villi than in the crypts (P <
0.014), especially before 3 years of age (P < 0.004). This
pattern was already found in gestational week 14, where
epithelial expression of ASS was still low (Figure 5A).
From week 23 onward, expression in the villus epithelium
was intermediate to strong. ASS expression remained high
during the first postnatal year (groups 2 and 3 vs. groups
5–8, P < 0.0001), and then declined via an intermediate
score between 1.5 and 3 years (group 4) to a near-absent
score between 3 and 5 years (group 5). ASS expression in
the crypts slowly declined after birth to become undetect-
able after 3 years of age (Figure 5B–F; [see also Additional
file 2]) (Groups 1–4 vs. groups 5–8 in a multiple compar-
ison of groups: P < 0.0001). As long as ASS expression was
high (i.e. in the first 3 years), ASS protein was present
throughout the enterocytes (Figure 5A–C), but in children
and young adults, it gradually became concentrated at the
basal side of the enterocytes (Figure 5D–F). No expression
of ASS was found in the epithelium of Brunner's glands
[see Additional file 3].
Developmental changes in expression of CPS, ASS, OAT and ARG2 in entero ytes of th  small intestineFigure 2
Developmental changes in expression of CPS, ASS, 
OAT and ARG2 in enterocytes of the small intestine. 
Sections represented in the top three panels (CPS, ASS and 
OAT) were stained simultaneously, whereas a subset of the 
samples with 2–4 individual sections per age group was 
stained later and is represented in the bottom panel (ARG2). 
The staining intensities were graded on a scale of 0 to 3. 
Medians of all observations of each age-group are indicated 
by diamonds and are plotted for villi (pink) and crypts (blue) 
separately. The vertical bars represent the first and third 
quartiles of each age group. When not drawn, the quartile 
coincides with the median. Age groups are: 1: fetus (14th – 
39th week of pregnancy); 2: 1–11 postnatal days; 3: 42–365 
days; 4: 1.5–3 years; 5: 3–5 years; 6: 5–7 years; 7: 14–22 
years; 8: 39–79 years; for details, consult Table 1. For CPS 
and ASS, expression in groups 1–4 was significantly higher 
than in groups 5–8, whereas for OAT, expression in prenatal 
group1 was higher than in the postnatal groups (for details, 
see main text). Significant differences in expression between 
villus and crypt enterocytes are indicated by an asterisk if P d 
0.005, a "#" if P d 0.017, and a "+" if P d 0.04. Significant dif-
ferences between age groups are described in the Results 
section.
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Arginase-1 (Figure 6A)
ARG1, the major arginine-catabolizing enzyme, was not
detectable immunohistochemically in the epithelium of
the small intestine at any of the ages investigated. West-
ern-blot analysis of samples from an adult duodenum
(age: 60 years) were also negative for ARG1, confirming
the immunohistochemical findings.
Arginase-2 (Figures 2D, 6A, and 7)
Western blots of the adult duodenum showed, instead,
expression of the mitochondrial isoform of arginase
(Figure 6A). We therefore investigated expression of
ARG2 in a subset of samples (2–4/group) from all age-
groups analyzed for ASS, CPS and OAT expression. ARG2
expression in fetal enterocytes was very weak (Figure 7A)
or absent, but in neonates and all older age groups,
expression was significantly higher (P < 0.02). After
birth, protein expression in enterocytes was stronger on
the villi than in the crypts (Figure 7B–F; P < 0.0001 for
all groups in a multiple comparison; due to the relatively
small sample size this difference was not significant for
all individual groups).
Developmental changes in expression of carbamoylphosphate synthetase in human small intestineFigure 3
Developmental changes in expression of carbamoylphosphate synthetase in human small intestine. Panel A: ges-
tational week 14; panel B: jejunum of a 3-day-old term male neonate; panel C: ileum of a 3-year-old male toddler; panel D: 
ileum of a 6-year-old male child; panel E: ileum of a 22-year-old female patient; panel F: ileum of a 70-year-old female patient. 
Scale bar: 100 Pm.
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NOS1 (Figure 6A)
Over-staining of sections with NOS1 yielded weak epithe-
lial staining. Enterocytes of the human small intestine
express high levels of NOS1 mRNA, but protein was not
detected [33]. In agreement, a Western blot of a protein
extract from villus epithelium did not show staining for
NOS1, demonstrating that the observed staining of the
sections was due to non-specific antibody binding.
NOS3 (Figure 6A)
We found weakly positive staining of villus epithelium
with our NOS3 antibody. NOS3 mRNA is not expressed in
enterocytes [33]. We, therefore, incubated a Western blot
of a protein extract from epithelial cells with the same
antibody as used for immunohistochemistry, but no
immunoreactivity with NOS3 could be demonstrated,
showing that the observed staining of the sections was due
to non-specific antibody binding.
Localization of enzymes involved in arginine biosynthesis (Figure 8)
Serial sections of the distal duodenum at postnatal day 1
demonstrated that the highest expression of CPS, ASS, and
OAT was found in the enterocytes covering the villi (Fig-
ure 8A, D, G). CPS-, OAT-, and ASS-positive enterocytes
did not express ARG1 (not shown). The positive staining
of the ARG1-rich lysed erythrocytes [34] inside vessels
served as an internal positive control for the absence of
ARG1 staining in enterocytes. ASS was also expressed in
Developmental changes in expression of ornithine aminotransferase in human small intestineFigure 4
Developmental changes in expression of ornithine aminotransferase in human small intestine. Panel A: gesta-
tional week 23; panel B: jejunum of a 3-day-old term male neonate; panel C: ileum of a 3-year-old male toddler; panel D: ileum 
of a 6-year-old male child; panel E: ileum of a 70-year-old female patient. Scale bar: 100 Pm.
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the endothelium of the small arteries (Figure 8E, arrow),
while OAT was present in the smooth muscle wall of these
vessels (Figure 8H, white arrowhead). In addition, ASS
and OAT were expressed in the ganglia of the myenteric
plexus (Figure 8F, I, arrows). Only ASS was prominent in
the varicose nerves of the circular muscle layer (Figure 8F,
arrow head) and, to a lesser extent, in those of the longi-
tudinal muscle layer.
Expression of enzymes in enteric nerves (Figure 6B)
Single neurons in the ganglia of both the myenteric and
the submucosal plexus stained very strongly for ASS, OAT,
ARG2, and NOS1, whereas other neurons in the same
ganglion stained weaker or not at all. The strongly OAT-
positive neurons were also positive for ASS and NOS1
(Figure 6B, black arrows), but some ganglia that were pos-
itive for both NOS1 and ASS did not express OAT (Figure
6B, white arrows). ASS- and NOS1-negative neuronal
bodies were not observed in ganglia. Considerable stain-
ing of varicose nerve fibers for ASS and NOS1, but not for
OAT, was observed in the circular and, to a lesser extent,
the longitudinal smooth-muscle layer (Figures 6B and
8F). Positive staining for ASS of single neurons in mye-
nteric ganglia was already found in gestational week 14
Developmental changes in expression of argininosuccinate synthetase in human small intestineFigure 5
Developmental changes in expression of argininosuccinate synthetase in human small intestine. Panel A: gesta-
tional week 14; panel B: jejunum of a 3-day-old term male neonate; panel C: ileum of a 3-year-old male toddler; panel D: ileum 
of a 6-year-old male child; panel E: ileum of a 22-year-old female patient; panel F: ileum of a 70-year-old female patient. Arrows 
in panel A indicate ASS-positive neurons in the myenteric plexus. Scale bar: 100 Pm.
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Expression of ASS, ARG and NOS in villus epithelium and neuronsFigure 6
Expression of ASS, ARG and NOS in villus epithelium and neurons. Panel A: 40 Pg of protein isolated from small-
intestinal scrapings of a 60-year-old patient were loaded per lane (left column). Positive controls (right column) included 25 Pg 
of human liver extract for ARG1, NOS1 and D-SMA, 25 Pg of human kidney extract for ARG2, and 25 Pg of mouse brain 
extract for NOS3. Absence of ARG1, NOS1 and NOS3 expression in the adult small-intestinal enterocytes is demonstrated. 
The density of the ARG2 band is approx. 10% of that in kidney. Panel B: Serial sections (5 Pm) of the ileal myenteric plexus of 
a 6-year-old male child were stained for ASS, NOS1, and OAT. Note colocalization of ASS, NOS1, and OAT in intensely stain-
ing neurons (black arrows). Also note OAT-negative ganglia (white arrows). Another section of the same specimen was stained 
for ARG2. Scale bar: 100 Pm.
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(Figure 5A, arrows), whereas NOS1 (data not shown) and
ARG2 were detectable in gestational week 23 (Figure 7A,
arrows). ASS, OAT, and ARG2 expression was also found
in ganglia of the outer and inner submucosal plexus (Fig-
ures 6B and 7F). The neurons of the myenteric plexus
stained stronger than those of the submucosal plexus,
except those positive for ARG2, which stained equally
strong in both.
Expression of enzymes in the wall of intestinal vessels
The endothelium of the small arterioles in the submucosa
and serosa always stained positive for the presence of ASS
(Figure 8E, arrow) and NOS3, but that of the larger arter-
ies, veins and lymph vessels was negative for both
enzymes. After birth, OAT and ARG2 expression was
demonstrable in the smooth-muscle cell layer of arterioles
(Figures 7F). No expression was found in the smooth-
muscle cell layer of veins.
Expression of enzymes elsewhere in the intestine
Single cells in the lamina propria that were strongly posi-
tive for NOS1 were also positive for CD68, a marker for
macrophages, but not for CD3, CD20, CD138, or CD1A
(lymphocytes and dendritic cells (not shown). Germinal
Developmental changes in expression of arginase-2 in human small intestineFigure 7
Developmental changes in expression of arginase-2 in human small intestine. Panel A: gestational week 23; arrows 
indicate positive neurons in submucosal and myenteric plexus; panel B: jejunum of a 3-day-old term male neonate; panel C: 
ileum of a 3-year-old male toddler; panel D: ileum of a 6-year-old male child; panel E: ileum of a 22-year-old female patient; 
panel F: ileum of a 70-year-old female patient; the white arrow shows staining of a submucosal ganglion, the black arrows indi-
cate staining of smooth muscle cells in the wall of arterioles. Scale bar: 100 Pm.
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centers within lymphocyte aggregates also stained positive
for NOS1 (not shown).
Discussion
The main result of this study is the observation that the epi-
thelium of the perinatal human small intestine expresses
the enzymes that exert control over the biosynthesis of
arginine from proline, bicarbonate, and ammonia, viz.
CPS, OAT and ASS (See Figure 1), and that the major
arginine-degrading enzyme ARG1 is absent during that
period. We deduced this conclusion from an enzyme-histo-
chemical analysis of 79 specimens less than 8 years old.
The human small intestine expresses key enzymes of 
arginine synthesis at midgestation
Although the developmental appearance of CPS, OAT,
and ASS in the enterocytes of the piglet and rodent small
intestine has been reported [6-9,35-38], such information
was only incompletely available for the human small
intestine. CPS expression in the human small intestine
starts as early as the 8th week of gestation [23,24]. Accord-
ingly, CPS was expressed in the enterocytes of all our sam-
ples. To our knowledge, OAT expression in human
enterocytes has not yet been reported, but its develop-
mental profile resembles that of CPS, ornithine car-
Expression of enzymes involved in arginine synthesis in human small intestine at postnatal day 1Figure 8
Expression of enzymes involved in arginine synthesis in human small intestine at postnatal day 1. Serial sections 
of the distal duodenum of a 1-day-old female neonate. Panels A-C show the expression of CPS; panels D-F: ASS; and panels G-
I: OAT. Endothelial expression of ASS in panel E is indicated by block arrows, while OAT expression in the smooth muscle 
layer of the same vessels is indicated by a white arrowhead (panel H). Panels C, F and I show the muscularis propria with the 
inner circular and outer longitudinal layer. Myenteric ganglia are indicated by black arrows in panels F and I. Varicose nerves in 
the circular muscle layer are indicated by an arrowhead in panel F. Scale bar: 100 Pm.
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bamoyltransferase and pyrroline-5-carboxylate reductase
in fetal piglets [37]. In agreement, OAT was, like CPS,
expressed in the enterocytes of all our samples. ASS,
finally, is expressed in Caco2 cells [39], but its expression
in normal human small intestinal enterocytes has not yet
been reported. ASS differed from CPS and OAT in that its
expression declined profoundly between 3 and 5 years of
age (Figure 2). The time course in ASS expression in the
postnatal human gut resembles that in piglets, which
declines towards weaning and then rises again [10]. In
rodents, on the other hand, ASS expression disappears
completely at weaning [6,40]. Concurrent with the devel-
opmental decline in ASS expression, its homogeneous
cytosolic distribution changed to one that is restricted to
the basal side of the enterocytes (Figure 5E, F). Asymmet-
ric localization of proteins in enterocytes has been previ-
ously described as a consequence of mRNA sorting [41],
but a change in enzyme localization during late postnatal
development has, to our knowledge, not yet been demon-
strated.
The crypt-villus gradient of postnatal CPS and ASS expres-
sion in the suckling human intestine resembles that in
piglets (our unpublished observations), but markedly dif-
fers from that in rodents. In both rats and mice [5,6], ASS
expression is confined to the enterocytes occupying the
apical half of the villi, whereas CPS is expressed in all ente-
rocytes. This expression pattern suggested to us that the
basal enterocytes synthesized citrulline, whereas the api-
cal enterocytes synthesized arginine [6]. A possible expla-
nation for this spatial separation of cells capable to
produce citrulline only and cells also capable of arginine
production is that the small-intestinal enterocytes are the
only cells in the body that can synthesize citrulline and
that this citrulline is necessary as substrate for arginine
synthesis elsewhere, e.g. the kidney and the endothelium.
Apparently, such a zonation of arginine metabolism is not
necessary in newborn pigs and humans.
The net production of ornithine by the small intestine is a
prerequisite for citrulline and arginine biosynthesis [42].
The severe deficiency of circulating ornithine and arginine
that develops in neonates lacking OAT [38,43] demon-
strates that, in the neonatal intestine, OAT indeed serves to
produce ornithine. Citrulline is exported from the mito-
chondria in exchange for ornithine via the ornithine carrier
ORNT. Accordingly, the ORNT1 isoform is expressed at ele-
vated levels in the small intestine of the mouse during the
suckling period [44]. However, the relatively high expres-
sion of ARG2, the mitochondrial isoform of arginase, in the
neonatal and adult human small intestine could poten-
tially nullify the cytosolic synthesis of arginine (in the
mouse small intestine, ARG2 becomes only expressed at
weaning [5,6]). Extensive degradation of cytosolic arginine
due to import into the mitochondria is, nevertheless,
unlikely, because the affinity of arginine for the ORNT car-
rier is ~10-fold lower than that of ornithine [45].
Together, our findings indicate that the human fetal intes-
tine has acquired the potential to produce arginine at 23
weeks of gestation and probably as early as 14 weeks, that
is, well before fetuses become viable outside the uterus.
Furthermore, NOS1, NOS3 and their downstream target
soluble guanylate cyclase (not shown) were expressed at
term levels in fetuses of ~23 weeks of pregnancy. This
indicates that at this time in gestation the fetus not only
has the potential to synthesize arginine, but also to use it
for NO and cyclic GMP production. Hypoargininemia,
nevertheless, often develops in preterm infants, in partic-
ular if they are maintained on total parenteral nutrition
[5,6,15], and appears to predispose them to the respira-
tory distress syndrome [46] and necrotizing enterocolitis
[19,20]. The hyperammonemia that frequently accompa-
nies hypoargininemia in preterms responds to intrave-
nous arginine supplementation [18], which indicates that
endogenous arginine biosynthesis is deficient. The strong
association with parenteral nutrition points to the intes-
tines and indicates that the intestines only produce
arginine if substrate is supplied from the intestinal lumen,
as was shown for the newborn piglet [11,12].
Intestinal neurons and arterioles express key enzymes of 
arginine synthesis
The neurons of the myenteric plexus abundantly express
OAT, ASS, and NOS1. Since the neurons do not express
CPS and, therefore, cannot synthesize citrulline from
ornithine, OAT most likely functions to produce gluta-
mate, while ASS probably functions to (re-)synthesize
arginine from citrulline [47]. It is conceivable that these
neurons require under certain conditions additional
arginine (synthesized by enterocytes) above their endog-
enous production. Such metabolic cooperation has been
demonstrated for the intestinal sphincters: neurons in
these sphincters can resynthesize arginine from citrulline,
but become dependent on external arginine during pro-
longed activity [48]. The expression pattern of soluble
guanylate cyclase (not shown) demonstrated that there
are many target cells for the NO produced by the neurons
of the myenteric plexus. In this respect, the inner, circular
layer of the muscularis propria differed markedly from the
outer, longitudinal layer both by the far more abundant
distribution of ASS- and NOS1-positive nerve fibres and
its much stronger expression of soluble guanylate cyclase
(not shown). The much stronger immunoreactivity for
NOS1 of the nerve fibers in the circular muscle has been
described [49]. Although nerve cell content and density of
the NOS-positive ganglia of the myenteric plexus [49-51]
markedly declines in the peri- and postnatal period, this
structural difference between both layers of the muscularis
propria is maintained throughout development.
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The constantly fed state of the neonatal small intestine
causes absorptive hyperemia, that is, a high intestinal
blood flow and a low intestinal vessel resistance [52]. NO
production in the vessel wall is the main determinant of
this vascular relaxation [53], in particular during the suck-
ling period [54]. Since neonatal hypoargininemia is
closely associated with the risk to develop necrotizing
enterocolitis, a disease of the intestinal vessels [55], we
speculate that arginine biosynthesis in both the entero-
cytes and the endothelial cells of the small vessels of the
intestinal submucosa is necessary to support this hypere-
mic state and to protect the neonatal intestine from
ischemia. Unfortunately, only one intervention trial [56]
without a conclusive outcome [57] has tested the pre-
dicted beneficial effect of arginine supplementation to
preterm neonates thus far. Although arteries of the 1st to
2nd order (out of 4 size categories) are considered to be the
major sites of resistance and blood flow regulation of the
gut [58], we did not observe ASS and NOS3 expression in
the endothelium of 1st order (largest) arteries. Further-
more, the downstream target of NO, soluble guanylate
cyclase, was found in the smooth-muscle layer of arteri-
oles only (not shown), suggesting that these 2nd order ves-
sels materially contribute to the peripheral vascular
resistance in the gut. A recent study showed a deficiency in
NO production but not in NOS3 expression as judged by
immunohistochemistry of intestinal arterioles of patients
with NEC [59], supporting our hypothesis that NOS sub-
strate deficiency plays a role in intestinal ischemia. In
addition to NO production, other factors are involved in
neonatal vascular dysfunction, such as the pro-inflamma-
tory cytokine IL-1E and endothelin-1 [60], but their effects
are mediated at least in part via a blunting of NOS3-medi-
ated NO production.
The decline of arginine-synthesizing enzymes in 
enterocytes and "weaning"
The age-dependent postnatal decline in the expression of
ASS in the enterocytes of the human small intestine is
most pronounced between 3 and 5 years of age. The time
course in ASS expression in the developing human gut
resembles that in piglets, where activity is highest during
the suckling period, declines to low levels around wean-
ing (under natural conditions occurring at 12–15 weeks
[61]) and then rises again [10]. In rodents, on the other
hand, ASS expression disappears completely at weaning
[5,6,15]. In humans, approximately 6 months of age is
considered to be an optimal time point for weaning, but
the natural weaning age for humans may be as late as 2.5–
3 years [25]. The prominent reduction of ASS expression
that we observed after three years of age, therefore, coin-
cides with this assumed natural weaning age.
There is a remarkable similarity in the developmental
timing of the decline in expression of ASS and lactase-
phlorizin hydrolase (hereafter called lactase), another
small-intestinal enzyme that is closely associated with
breast-feeding. In rodents, lactase expression declines
to undetectable levels at weaning [62], whereas in pig-
lets, the decline occurs more gradually during the first
8–16 weeks of life [63]. In lactase-nonpersistent
humans, lactase activity begins to decline between 2
and 3 years [64]. The temporal coincidence of the intes-
tinal capacity to digest lactose and to produce arginine
does support a relation to milk as the main source of
food and underscores the notion that mammalian milk
does not contain enough arginine to support rapid
postnatal growth [17], so that intestinal arginine syn-
thesis is necessary. Although we did find low levels of
ASS in adult intestine, it was recently reported that the
human intestine (age range 37–69 years) does not pro-
duce arginine [65]. This finding does not exclude a role
for local arginine synthesis in e.g. neurons and
endothelial cells that is directly coupled to NO produc-
tion within the same cell.
Conclusion
Our data show that CPS, ASS, and OAT expression is
strong in the enterocytes of fetuses, neonates, infants and
toddlers. Humans, therefore, resemble other mammals in
that the enterocytes of their small intestine are major pro-
ducers of arginine during the suckling period. Although
the relative deficiency of arginine in milk seems to under-
lie this temporary function of the gut, the intestinal or sys-
temic functions that require the arginine that is produced
in the gut remain to be delineated. We submit that relaxa-
tion of the circular smooth muscle layer of the muscularis
propria [49,66] and that of the intestinal arterioles [54]
stand out in this respect.
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$EVWUDFW
6XFNOLQJPDPPDOV LQFOXGLQJPLFH GLIIHU IURP DGXOWV LQ WKH DEXQGDQW H[SUHVVLRQ RI HQ]\PHV WKDW
V\QWKHVL]H DUJLQLQH IURP FLWUXOOLQH LQ WKHLU HQWHURF\WHV 7R LQYHVWLJDWH WKH LPSRUWDQFH RI WKH VPDOO
LQWHVWLQDODUJLQLQHV\QWKHVLVIRUZKROHERG\DUJLQLQHSURGXFWLRQLQVXFNOLQJPLFHZHIOR[HGH[RQRI
WKHDUJLQLQRVXFFLQDWHV\QWKHWDVH$VVJHQHZKLFKFRGHVIRUDNH\HQ]\PHLQDUJLQLQHELRV\QWKHVLV
DQG VSHFLILFDOO\ DQG FRPSOHWHO\ DEODWHG $VV LQ HQWHURF\WHV E\ FURVVLQJ $VVIO DQG 9LOOLQ&UH PLFH
8QH[SHFWHGO\$VVIOIO9LO&UHWJPLFH VKRZHGQRGHYHORSPHQWDO LPSDLUPHQWV$PLQRDFLG IOX[HVDFURVV
WKH LQWHVWLQH OLYHUDQGNLGQH\VZHUHFDOFXODWHGDIWHUGHWHUPLQLQJ WKHEORRG IORZ LQ WKHSRUWDOYHLQ
DQGKHSDWLFDQGUHQDODUWHULHVDQGUHVSHFWLYHO\RIWKHWUDQVKHSDWLFEORRGIORZLQ
GD\ROGPLFH5HODWLYHWRFRQWUROPLFHFLWUXOOLQHSURGXFWLRQLQWKHVSODQFKQLFUHJLRQRI$VVIOIO9LO&UHWJ
PLFHGRXEOHGZKLOHDUJLQLQHSURGXFWLRQZDVDEROLVKHG )XUWKHUPRUH WKHQHWSURGXFWLRQRIDUJLQLQH
DQGPRVWRWKHUDPLQRDFLGVLQWKHOLYHURIVXFNOLQJFRQWUROPLFHGHFOLQHGWRQDXJKWRUHYHQFKDQJHGWR
FRQVXPSWLRQLQ$VVIOIO9LO&UHWJPLFHDQGKDGWKXVEHFRPHUHPDUNDEO\VLPLODUWRWKDWRISRVWZHDQLQJ
ZLOGW\SHPLFHZKLFKQRORQJHUH[SUHVVDUJLQLQHELRV\QWKHVL]LQJHQ]\PHVLQWKHLUVPDOOLQWHVWLQH7KH
DGDSWLYHFKDQJHVLQOLYHUIXQFWLRQZHUHDFFRPSDQLHGE\DQLQFUHDVHGH[SUHVVLRQRIJHQHVLQYROYHGLQ
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DQGWUDQVSRUW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ZKHUHDVQRVXFKFKDQJHVZHUHIRXQGLQWKHLQWHVWLQH2XUILQGLQJVVXJJHVWWKDWWKHJHQHWLF
SUHPDWXUH GHOHWLRQ RI DUJLQLQH V\QWKHVLV LQ HQWHURF\WHV FDXVHV D SUHPDWXUH LQGXFWLRQ RI WKH SRVW
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(GLWRU)UDQ©RLV%ODFKLHU1DWLRQDO,QVWLWXWHRI$JURQRPLF5HVHDUFK)UDQFH
5HFHLYHG)HEUXDU\$FFHSWHG0D\3XEOLVKHG-XQH
&RS\ULJKW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/LFHQVHZKLFKSHUPLWVXQUHVWULFWHGXVHGLVWULEXWLRQDQGUHSURGXFWLRQLQDQ\PHGLXPSURYLGHGWKHRULJLQDODXWKRUDQGVRXUFHDUH
FUHGLWHG
)XQGLQJ7KLVVWXG\ZDVVXSSRUWHGE\DJUDQWIURPWKHJUDGXDWHVFKRRO1875,00DDVWULFKW8QLYHUVLW\WR:+/7KHIXQGHUVKDGQR
UROHLQVWXG\GHVLJQGDWDFROOHFWLRQDQGDQDO\VLVGHFLVLRQWRSXEOLVKRUSUHSDUDWLRQRIWKHPDQXVFULSW
&RPSHWLQJLQWHUHVWV7KHDXWKRUVKDYHGHFODUHGWKDWQRFRPSHWLQJLQWHUHVWVH[LVW
(PDLO/HR.RHKOHU#PDDVWULFKWXQLYHUVLW\QO
,QWURGXFWLRQ
$UJLQLQH LV D VXEVWUDWH IRU WKH V\QWKHVLV RI QLWULF
R[LGH XUHD RUQLWKLQH FLWUXOOLQH FUHDWLQH DJPDWLQH
JOXWDPDWH DQG SUROLQH >@ 7KH UDWHGHWHUPLQLQJ
HQ]\PH RI DUJLQLQH V\QWKHVLV IURP FLWUXOOLQH DQG
DVSDUWDWH LV DUJLQLQRVXFFLQDWH V\QWKHWDVH $66 (&
 >@7KHHQGRJHQRXVELRV\QWKHWLFFDSDFLW\ IRU
DUJLQLQH VXIILFHV WRPHHW WKH GDLO\ UHTXLUHPHQW XQGHU
QRUPDO FRQGLWLRQV EXW D GLHWDU\ VRXUFH RI DUJLQLQH
EHFRPHV QHFHVVDU\ ZKHQ GHPDQG LQFUHDVHV XQGHU
DQDEROLFRUFDWDEROLFFRQGLWLRQV >઼@)RU WKLV UHDVRQ
DUJLQLQHLVDFRQGLWLRQDOO\HVVHQWLDODPLQRDFLG
7KHVH JHQHUDO FRQFOXVLRQV DSSO\ WR SRVWZHDQLQJ
LQGLYLGXDOV WKDW FDQ DGDSW WKHLU VRXUFHV RI IRRG
+RZHYHU DUJLQLQH PHWDEROLVP LQ WKH HDUO\ SRVWQDWDO
SHULRG GLIIHUV FRQVLGHUDEO\ IURP WKDW LQ WKH DGXOW
SUREDEO\EHFDXVHWKHUDSLGO\JURZLQJVXFNOLQJDQLPDOV
KDYHQRFKRLFHRIIRRG6LQFHWKHVXSSO\RIDUJLQLQHYLD
WKH PLON LV QRW VXIILFLHQW WR VXSSRUW RSWLPDO SURWHLQ
V\QWKHVLV >઼@ VXFNOLQJ DQLPDOV QHHG D KLJKHU
HQGRJHQRXV FDSDFLW\ IRU DUJLQLQH V\QWKHVLV 7KH
DEXQGDQWH[SUHVVLRQRI WKHHQ]\PHVQHFHVVDU\ IRUGH
QRYR DUJLQLQH ELRV\QWKHVLV LQ WKH HQWHURF\WHV RI WKH
VPDOO LQWHVWLQH RI SHULQDWDO URGHQWV >઼@ SLJOHWV
>@DQGKXPDQV>@DQGWKHDEVHQFHRIF\WRVROLF
DUJLQDVH H[SUHVVLRQ >઼@ VXJJHVW WKDW WKH


$PLQRDFLGFRQFHQWUDWLRQ
%ORRG ZDV FROOHFWHG LQWR KHSDULQFRDWHG WXEHV DQG
FHQWULIXJHG DW J IRU  PLQ DW r&  w/ RI
SODVPD ZDV DGGHG WR  PJ RI O\RSKLOL]HG
VXOSKRVDOLF\OLFDFLG YRUWH[HG DQG VWRUHG DW r&
$PLQRDFLG FRQFHQWUDWLRQV ZHUH GHWHUPLQHG E\ +3/&
DVGHVFULEHG>@$PLQRDFLGIOX[HVZHUHFDOFXODWHGDV
GHVFULEHG>@%HFDXVHRQO\WKHUHODWLYHGLVWULEXWLRQRI
IORZVDFURVVRUJDQVFRXOGEHPHDVXUHGQH[WVHFWLRQ
IOX[HV ZHUH H[SUHVVHG DV WKH SURGXFW RI WKH DUWHULR
YHQRXV GLIIHUHQFHV LQ DPLQRDFLG FRQFHQWUDWLRQV DQG
WKHUHODWLYHIORZDFURVVWKHUHVSHFWLYHRUJDQV
%ORRGIORZGLVWULEXWLRQXVLQJUDGLRDFWLYH
PLFURVSKHUHV
5DGLRDFWLYHPLFURVSKHUHV wPGLDPHWHU ODEHOHG
ZLWK 5X ZHUH SXUFKDVHG IURP 3HUNLQ(OPHU 86$
1(0$8& )RXUWHHQGD\ROG PLFH  JUDP
ERG\ ZHLJKW ZHUH DQHVWKHWL]HG E\ LQWUDSHULWRQHDO
LQMHFWLRQ RI  wJJ NHWDPLQH 3IL]HU   wJJ
[\OD]LQH $IWHU RSHQLQJ WKH WKRUD[ WKURXJK WKH IRXUWK
OHIW LQWHUFRVWDO VSDFH  w/ RI D  7ZHHQ
VDOLQH VROXWLRQ FRQWDLQLQJ  PLFURVSKHUHV a
.%TZDV LQMHFWHG LQWR WKH OHIW YHQWULFOH2UJDQVZHUH
LVRODWHG WUDQVIHUUHG WR D SODVWLF FRXQWLQJ YLDO
FRQWDLQLQJP/RIVDOLQHDQGPHDVXUHGZLWKDJDPPD
FRXQWHU:DOODF:L]DUG3HUNLQ(OPHU86$
:HVWHUQEORWWLQJDQGKLVWRORJ\
7LVVXHV ZHUH FUXVKHG LQ D OLTXLG QLWURJHQFRROHG
PRUWDU VRQLFDWHG LQ 5,3$ EXIIHU  P0
7ULVy+&OS+   P0 1D&O  13  1D
GHR[\FKRODWH  1DGRGHF\OVXOIDWH FRQWDLQLQJ D
SURWHDVH LQKLELWRU FRFNWDLO &RPSOHWH 5RFKH 7KH
1HWKHUODQGV7ZHQW\ILYHwJRISURWHLQZDVORDGHGSHU
ODQH (TXDO SURWHLQ ORDGLQJ SHU ODQH ZDV YHULILHG E\
3RQFHDX6VWDLQLQJRIWKHEORWVSULRUWRLQFXEDWLRQZLWK
DQWLVHUXP$66ZDVYLVXDOL]HGE\ LQFXEDWLQJ WKHEORWV
ZLWK UDEELW DQWLPRXVH $66 DQWLVHUXP 
>@ IROORZHG E\ DONDOLQH SKRVSKDWDVHFRXSOHG
JRDW DQWLUDEELW DQWLERG\ DQG 6XSHU 6LJQDO :HVW
)HPWR 0D[LPXP 6HQVLWLYLW\ 6XEVWUDWH 3LHUFH 

'XRGHQDO  FP GLVWDO WR WKH S\ORULF VSKLQFWHU DQG
LOHDOFPSUR[LPDOWRWKHLOHRFHFDOMXQFWLRQVHJPHQWV
ZHUH IL[HG LQ LFHFROG EXIIHUHG  IRUPDOGHK\GH
HPEHGGHG LQ 3DUDSODVWp DQG VHFWLRQHG DW  wP
*REOHWFHOOVZHUHYLVXDOL]HGZLWK$OFLDQEOXH%'+
7KH1HWKHUODQGV LQ  DFHWLF DFLG S+   IRU 
PLQ1XFOHLZHUHYLVXDOL]HGZLWK1XFOHDU )DVW5HG
&KURPD )OXND IRU  PLQ )RU LPPXQRVWDLQLQJ
VHFWLRQVZHUHVXEMHFWHGWRDQWLJHQUHWULHYDOPLQDW
r& LQ  P0 1DFLWUDWH S+  EORFNHG ZLWK
7HQJ7  P0 7ULV S+   P0 ('7$  P0
1D&O  JHODWLQ  7ZHHQ  QRUPDO
JRDWVHUXP1*6*LEFR7KH1HWKHUODQGV IRUPLQ
DQG LQFXEDWHG RYHUQLJKW LQ D  GLOXWLRQ RI WKH
$66 DQWLERG\ >@ LQ 7HQJ7 1*6 $IWHU
ZDVKLQJZLWK3%6DQGDQRWKHUEORFNLQJVWHSZLWK7HQJ
7 1*6 IRUPLQ VHFWLRQVZHUH LQFXEDWHGZLWK
JRDWDQWLUDEELWDQWLVHUXP6LJPD$GLOXWHG
LQ 7HQJ7  1*6 IRU  PLQ $IWHU ZDVKLQJ WKH
VOLGHV ZHUH LQFXEDWHG ZLWK QLWUREOXH WHWUD]ROLXP
FKORULGHEURPRFKORURLQGRO\O SKRVSKDWH 1%7
%&,35RFKHDWr&XQWLOVWDLQLQJUHDFKHGDQ
RSWLFDOGHQVLW\QRWH[FHHGLQJ


WKRVHRIO\VLQH>઼@&RPSDUHGWR$VV&RQPLFH
WKH FLUFXODWLQJ FRQFHQWUDWLRQ RI DUJLQLQH LQ SODVPD RI
$VV.2,PLFHGLGQRWFKDQJHVLJQLILFDQWO\ LQWKHDRUWD
DQGSRUWDOYHLQEXWGHFUHDVHGWRaLQWKHKHSDWLF
YHLQDQGLQFUHDVHGaLQWKHUHQDOYHLQ)LJXUH$
&LUFXODWLQJ FRQFHQWUDWLRQV RI WKH DUJLQLQH SUHFXUVRU
FLWUXOOLQH FKDQJHG PRUH SURIRXQGO\ EHLQJ aIROG
KLJKHULQWKHDRUWDDQGKHSDWLFYHLQDQGaIROGKLJKHU
LQ WKH SRUWDO DQG UHQDO YHLQV RI$VV.2, WKDQ RI$VV
&RQ PLFH )LJXUHV % DQG ' 7KH FRQFHQWUDWLRQ RI
RUQLWKLQH ZDV GHFUHDVHG LQ WKH KHSDWLF YHLQ DQG
LQFUHDVHG LQ WKH UHQDO YHLQ RI $VV.2, FRPSDUHG WR
$VV&RQPLFH)LJXUH&3ODVPDO\VLQHFRQFHQWUDWLRQV
ZHUH QRW GLIIHUHQW EHWZHHQ FRQWURO DQG H[SHULPHQWDO
DQLPDOV )LJXUH ':LWK UHVSHFW WR WKH RWKHU DPLQR
DFLGV DQG FRPSDUHG WR $VV&RQ PLFH JOXWDPDWH
DODQLQHDQG WDXULQH LQFUHDVHG LQ WKHDRUWDJOXWDPDWH
JOXWDPLQH WKUHRQLQH DODQLQH WDXULQH YDOLQH DQG
OHXFLQH LQFUHDVHG LQ WKH SRUWDO YHLQ DQG DODQLQH
WDXULQH YDOLQH LVROHXFLQH OHXFLQH LQ WKH UHQDO YHLQRI
$VV.2, PLFH ZKHUHDV JOXWDPDWH YDOLQH LVROHXFLQH
WU\SWRSKDQDQG OHXFLQHGHFUHDVHG LQ WKHKHSDWLFYHLQ
7DEOH6 ,QDJUHHPHQWZLWK WKHVH ILQGLQJV WKHVXP
RIDPLQRDFLGVZDVKLJKHULQWKHDRUWDDQGSRUWDODQG
UHQDO YHLQV DQG ORZHU LQ WKH KHSDWLF YHLQ RI$VV.2,
WKDQ RI $VV&RQ PLFH 6WULNLQJO\ WKH GDWD RI WKH
H[SHULPHQWDO JURXS ZHUH PRUH KHWHURJHQHRXV WKDQ
WKRVHRIWKHFRQWUROJURXS

&KDQJHVLQDPLQRDFLGIOX[HVLQWKHDEVHQFH
RI$66LQHQWHURF\WHV
7KH XSWDNH RU UHOHDVH RI DPLQR DFLGV DFURVV WKH
LQWHVWLQHOLYHUDQGNLGQH\VRIVXFNOLQJ1'PLFHZDV
GHWHUPLQHG E\ PXOWLSO\LQJ WKH YHQRDUWHULDO
FRQFHQWUDWLRQ GLIIHUHQFHV DQG WKH EORRG IORZ DFURVV
WKHVH RUJDQV 7R PHDVXUH WKH EORRG IORZ DFURVV WKH
RUJDQV ZH GHWHUPLQHG WKH GLVWULEXWLRQ RI UDGLRDFWLYH
PLFURVSKHUHV LQMHFWHG LQWR WKH OHIW YHQWULFXODU FDYLW\
)LJXUH $ 6LQFH ZH ZHUH QRW DEOH WR KDUYHVW
UHIHUHQFH VDPSOHV IURP WKH DEGRPLQDO DRUWD RI WKHVH
VPDOOPLFH aJUDPRQO\ WKH UHODWLYHGLVWULEXWLRQRI
WKH FDUGLDF RXWSXW DFURVV RUJDQV DQG KHQFH WKH
PHWDEROLFIOX[HVLQWKHSRUWDOGUDLQHGYLVFHUDOLYHUDQG
NLGQH\V FRXOG EH FDOFXODWHG $W 1' a RI WKH
WUDQVKHSDWLF EORRG IORZ RULJLQDWHG LQ WKH SRUWDO YHLQ
DQG a LQ WKH KHSDWLF DUWHU\ ZKLOH EORRG IORZ
WKURXJK WKH NLGQH\V DPRXQWHG WR a RI WKDW
WKURXJK WKH OLYHU ZLWKRXW VLJQLILFDQW GLIIHUHQFHV
EHWZHHQ JHQRW\SHV 5HODWLYH WR $VV&RQ PLFH WKH
SURGXFWLRQ RI DUJLQLQH RUQLWKLQH DQG O\VLQH LQ WKH
SRUWDOGUDLQHG YLVFHUD KDG QRW FKDQJHG LQ $VV.2,
PLFHEXWWKHOLYHUKDGEHFRPHDQDUJLQLQHDQGO\VLQH
FRQVXPLQJ RUJDQ VLJQLILFDQFH DW WKH WUHQG OHYHO VR
WKDW WKH FRQWULEXWLRQ RI WKH VSODQFKQLF UHJLRQ WR
V\VWHPLF DUJLQLQH HYHQ EHFDPH QRQH[LVWHQW )LJXUH
$ULJKWSDQHO$UJLQLQHSURGXFWLRQLQWKHNLGQH\KDG
PRUH WKDQ GRXEOHG EXW WKLV FRPSHQVDWHG RQO\a
RIWKHGHFUHDVHLQDUJLQLQHSURGXFWLRQLQWKHVSODQFKQLF
DUHD &LWUXOOLQH ZDV WKH RQO\ DPLQR DFLG ZLWK DQ
LQFUHDVHG aIROG SURGXFWLRQ LQ WKH SRUWDO GUDLQHG
YLVFHUD RI $VV.2, PLFH GXH WR WKH DEVHQFH RI $66
)LJXUH % ULJKW SDQHO 7KH WUHQGV RI DUJLQLQH DQG
O\VLQHZHUHIROORZHGE\WKHRWKHUDPLQRDFLGVRQO\WKH
SURGXFWLRQ RI JO\FLQH DQG WDXULQH GHFUHDVHG
VLJQLILFDQWO\ LQWKHSRUWDOGUDLQHGYLVFHUDZKHUHDVWKH
OLYHUFKDQJHGIURPSURGXFWLRQWRXSWDNHIRUJOXWDPDWH
JOXWDPLQH WDXULQHYDOLQH LVROHXFLQH OHXFLQHDQG WKH
VXP RI DOO DPLQR DFLGV 7DEOH 6 )LJXUH %
)XUWKHUPRUHDWUHQGZLWKWKHVDPHHIIHFWZDVVHHQIRU
VHULQH WKUHRQLQH DQG PHWKLRQLQH 7KHVH GDWD
WKHUHIRUH VKRZ WKDW GHOHWLRQ RI $VV IURP WKH
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Suckling “F/A2” mice, which overexpress arginase-I in their
enterocytes, develop a syndrome (hypoargininemia, reduced
hair and muscle growth, impaired B-cell maturation) that
resembles IGF1 deficiency. The syndrome may result from an
impaired function of the GH-IGF1 axis, activation of the stress-
kinase GCN2, and/or blocking of the mTORC1-signaling path-
way. Arginine deficiency inhibited GH secretion and decreased
liver Igf1 mRNA and plasma IGF1 concentration, but did not
change muscle IGF1 concentration. GH supplementation
induced Igf1mRNAsynthesis, but did not restore growth, ruling
out direct involvement of the GH-IGF1 axis. In C2C12 muscle
cells, arginine withdrawal activated GCN2 signaling, without
impacting mTORC1 signaling. In F/A2 mice, the reduction of
plasma and tissue arginine concentrations to25% of wild-type
values activated GCN2 signaling, but mTORC1-mediated sig-
naling remained unaffected.Gcn2-deficient F/A2 mice suffered
from hypoglycemia and died shortly after birth. Because com-
mon targets of all stress kinases (eIF2 phosphorylation, Chop
mRNA expression) were not increased in these mice, the effects
of arginine deficiency were solely mediated by GCN2.
Arginine is a substrate for the synthesis of proteins, creatine,
agmatine, ornithine, and nitric oxide (1). In addition, it func-
tions as a secretagogue for hormones, such as growth hormone
(GH) and insulin (2–4). Under normal conditions, endogenous
arginine synthesis in adult mammals suffices to sustain daily
requirements (5), but a dietary source of arginine may become
necessary when demand increases under anabolic or catabolic
conditions (5). For this reason, arginine is considered a condi-
tionally essential amino acid.
Arginine deficiency represents a significant metabolic prob-
lem in premature infants (6), but its cause remains unknown. In
rapidly growing suckling rodents, endogenous arginine biosyn-
thesis is crucial to compensate for the insufficient supply of
arginine via the milk (7). The intestine rather than the kidney is
primarily responsible for endogenous arginine synthesis in
suckling piglets (8, 9). In suckling rodents, the enterocytes of
the small intestine also express all enzymes necessary to synthe-
size arginine (10–13), while arginase is not expressed, thus
allowing efficient de novo arginine biosynthesis. To examine
the function of intestinal arginine synthesis, a transgenicmouse
model that overexpresses arginase-I in the enterocytes of the
small intestine was produced (14–17). During the suckling
period, these “F/A2”4 mice suffer from a selective deficiency of
circulating arginine (which declines to 25% of controls),
reduced growth of hair and skeletal muscle, and inhibition of
B-cell maturation (14). The phenotype can be rescued with
arginine supplementation (14), but could not be ascribed to a
deficiency of arginine metabolites, such as creatine or poly-
amines, or to arginine-dependent ADP-ribosylation of proteins
(14–17). Furthermore, the features of the “arginine-deficiency
syndrome” are not seen in mice that are deficient in all three
nitric-oxide synthases (18). This leaves two functions of argi-
nine as likely candidates to account for the highly characteristic
phenotype of arginine deficiency in sucklingmice, viz. its role as
a building block in protein synthesis and as a secretagogue of
hormones.
Amino acids, including arginine, control translation by two
well-established mechanisms. Whenever the intracellular con-
centration of free arginine decreases below20 M, the charg-
ing process of its corresponding tRNA slows down and the con-
centration of uncharged tRNA increases (19). Uncharged
tRNAs activate the ubiquitously expressed “general control
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non-derepressible2” (GCN2) stress kinase, which then phos-
phorylates the -subunit of the eukaryotic initiation factor 2
(eIF2) and thereby initiates the “integrated stress response”
(20–22). This response blocks cap-dependent protein synthe-
sis, facilitates the translation of specific mRNAs, such as Atf4
and Cat-1, from internal ribosome entry sites, and increases
expression of specific transcription factors such as ATF2,
ATF4, and CHOP (23), which, in turn, induce the transcription
of genes necessary for amino acid synthesis and transport. The
other mechanism senses, instead, increases in amino acid con-
centration, probably via the Rag GTPase complex (24), and
results in the activation of the mTORC1 kinase. mTORC1, in
turn, regulates cap-dependent translation through the phos-
phorylation of 4EBP1 and S6K1 (25, 26). The essential amino
acid leucine is the prototypic regulator of both branches of
amino acid-dependent translational regulation (22, 27). How-
ever, for a non-essential amino acid, arginine has an unexpect-
edly strong effect on mTORC1-dependent signaling (28) and
quantitatively rivals leucine in vitro (29, 30). The F/A2 pheno-
type could, therefore, be mediated by activation of GCN2 sig-
naling and/or inhibition of mTORC1-mediated signaling.
The more remarkable phenotypic features of F/A2 mice,
namely impaired muscle and hair growth and impaired B-cell
maturation, are all also affected by insulin-like growth factor-1
(IGF1) signaling (31–35). Like amino acids, growth factor sig-
nals, including those arising from IGF1, stimulate protein syn-
thesis via the mTORC1 pathway (36). The production of IGF1,
in turn, is largely dependent on growth-hormone (GH) signal-
ing (37). Arginine, finally, is also a potent growth-hormone
secretagogue (38). Arginine deficiency could, therefore, also
cause insufficient signaling via themTORC1 pathway due to an
inactive somatotropic axis.
In the present study, we used a combination of in vivo and in
vitro approaches to test the hypotheses that arginine deficiency
activates GCN2 signaling or blocks mTORC1 signaling, or
both. Our findings demonstrate that arginine deficiency in the
neonatal and suckling period activates the GCN2 stress-kinase
pathway, without affecting the mTORC1 pathway.
EXPERIMENTAL PROCEDURES
Transgenic Mouse Lines and Animal Husbandry—Trans-
genic mice that overexpress arginase-I in their small-intestinal
enterocytes (F/A2 line (14)) were bred hemizygously. Gcn2/
mice (39) originated from the colony ofD. Ron (NewYork,NY).
Control animals were littermates of the experimental animals.
Animal studies were reviewed and approved by the committee
for animal care and use of Maastricht University.
GH Administration—Litters were limited to 5 animals on
neonatal day 1 (ND1) and weighed daily. Starting on ND3, 3
mg/kg body weight of human recombinant growth hormone
(hrGH; Humatrope, Lilly, Indianapolis, IN) was administered
subcutaneously in 25 l of vehicle twice daily (40). Control
animals were injected with vehicle alone.
Blood and Tissue Collection—Animals were sacrificed by
decapitation. Blood was collected into heparin-containing
tubes and centrifuged at 2,000  g for 5 min at 4 °C. IGF-1
protein concentrations were measured in plasma, whereas
amino acids were measured in deproteinized plasma. 80 l of
plasma was added to 6.4 mg of lyophilized sulfosalicylic acid,
vortexed, and stored at20 °C. For amino acid measurements,
the tissues were homogenized with silica mini-beads in 0.33 M
sulfosalicylic acid. Tissueswere collected atND0,ND10,ND17,
and ND21. Amino acid concentrations were determined by
HPLC (41). Tissues for protein and mRNA analysis were iso-
lated, snap frozen in liquid nitrogen and stored at 80 °C. For
histological analysis, tissues were fixed in 4% buffered formalin
and embedded in paraffin.
IGF-1 Assay—Mouse IGF-1 concentration in plasma andmus-
cle was measured by the m/r IGF-1 E25 enzyme immunoassay,
as detailed by the manufacturer (Mediagnost, Reutlingen, Ger-
many). This assay eliminates IGFBP interference with the
IGF-1 measurement.
RNA Extraction and Quantitative PCR—Total RNA was ex-
tracted with Trizol (Sigma). 1g of total RNAwas reverse tran-
scribed with the iScript cDNA synthesis kit (Bio-Rad). Primer
sequences (supplemental Table S1) were optimized for an
annealing temperature of 60 °C, except for the Igf1 primers that
were annealed at 70 °C. cDNA samples for mRNA determina-
tion were diluted 60-fold before use and those for 18 S rRNA
200-fold. Primary fluorescent data were exported and analyzed
with the Lin-RegAnalysis program (42). If reverse transcriptase
was omitted, no product formed. mRNA concentrations were
expressed relative to 18 S rRNA content. Between session vari-
ations in replicate experiments were corrected using factor cor-
rection (43).
Western Blots, Immunostaining, and Immunofluorescence—
ForWestern blot assays, 100g of proteinwere loaded per lane.
Antibody (supplemental Table S2) bindingwas visualized using
the Super Signal West Femto Maximum Sensitivity Substrate
(Pierce). For detection of the phosphorylated and unphospho-
rylated forms of eIF2, the Odyssey Infrared Imaging system
(Li-cor Bioscience, UK) was used.
For immunostaining, 5-m sections of tissues were pre-
pared. After deparaffinization, sectionswere preincubatedwith
Teng-T (10mMTris (pH7.6), 5mMEDTA, 150mMNaCl, 0.25%
gelatin, 0.05%Tween-20)/10% normal goat serum (NGS) for 30
min, followed by an overnight incubation with the primary
antibody diluted in Teng-T/10%NGS. Slides were then washed
with PBS and incubated with Teng-T/10% NGS for 15 min,
followed by 90 min incubation with the secondary antibody
(supplemental Table S2) in Teng-T/10% NGS. After washing,
the slides were incubated with alkaline phosphatase substrate
(NBT/BCIP tablets; Roche) at 37 °C. Digital images of the sec-
tions were analyzed with the Leica Quantimet 500 Image Anal-
ysis System, v3.2 (44).
Statistical Analysis—The significant difference for one vari-
able between two distinct groups was analyzed using an
unpaired Student’s t test. For more complex analyses of signif-
icance for variables with different controls, each gene was ana-
lyzed using Gaussian linear regression, including 18 S as house-
keeping gene. When appropriate, additional explanatory
variables such as tissue type, strain, and time were included in
the model. Finally, interactions among the included variables
were considered. The inference criterion used for comparing
themodels is their ability to predict the observed data, i.e.mod-
els are compared directly through their minimized minus log-
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likelihood. When the numbers of parameters in models differ,
they are penalized by adding the number of estimated parame-
ters, a form of the Akaike information criterion (45). If themost
likely model contains the treatment effect, the fold change rep-
resenting the ratio between the variable of the treated group
and the same variable for the control is computed, as well as its
95% confidence interval.
RESULTS
The GH/IGF1 Axis Is Functional but Repressed in F/A2Mice—
The phenotype of F/A2 mice is compatible with a deficiency of
GH and/or IGF1.We, therefore, investigated theGHcontent in
the pituitary gland by quantitative immunohistochemistry (Fig.
1A). The somatotropes of 3-week-old hemi- and homozygous
F/A2 mice contained 1.4- and 2.2-fold more GH, respectively,
than those of their wild-type counterparts (Fig. 1B), indicating
an inverse correlation with the severity of the F/A2 phenotype
(14, 16).
We then used the rat pituitary cell line GH3, which produces
GH (46, 47), to assess the direct effects of arginine on GH pro-
duction and secretion. GH content in the GH3 cells was
assessed by quantitative immunohistochemistry (supplemental
Fig. S1, A and B) and ELISA (supplemental Fig. S1C). Both
assays showed that, after 24 h of culture, the cellular GH con-
tent was inversely correlated with extracellular arginine con-
centration and decreased from50 to25 pg of GH per cell at
0 and 200Marginine in themedium, respectively (supplemen-
tal Fig. S1C; significant at 50 M arginine). This decrease in
cellular GH content was accounted for by a 1.5-fold increase in
concentration of GH in the medium (significant at 25 M
arginine). Because the total GH content of the cells and the
medium combined did not vary with arginine concentration in
the medium, these findings reveal a pronounced concentra-
tion-dependent effect of arginine on GH secretion. The
dependence of GH secretion on the ambient concentration of
arginine after 72 h of culture was similar to that observed after
24 h (not shown). These data show that, below a concentration
of 50 M ambient arginine, GH secretion is reduced, with a
half-maximal effect at20 M arginine.
As early as 3 days after birth (ND3), F/A2mice can be distin-
guished from their wild-type littermates by a lower bodyweight
(14). To assess whether the typically hypomorphic tissues of
F/A2 mice (muscle, hair, and B-cells (15)) respond to GH sup-
plementation, mice were subcutaneously injected twice daily
with 3 mg/kg recombinant human (rh)GH fromND3 onwards.
This dose of rhGH mediates growth in liver IGF-1-deficient
mice (40). Fig. 1C shows that the growth rate of homozygous
F/A2 mice was 50% of that of wild-type mice and that treat-
ment with rhGH had no effect on the growth rate of either
wild-type or F/A2 mice.
GH action is mediated by GH receptors (GHR) and results in
the synthesis and secretion of IGF1 in target tissues.GhrmRNA
concentrations in the livers of ND1, ND10, and ND21 mice
increasedwith age, butwere not different inwild-type and F/A2
mice (supplemental Fig. S2). To assess the functionality of these
GHRs and their downstream signaling pathway, Igf1 mRNA
concentrations were quantified in liver and muscle of GH-
treated and control mice (Fig. 1D). In both tissues, Igf1mRNA
concentrations in F/A2 mice were only 10–15% of those in
wild-type mice. Although the rhGH injections increased Igf1
mRNA concentration in liver and muscle of both F/A2 and
wild-type mice considerably (8- and 2.5-fold, respectively;
p  0.01), Igf1 mRNA levels in the liver and muscle of treated
F/A2 mice increased to only 65 and 25%, respectively, of
that in untreated wild-type mice. We then measured plasma
and tissue IGF1 concentrations to assess whether F/A2 mice
suffer from a low production of IGF1 (Fig. 2). In wild-type and
FIGURE 1. Role of growth hormone in the phenotype of F/A2mice. Panels
A and B: Detection of GH in pituitary somatotropes of ND21 mice. A, sections
of pituitary glands ofND21WT, hemizygous F/A2mice (He), andhomozygous
F/A2 mice (Ho) were stained for the presence of GH. Bar: 5 m. B, optical
density (OD) in GH-positive cells (n  3 mice per genotype) increases from
wild-type via hemizygous to homozygous F/A2mice. Panels C andD, effect of
GH treatment onweight gain in suckling F/A2mice.C, change in bodyweight
of F/A2 mice and their wild-type littermates during treatment with GH (twice
daily 3 mg rhGH/kg body weight subcutaneously) between ND3 and ND21
(n 6mice per genotype). Note that F/A2mice showa3-fold lower growth
rate compared with wild-type mice. D, quantification of Igf1 mRNA in liver
(left) andmuscle (right) of vehicle andGH-injectedND17mice. n 3mice per
genotype. *, p 0.01.
FIGURE 2. Plasma and tissue IGF1 protein concentrations in F/A2 mice.
Panel A, differences in plasma, muscle and liver IGF1 protein concentration in
ND1 F/A2//Gcn2/ (wild-type), F/A2tg//Gcn2/ (F/A2 transgenic),
F/A2//Gcn2/ (Gcn2-KO), and F/A2tg//Gcn2/ (F/A2/Gcn2-KO double
mutant)mice (n 6 per genotype). The plasma IGF1 concentration in F/A2tg//
Gcn2/ tended tobe lower than inF/A2//Gcn2/mice (p0.055).Panel
B, changes in plasma and muscle IGF1 protein concentration during the
first 5 postnatal weeks in wild-type (black diamonds) and F/A2 mice (white
squares); (n 3 per genotype except at ND1). *, p 0.05; #, p 0.01. The
age-dependent changes in muscle IGF1 content were highly significant
(p  0.01).
The Arginine Deficiency Syndrome
8868 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 11•MARCH 18, 2011
 at UKB - Universiteit M
aastricht on October 14, 2014
http://www.jbc.org/
Downloaded from 

F/A2ND1mice, no differences in plasma, muscle, or liver IGF1
protein were detected (Fig. 2A). However, plasma IGF1 levels
increased 7-fold faster in wild-type than F/A2 mice during
the first 5 postnatal weeks (Fig. 2B, left panel; p  0.001)).
Plasma IGF1 levels reflect hepatic IGF1 production, but liver
IGF1 does not affect growth until 6 weeks postnatally (48, 49).
We, therefore, measured IGF1 levels in an affected tissue (calf
muscle) of the same mice (Fig. 2B, right panel). Muscular IGF1
concentration decreased gradually between 1 and 3 weeks after
birth, without difference between F/A2 and wild-type mice.
After weaning, the IGF1 concentration in muscle increased
again, with a1 week delay in F/A2 relative to wild-type mice.
Although the age-dependent changes in muscle IGF1 content
were significant (p  0.01), they did not differ between F/A2
and wild-type mice. Because IGF1 in skeletal muscle affects
growth only after the 3rd postnatal week (32), that is, coincident
with the resumption of growth in F/A2 mice (14), we further
concluded that, although the GH-IGF-1 axis did not function
properly in F/A2mice, its disturbed function could not account
for the marked hypotrophy seen in these animals.
Arginine Is Essential for Muscle Development—F/A2 skeletal
muscles have an immature appearance (14). We, therefore,
investigated if arginine directly affects muscle development in
differentiating C2C12myoblasts that were cultured in the pres-
ence of different concentrations of arginine. Supplemental Fig.
S3A shows representative pictures after 4 days of myogenic dif-
ferentiation in the presence (200 M) or absence of arginine.
Both themyogenic index (the fraction of nuclei residing in cells
with three or more nuclei and considered an early differentia-
tion parameter; supplemental Fig. S3B) and the cellular concen-
tration of the late differentiation marker creatine kinase-M
(supplemental Fig. S3C) increased with increasing arginine
concentration to plateau at 25–50 M arginine. Myogenic dif-
ferentiation is, therefore, clearly dependent on arginine avail-
ability, with a half-maximal effect at 10–20 M arginine in the
medium.
Arginine Deficiency Induces the Integrated Stress Response in
Vitro—Amino acid deficiency can activate the GCN2 stress
kinase pathway (50). An early step is the phosphorylation of
translation factor eIF2 (51). As anticipated, arginine depriva-
tion of C2C12 cells at 80% confluence induced phosphorylation
of eIF2 on serine 51 within 30 min. The protein remained
phosphorylated for at least 2 h (supplemental Fig. S4A). Fur-
thermore, arginine depletion induced the accumulation of the
transcription factors ATF4 and CHOP, which are well-estab-
lished downstream mRNA targets of the GCN2 stress-kinase
pathway (23, 52), in a concentration-dependent way in both
C2C12 and GH3 cells (supplemental Fig. S4B). In both cell
types, Chop mRNA concentration increased more gradually
with declining arginine concentration in themedium thanAtf4
mRNA, indicating that Chop mRNA accumulation was more
sensitive to arginine removal than that of Atf4 mRNA. The
adaptive response of Atf4 and Chop mRNA expression in pri-
mary cultures of mouse B-lymphocytes, another hypomorphic
tissue in F/A2 mice, to arginine deprivation was similar to that
of C2C12 and GH3 cells (not shown). Supplemental Fig. S4C,
finally, shows that ATF4 protein accumulates at arginine con-
centrations below 25 M (see Ref. 52). These findings reveal
that the integrated stress response becomes induced at arginine
concentrations in the medium below 50 M, with an EC50 of
12.5 M.
Arginine Deficiency Does Not Affect Signaling through the
mTORC1 Pathway—Amino acid deficiency can regulate pro-
tein synthesis by up-regulating signaling via theGCN2 pathway
and by down-regulating signaling via the mTORC1 pathway.
We, therefore, compared the effects of 0, 12.5, and 200 M
arginine in the culture medium on the degree of phosphoryla-
tion of the translation factors eIF2 as target of GCN2 kinase
and 4EBP1, and S6K1 as targets of mTORC1 kinase in the same
cell extracts (supplemental Fig. S5, column “Ctrl”). As expected,
arginine deficiency caused a significant 2-fold increase in
eIF2 phosphorylation, but did not significantly affect either
S6K1- or 4EBP1 phosphorylation (p  0.13 and 1.0, respec-
tively). Furthermore, arginine deficiency increased the mRNA
concentrations of Atf4, ATF4 target Chop, and CHOP target
Gadd34, which dephosphorylates eIF4-P. In addition, the
expression of the ATF4 target Cat-1 was induced. Collectively,
these data show that the ambient arginine concentration affects
the activity or expression of all investigated parameters except
the mTORC1 targets S6K1 and 4EBP1.
The eIF2P-specific phosphatase inhibitor salubrinal was
used to assess to what extent arginine deficiency induced max-
imal eIF2 phosphorylation and whether the degree of eIF2
phosphorylation affected the stress-kinase esponse only quan-
titatively or also qualitatively (supplemental Fig. S5, column
“Sal”). At the concentration used (50 M), salubrinal increased
eIF2 phosphorylation 3-fold over basal levels (p  0.001)
and abolished the dependence of eIF2 phosphorylation and its
downstream targets on arginine concentration. Furthermore,
salubrinal decreased overall S6K1 phosphorylation levels
3-fold (p 0.001) and increased themRNAs ofAtf4 (3-fold;
p 0.001), Chop (20-fold; p 0.001),Gadd34 (6-fold; p
0.001), and Cat-1 (3-fold; p  0.001), that is, the 3-fold
increase in eIF2 phosphorylation had quantitatively a dispro-
portional effect on its downstream targets. These data reveal
that the effects of a graded phosphorylation of eIF2 due to
arginine deficiency differ both qualitatively and quantitatively
from the effects of amaximal phosphorylation due to salubrinal
treatment.
Constitutive Gcn2 knockdown in C2C12 muscle cells by
integration of a viral vector carrying Gcn2-specific shRNA
reduced Gcn2 mRNA expression to 25% of control values
(not shown). It strongly inhibited myotube formation, suggest-
ing thatGCN2 activation is involved inmyocyte differentiation.
This level of knockdown did, however, not affect the arginine-
dependent stress-kinase response (supplemental Fig. S5, col-
umn “Gcn2-kd”). Similarly, treatment with the muscle growth
factor IGF1 did not mediate, at the concentration used (0.13
nM), a change in effects on the arginine-dependent phosphoryl-
ation of eIF2, S6K1, or 4EBP1 (p  0.05, p  0.18, and p 
0.66, respectively) or their downstream targets.
Collectively, these data show that arginine deficiency
induced a graded and comparatively mild increase in eIF2
phosphorylation and ATF4-dependent gene expression, but
did not affect phosphorylation of S6K1 or 4EBP1. However,
when eIF2 became hyperphosphorylated after treatment with
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the phosphatase inhibitor salubrinal, this specificity was lost.
Gcn2 knockdown blocked myotube differentiation, without
totally eliminating the dependence of eIF2 phosphorylation
on ambient arginine concentrations. The muscle growth factor
IGF1, finally, increased the effect of arginine deficiency.
The Stress Kinase Pathway Is Activated in F/A2 Mice—On
neonatal day 1, the tissue concentration of arginine in skeletal
muscle was only 20% (p  0.01) and that in intestine and liver
50% (p  0.01 and 0.05, respectively) in F/A2 compared
with wild-type mice (Fig. 3A, top subpanel). The low concen-
tration of arginine in liver can be ascribed to the high concen-
tration of the urea cycle enzyme arginase-1 in the liver. The low
tissue arginine concentration induced ChopmRNA expression
8-fold in all tissues investigated (p  0.001; Fig. 3A, middle
subpanel), but Atf4 mRNA expression in skeletal muscle only
(3-fold; p 0.05; Fig. 3A, bottom subpanel). These findings in
vivo reveal that the tissue arginine concentration had decreased
most inmuscle and thatChopmRNAconcentrationwas amore
sensitive parameter to monitor the stress-kinase response to
amino acid deprivation than Atf4mRNA.
Because phosphorylation of eIF2 facilitates translation of
Atf4mRNA (53), we also determined ATF4 protein concentra-
tion in ND1 mice (Fig. 3A, bottom subpanel). Western blot
analysis of muscles of F/A2 mice showed the expected 38-kDa
band (bold arrow in supplemental Fig. S6) and a much weaker
band at 50kDa (small arrow), whereas these bands were
absent in muscle of wild-type mice. The 50kDa band may
correspond to an ubiquitinated form of ATF4 (54). ATF4 pro-
tein was 3–4-fold higher in muscle, small intestine, and liver of
F/A2 than of wild-type animals (Fig. 3A, bottom subpanel; p
0.01,0.02, and0.01, respectively). The data in Fig. 3A dem-
onstrate that ChopmRNA and ATF4 protein are equally sensi-
tive parameters to assess the response to arginine deficiency in
muscle, intestine, and liver.
On neonatal day 21, the concentration of arginine in wild-
typemuscle was similar to that onND1, but in the intestine and
liver, it had decreased to 15 and 30% of that on ND1 (p 
0.01). This pronounced decline can be ascribed to the cessation
of intestinal arginine biosynthesis just prior toweaning (10) and
the continued maturation of the function of the urea cycle in
the liver (55). The arginine concentration in F/A2 muscle had
increased 2-fold relative to that on ND1 (p 0.05) and was no
longer different from that in controls (Fig. 3B, top subpanel).
However, the concentration of arginine in F/A2 intestine and
liver remained depressed (p  0.05). Tissue Chop and Atf4
mRNA concentration had increased 20-fold and 10-fold,
respectively, relative to ND1 (Fig. 3B, middle and bottom sub-
panels).ChopmRNAconcentrationswere still significantly ele-
vated in F/A2 tissues (p  0.01; Fig. 3B, middle subpanel, but
Atf4mRNAconcentrations in F/A2mice were no longer differ-
ent from those in control mice (Fig. 3B, bottom subpanel).
Together, these in vivo data show that the stress-kinase
response pathway is strongly activated in neonatal F/A2 mice.
This activation persists throughout the suckling period,
although its severity appears to decline, in agreement with the
disappearance of the phenotype after weaning.
GCN2Mediates the Activation of the Stress Response in Argi-
nine-deficient Neonatal Mice—In addition to GCN2, three
other stress kinases can phosphorylate eIF2. To demonstrate
that GCN2 is the only stress kinase that becomes activated in
neonatal F/A2 mice, we crossed F/A2tg/ mice with Gcn2/
mice. Table 1A lists the genotypes of the offspring and shows
that the respective genotypes were born at the expected Men-
delian frequency. This Table also shows that all F/A2 mice that
were deficient for Gcn2 (F/A2tg/?/Gcn2/) died within 48 h
after birth (p  0.001). The plasma arginine concentration in
F/A2 neonates was only 25–40% of that in control neonates,
irrespective of whether Gcn2 was or was not expressed (p 
0.01; Fig. 4A).Gcn2-deficient F/A2neonates did drink, but their
plasma glucose concentration on ND1 was significantly lower
FIGURE 3. The stress-kinase pathway is activated in neonatal F/A2 mice.
Panel A, concentration of arginine, Chop mRNA, and Atf4 mRNA and ATF4
protein in skeletal muscle (M), small intestine (I), and liver (L) of ND1 F/A2 and
wild-type mice. mRNA concentrations were corrected for 18 S rRNA content,
while equal protein loading was checked by pre-staining Western blots with
Ponceau-S. n 8–12 mice per genotype for arginine and mRNA concentra-
tion, and n 3 for ATF4 protein. Panel B, concentration of arginine, and Chop
and Atf4 mRNA concentration in muscle, small intestine, and liver of ND21
F/A2 andwild-typemice.n 8–12mice per genotype. *,p 0.05; #,p 0.01.
TABLE 1
Distribution of genotypes and plasma glucose concentrations in the
offspring of crosses of hemizygous F/A2 (F/A2tg/) mice and heterozy-
gous Gcn2 (Gcn2/) mice
Panel A: six different genotypes could be identified by PCR (F/A2tg/ and F/A2tg/tg
mice could not be distinguished; F/A2/mice denotewild-type animals). A total of
60 mice (dead and alive) were analyzed. Four newborn mice disappeared from the
nests in the first two days and could not be analyzed. Panel B: blood was collected
from mice at ND1.
Genotype (A) Expected
Day 0 Day 2
Alive Alive Dead
F/A2//Gcn2/ 4 0
F/A2//Gcn2/ 8 10 10
F/A2//Gcn2/ 4 6 5 1
F/A2tg/?/Gcn2/ 11 10 10
F/A2tg/?/Gcn2/ 22 23 23
F/A2tg/?/Gcn2/ 11 7 0 7
F/A2?/?/Gcn2?/? 4 4
Total 60 48 12
Genotype (B)
Plasma glucose
mM N
F/A2//Gcn2/ 3.3
 0.2 23
F/A2//Gcn2/ 2.8
 0.3 7
F/A2tg/?/Gcn2/ 3.2
 0.2 25
F/A2tg/?/Gcn2/ 2.7
 0.2 15
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than that in wild-type controls (p 0.01), with Gcn2-deficient
and F/A2 neonates taking intermediate positions (Table 1B).
To establish whether Gcn2 deficiency prevented the activa-
tion of the stress response, we determined Chop mRNA con-
centrations inmuscle, small intestine and liver of neonatalwild-
typemice (F/A2//Gcn2/), F/A2mice (F/A2tg/?/Gcn2/)
and F/A2 mice that were also Gcn2-deficient (F/A2tg/?/
Gcn2/) (Fig. 4B). As expected, Chop mRNA concentrations
were low in muscle, liver and gut of wild-type (F/A2//
Gcn2/) mice and elevated in the same organs of F/A2
(F/A2tg/?/Gcn2/) mice (p 0.01,0.01, and0.05, respec-
tively). However, the elevation of Chop mRNA concentration
was not found in muscle, liver, and gut of the F/A2 neonates
that were, in addition, deficient for Gcn2 (F/A2tg/?/ Gcn2/).
Similarly, the degree of phosphorylation of eIF2 inmuscle was
increased in F/A2 mice (p  0.01), but not in F/A2 mice that
were also deficient in Gcn2 (Fig. 4C, left subpanel, and supple-
mental Fig. S6). These findings demonstrate that GCN2 activa-
tion is necessary for postnatal survival in F/A2mice and that the
phosphorylation of eIF2 and the induction ofChop expression
in these mice are solely dependent on GCN2 activation. Gcn2-
deficient neonates further had a significantly higher plasma
IGF1 level than wild-type or F/A2 mice (Fig. 2A, left subpanel).
F/A2 neonates had a lower plasma IGF1 level than wild-type or
Gcn2-deficient neonates, but the difference was significant for
only the latter.
mTORC1-mediated Translational Control Is Not Affected in
Arginine-deficient Neonatal Mice—The degree of phosphoryl-
ation of S6K1 and 4EBP1 in neonatal skeletal muscle was not
significantly different in any of the four genotypes (Fig. 4C and
supplemental Fig. S6; p  0.36 and 0.71, respectively). These
findings indicate that the reduction in circulating arginine con-
centration in F/A2 mice does not affect signaling through the
mTORC1 signaling pathway.Ckm,Myhc1, andMyhc2BmRNA
concentrations were not affected either by arginine or Gcn2
deficiency in neonates (supplemental Fig. S7).
DISCUSSION
Suckling F/A2 mice, which express arginase I from the
Fabp1-promoter exclusively in the enterocytes of the small
intestine (14), suffer from a severe reduction in plasma arginine
levels (70 M versus 230 M), reduced hair and muscle
growth, and a specific block in B-cell development (14–17). In
this study, we show that the deficiency of arginine causes an
impaired function of the endocrine GH/IGF1 axis of these
mice, but that the compromised function of the somatotropic
axis does not account for the observed growth deficiency.
Instead, activation of theGCN2-dependent stress response was
found to be responsible for the hampered growth and even to be
necessary for postnatal survival. Arginine deficiency does not
suppress growth factor (mTORC1)-dependent signaling.
The SomatotropicAxis IsNot Responsible for the Runting Phe-
notype of F/A2 Mice—The gradual accumulation of GH in the
pituitary gland fromwild-typemice via hemizygous to homozy-
gous F/A2mice suggests that decreasing circulating concentra-
tions of arginine progressively suppresses GH synthesis or
secretion. Using GH3 cells, we could demonstrate that arginine
deficiency blocks GH secretion rather than synthesis. Our find-
ings, therefore, complement the recent finding that chronic
arginine supplementation stimulates GH secretion (56) and
imply that a broad dose-response relation exists between circu-
lating arginine and GH secretion. The severely reduced plasma
IGF1 concentration in suckling and weanling F/A2 mice also
underscores the presence of a GH deficiency in F/A2 suckling
mice, as IGF1 production is dependent upon GH stimulation
(38, 57) and75% of plasma IGF1 is produced by the liver (48,
49). In vivo, the effects of arginine deficiency on growth in suck-
ling mice become apparent when the circulating arginine con-
centration falls below80 M (14), which compares well with
our present finding in vitro that arginine concentrations below
50 M inhibit GH secretion (neonatal plasma arginine concen-
trations are1.6-fold higher than those after weaning (14, 16)).
However, neonatal F/A2 mice are not growth-retarded, even
though their plasma arginine concentration is low, whereas
Igf1-deficient mice are (58, 59). Furthermore, GH supplemen-
tation could not restore growth in suckling F/A2mice. In addi-
tion, IGF1 concentration in skeletal muscle, one of the most
severely affected tissues, was similar in F/A2 and wild-type
mice. These findings demonstrate that the activity of the soma-
totropic axis is impaired in arginine-deficient suckling mice,
but not directly responsible for the runted phenotype observed
in these mice.
Arginine Deficiency Selectively Induces the Integrated Stress
Response in Vitro—Because skeletal muscle is a severely
affected tissue in F/A2 mice (14), we used the C2C12 muscle
cell line to investigate the mechanism underlying the observed
effects of arginine deficiency. Whereas arginine withdrawal
increased, as expected, eIF2 phosphorylation and the expres-
sion of its established downstream targets Atf4, Chop, Gadd34,
andCat-1 (39, 60, 61), it did not significantly affect the degree of
phosphorylation of S6K1 or 4EBP1, demonstrating that, in
vitro, a deficiency of arginine activates the stress kinase GCN2,
but does not block mTORC1 signaling. The pronounced effect
of arginine deficiency on GCN2 activation contrasts with an
FIGURE 4. GCN2 is responsible for the induction of the integrated stress
response in neonatal F/A2 mice. Panel A, arginine concentration in trunk
bloodof ND1mice. Panel B,ChopmRNAexpression inmuscle, small intestine,
and liver of the same mice as shown in panel A. Panel C, Ser51-eIF2, Ser65–
4EBP1, and Thr389-S6K1phosphorylation in skeletalmuscle of ND1mice.n
8–12 mice per genotype. *, p 0.05; #, p 0.01.
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earlier report that the depletion of all essential amino acids for
6 h does not activate the GCN2 pathway in C2C12 myotubes
(62). It is well possible that, as the authors themselves suggest
(62), the complete removal of all essential amino acids strongly
induces intracellular proteolysis in myotubes, whereas the
selective depletion of arginine does not, or to a much lesser
extent, as shown by the absence of an effect of arginine with-
drawal on the expression of the ubiquitin ligases Atrogin1 and
Murf-1.5 These discrepant findings underscore, nevertheless,
that results obtained after complete removal of amino acids (e.g.
Ref. 62), sometimes followed by adding back a single amino acid
(30), often differ from results obtained after selectively remov-
ing a single amino acid from a complete mixture (29, 63) and
present study). We opted to selectively remove arginine,
because that intervention best mimicked the difference in
plasma amino acid concentration between wild-type and F/A2
mice (14, 16).
The restriction of the effects of arginine deficiency to acti-
vation of the GCN2 stress-kinase pathway appears to reflect
a limited increase in eIF2 phosphorylation, because maxi-
mizing the degree of phosphorylation of eIF2 with salubri-
nal caused a severe suppression of S6K1 phosphorylation
and a disproportionate up-regulation ofAtf4,Chop,Gadd34,
and Cat-1 expression. These data suggest that crosstalk of
the stress-kinase and the mTORC1 pathways only occurs
when eIF2 phosphorylation reaches an unphysiologically
high level. Gcn2 knockdown in C2C12 myoblasts almost
completely prevented myotube formation, but did not affect
the degree of phosphorylation of eIF2, S6K1, or 4EBP1.
Treatment with the growth factor IGF1 also did not affect
eIF2, S6K1, or 4EBP1 phosphorylation in response to argi-
nine withdrawal. Our findings in C2C12 cells, therefore, sup-
port the hypothesis that arginine deficiency selectively
affects the GCN2 stress-kinase pathway.
Arginine Deficiency Selectively Induces the Integrated Stress
Response in Vivo—Based on the degree of phosphorylation of
eIF2 and the expression of Chop mRNA, the GCN2 signal-
ing pathway was activated in all F/A2 tissues tested on post-
natal day 1. Atf4 mRNA was only up-regulated in skeletal
muscle of 1-day-old F/A2 mice, but ATF4 protein concen-
tration was elevated in all tissues. These findings underline
the severity of the muscle phenotype in F/A2 mice and the
primarily translational regulation of ATF4 expression (52,
53). The concentration gradient of arginine between plasma
and muscle was similar in control and F/A2 mice (4–5-fold),
but the absolute concentrations were 3–4-fold lower in F/A2
than in wild-type mice, in agreement with an arginine supply
rather than transport problem. F/A2 homozygotes resume
growth around weaning (14), in all likelihood due to the
increasing cellular arginine, IGF1, and IGF1R1 (64) concen-
trations in target tissues. In combination, these data, there-
fore, indicate that the GCN2 signaling pathway in muscle in
vivo becomes activated when intracellular arginine concen-
trations in muscle decrease below 400 mol/kg. GCN2
activation in the neonatal intestine appears to have a similar
sensitivity to arginine, but despite much lower tissue argi-
nine concentrations, Chop mRNA and ATF4 protein con-
centrations in liver are similar to those in muscle and
intestine.
Neonatal F/A2 mice did not show a reduced degree of S6K1
or 4EBP1 phosphorylation, which demonstrates that the effects
of arginine deficiency are restricted to GCN2 activation both in
vitro and in vivo. In this respect, arginine deficiency differs from
leucine deficiency, which, at least in adult mice, causes both a
GCN2-dependent phosphorrylation of eIF2 and a hypophos-
phorylation of S6K1 and 4EBP1 (65).
GCN2 Is Necessary to Cope with and Survive Neonatal Argi-
nine Deficiency—The absence of an increase in eIF2 phospho-
rylation and Chop mRNA expression in neonates of crosses of
F/A2 and Gcn2-deficient mice confirmed our in vitro data that
GCN2 was necessary to mediate the response to arginine defi-
ciency. These data also highlighted the vital role of GCN2 acti-
vation for postnatal survival of arginine-deficient pups.When a
leucine-deficient diet was fed to pregnantGcn2/ dams, neo-
natal survival of their Gcn2-deficient offspring was only40%
(22), but F/A2 neonates show a complete loss of vitality when
the concentration of arginine falls to30% of normal.We have
not yet identified the dysfunction that killsGcn2-deficient F/A2
pups, but, in all likelihood, the decline in plasma glucose con-
centration, possibly in conjunction with an increase in plasma
IGF1 concentration, is a contributing factor to their untimely
death. A similar correlation between stress-kinase signaling
and lethal hypoglycemia was also noted in pups carrying the
phosphorylation-resistant Ser51Ala mutation of eIF2 (66),
but these latter pups died earlier (18 h) and with lower blood
glucose concentrations (	1 mM) than Gcn2-deficient F/A2
neonates (48 h and3mM, respectively). Apparently, GCN2-
independent phosphorylation of eIF2 is also necessary to sur-
vive neonatally.
Arginine Is a Signaling Molecule in Its Own Right—The dis-
cussion of arginine-dependent signaling in tissues often focuses
on arginine metabolites, such as NO, agmatine, polyamines,5 S. E. Kohler, unpublished observations.
FIGURE 5. Proposed mechanism underlying the arginine-deficient phe-
notype in mice. Arginine is the precursor for NO, polyamines, and creatine
synthesis, and regulates ADP-ribosylation, but these molecules do not medi-
ate thedevelopmental impairmentof F/A2mice. The somatotropic (GH/IGF1)
axis does not function properly in arginine-deficient mice, but although GH
supplementation increases Igf1 mRNA concentration to wild-type values, it
cannot restore growth. Arginine deficiency, finally, does not block mTORC1
phosphorylation-dependent signaling, but does activate the stress kinase
GCN2 in neonatal and suckling F/A2 mice. The sole activation of the GCN2-
mediated integrated stress response is apparently necessary and sufficient to
block growth in a highly distinctive way.
The Arginine Deficiency Syndrome
8872 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 11•MARCH 18, 2011
 at UKB - Universiteit M
aastricht on October 14, 2014
http://www.jbc.org/
Downloaded from 

creatine, or on arginine-mediated modifications such as ADP-
ribosylation. This and earlier studies of the F/A2 mouse (14–
17) demonstrate that the arginine-deficient phenotype is not
mediated by a metabolite of arginine (Fig. 5). Instead, it is the
low circulating concentration of arginine itself, which sup-
presses the somatotropic axis and activates theGCN2-signaling
pathway without affecting mTORC1-mediated signaling. We
would, therefore, like to propose that the striking phenotype of
suckling F/A2mice is a paradigm for selective GCN2 activation
(Fig. 5).
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GENERAL DISCUSSION 
In this thesis, I have described several genetically modified mouse models that allowed us to 
investigate arginine metabolism or to manipulate arginine availability. The models that were 
used affect arginine synthesis (conditional KO of argininosuccinate synthetase, Ass) or arginine 
degradation (conditional KO of arginase1, Arg1, and transgenic overexpression of rat arginase1 
in mouse enterocytes, F/A2). Arginine metabolism in macrophages was reviewed (Chapter I) and 
an experimental analysis of mice with arginase 1 ablation in macrophages was described 
(Chapter III). The capacity of suckling mice to synthesize arginine in the enterocytes of the small 
intestine was confirmed for human infants (Chapter IV). Overexpression of arginase 1 in small 
intestinal enterocytes caused the surprisingly specific “neonatal arginine deficiency syndrome” 
(hypoargininemia, deficient muscle and hair growth and underdevelopment of Peyer’s patches) 
in the suckling period (Chapter VI), whereas elimination of Ass in the same tissue did not 
(Chapter V). With the experience of generating several knockout models a troubleshooting guide 
was written (Chapter II).  
Arginine is a substrate for the synthesis of proteins, ornithine, creatine, agmatine and nitric oxide 
(NO) (1). Arginine is also a secretagogue for growth hormone, insulin, glucagon and prolactin 
(2-4). Under normal conditions, endogenous arginine synthesis in adult mammals suffices to 
sustain daily requirements (5). A dietary source of arginine may, however, become necessary 
when demand increases under anabolic or catabolic conditions (5). For this reason, arginine is 
considered a conditionally essential amino acid.  
Once inside cells, there are multiple pathways for arginine degradation to produce NO, ornithine, 
urea, polyamines, proline, glutamate, creatine and/or agmatine (1). These pathways are initiated 
by arginase, nitric oxide synthase, arginine:glycine amidinotransferase, and arginine 
decarboxylase. In mammals, the arginase pathway is quantitatively most important for arginine 
catabolism. Arginase 1 and 2 are encoded by two different genes, but hardly differ in their 
kinetic properties (6).  
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All arginine-metabolizing enzymes except arginase 2 are cytosolic and do potentially compete 
for their common substrate arginine (7, 8). The functionally most important competition is 
probably between arginase 1 and nitric oxide synthase (NOS). Therefore, relative changes in 
their enzymatic activities serve as major determinants of NO production in e.g. endothelial cells 
and macrophages (9). Both arginase and arginine decarboxylase activity can mediate the 
increased production of the polyamine precursors ornithine and agmatine, respectively. 
Agmatine is also an inhibitor of NOS activity. Though it is often claimed that arginase-
dependent polyamine production is very important, Arg1-deficient macrophages (10) produced 
all polyamines more efficiently than wild-type macrophages (11). In line with our observations, 
Arg1 and Arg2 single and double KO mice did not differ from controls with respect to polyamine 
concentrations.  
Arginine Deficiency 
There are a number of arginine-deficiency syndromes, involving immune and endothelial 
dysfunction, depending on the disease context in which arginine deficiency occurs. For some 
disorders, elevated plasma arginase concentrations may be more important as a marker of organ 
damage than as a mechanistic component of the disease process. The liver contains the largest 
amount of arginase 1 in the body. Any disease or damage to the liver that results in elevated 
plasma levels of transaminases or other liver enzymes also will result in elevated plasma levels 
of arginase 1 (12-14). Enzymatically active arginase 1 is also present in red blood cells of 
humans (there is much less arginase in rodent red blood cells (15)), is released upon hemolysis, 
and remains active for some time following release into the plasma. For this reason, hemolytic 
blood samples contain low plasma arginine values (16). For the same reason, high concentrations 
of arginase and low concentrations of arginine are found in plasma samples of individuals with 
chronic hemolytic anemias, such as sickle cell disease (17-20) and paroxysmal nocturnal 
hemoglobinuria (20). Conflicting reports exist regarding plasma arginine concentrations in 
sepsis. Several studies suggest that plasma L-arginine concentrations are not decreased in sepsis 
(21, 22) or that they are more markedly decreased in trauma than in sepsis (23-26), but a recent 
meta-analysis concluded that plasma arginine concentrations are indeed reduced in sepsis in the 
absence of trauma or surgery (27). 
Low values of the plasma [arginine]/([ornithine]+[citrulline]) ratio, the so-called “global arginine 
bioavailability ratio” (GABR), represent an independent risk factor for morbidity and mortality 
in sickle-cell and thalassemic patients (17, 28) and are also correlated with pulmonary 
hypertension in this patient population (17, 29). GABR values in asthma patients were, 
nevertheless, greater than in healthy controls, despite higher plasma arginase concentrations in 
the asthma group (30). Since plasma arginase activity was not determined, it is also possible that 
the arginase 1 protein in plasma may not have been active.  
It has also been suggested, that cells expressing the cationic amino-acid transporter CAT1 can be 
depleted of their intracellular arginine if, there is a high ambient concentration of arginase (e.g. 
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due to cell lysis) or if ambient arginine is high in combination with a high intracellular arginase 
content in a neighboring cell (31), such as myeloid-derived suppressor cells (see Chapter I). This 
depletion results from concentration-dependent trans-stimulation of CAT1-mediated arginine 
transport by other cationic amino acids, such as ornithine or lysine. As a result, sensitive 
neighboring cells, such as T-cells, are rapidly depleted of arginine and become anergic (32, 33). 
The CAT1 transporter exhibits the highest trans-stimulation, but CAT2B and CAT3 also exhibit 
this property (34-36). As far as we know, however, none of these CAT isoforms is expressed.  
Studies with cultured cells have demonstrated that arginine deficiency in the culture medium can 
result in T-cell dysfunction via reduced expression of the CD3ζ chain of the T-cell receptor 
complex (37) and cell cycle arrest (38), suggesting that similar effects might be observed in 
patients with arginine deficiency. Arginine deficiency would then result in an impaired immune 
response (39). Arginine deficiency also inhibits the maturation of B cells (40). Available 
evidence suggests that arginine is also required for defense against viruses, bacteria, fungi, 
malignant cells, and intracellular parasites (39). Although these findings suggest that arginine 
plays an important role in the immunity of (young) mice, our findings in a mouse model of 
severe arginine deficiency generated by arginase 1 overexpression in enterocytes demonstrates 
that arginine deficiency activates the general control non-derepressible 2 (GCN2) stress kinase 
pathway in vivo (41). Activation of the GCN2 kinase was recently also shown to underlie cell 
cycle arrest in T-cells (38). Indeed, the activation of the GCN2 kinase stress response pathway as 
a consequence of arginine deficiency has now been demonstrated in several cell types (38, 42). 
The T-cell dysfunction that is observed fin chronic inflammatory disease and after physical 
injury (e.g. trauma or surgery) is associated with increased arginase activity in human 
granulocytes (43-46) and may, therefore, also result from activation of the stress kinase pathway. 
The non-specific immune response in the presence of abundant arginine, therefore, appears to 
depend on NO production and that during arginine deficiency on the integrated stress response.  
Benefits of arginine supplementation 
Arginine is stable under sterilization conditions (e.g. high temperature and high pressure) and is 
not toxic to cells (47). Thus, its administration appears safe for animals and humans, although a 
recent study (48) reported a higher mortality of subjects receiving L-arginine. Many claims were 
raised to supplement arginine as a strategy to support arginine homeostasis and, thus, improve 
health and productivity under many physiological and pathological conditions. We cite a few 
examples with an emphasis on polyamines (reproduction), intestinal arginine synthesis (neonatal 
hyperammonemia), and NOS stabilization (endothelial dysfunction). 
Polyamines, the polycationic products of arginine degradation, are thought to be important for 
cell growth and differentiation (see Chapter I for a more extensive discussion). Seminal fluid is 
abundant in polyamines (49). The oral administration of arginine-HCl (0.5g or 2.4 mmol/day) to 
infertile men for 6-8 weeks reportedly increased sperm counts and motility markedly in most 
patients and resulted in successful pregnancies (50). As usual, the underlying mechanism was not 
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studied, but was, in spite of the homeopathically low dose, suggested to be enhanced synthesis of 
polyamines and histones in sperm cells, and increased availability of NO for better sperm 
motility and capacitation (51). Similarly, arginine is claimed to extend the temporal window of 
oocytes for optimal fertilization (52) and to enhance embryonic and fetal survival and growth 
(53-58). As explanation, the stimulatory effects of polyamines and NO on angiogenesis and 
placental growth were mentioned (59). The beneficial effect of intravenous arginine 
supplementation on the reduction of spontaneous uterine contractility in women with the preterm 
onset of uterine contractions is explained by the relaxing effect of NO on smooth muscles (60). 
Arginine deficiency in preterm infants (<30 μmol/L in plasma) is associated with severe 
hyperammonemia (61). This type of hyperammonemia often develops if the preterm infants are 
maintained on parenteral nutrition (62-64) and appears to predispose them to the respiratory 
distress syndrome (65) and necrotizing enterocolitis (66, 67). The reason for the observed 
arginine deficiency may well be that parenteral nutrition bypasses the gut. In newborn piglets, 
parenteral nutrition induces hypoargininemia, whereas infusion of the same solution into the gut 
prevents it, showing that (small-intestinal) enterocytes are a crucial source of de novo arginine 
synthesis (68, 69). Our data show the human small intestine acquires the potential to produce 
arginine well before fetuses become viable outside the uterus (70). The perinatal human intestine 
therefore resembles that of rodents and pigs in this respect. Supplementing arginine appears to 
prevent the hyperammonemia (61) and to counteract pulmonary hypertension (71) and 
necrotizing enterocolitis (72) in preterm infants.  
NO deficiency is a major factor contributing to endothelial dysfunction, which occurs in a 
variety of metabolic disorders, including diabetes, hypercholesterolemia, hypertension, smoking 
and malaria (73). Dietary supplementation with arginine or watermelon (rich in citrulline) 
increased circulating levels of arginine, endothelial BH4 (co-factor of NOS) availability and NO 
synthesis, and enhanced endothelium-dependent relaxation in Zucker diabetic fatty rats (74). 
Hypertension in adult rats with intestinal resection (taking away the animal’s capacity to produce 
citrulline (75) or patients with lysinuric protein intolerance (deficiency of the y+L amino acid 
transporter (Slc7a7 gene) which causes a rare autosomal recessive defect of dibasic amino acid 
transport resulting in a L-arginine deficiency (76)) could be prevented by parenteral 
administration of arginine. Either arginine or BH4 becomes deficient, NOS “uncouples” and 
releases free superoxide (O2-) radicals (77), which enhance oxidative stress and BH4 oxidation 
(78). This mechanism is responsible for many of the observed features and may explain why 
arginine supplementation may not only cause recovery of endothelial NO synthesis and reduction 
of superoxide production but also reduction of vascular oxidative damage and inhibition of 
platelet adherence and aggregation, leukocyte adherence to the endothelium, and inhibition of the 
proliferation of vascular smooth muscle cells (73, 79). The beneficial effects of arginine 
supplementation on renal diseases that cause systemic hypertension (80, 81), gastric ulcer 
healing (82), (hepatic) ischemia/reperfusion injury (83-85) and pulmonary function in patients 
with cystic fibrosis (86) probably all have a similar mechanistic basis. 
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In some cases, arginine supplementation appears to exert its beneficial effects via more than one 
mode of action. The beneficial effect of subcutaneous administration of arginine at the site of 
foot ulcers in diabetic patients (87) may involve both enhanced proline and polyamine synthesis, 
and NO-dependent increases in blood flow and nutrient supply. The basal arginine and ornithine 
fluxes are distinctly higher in burn patients than in healthy controls, conforming an accelerated 
turnover of arginine after burn injury (88). The function of arginine may also change with the 
progress of the condition it affects. The majority of in vivo studies showed that arginine 
supplementation from the time of tumor induction or inoculation was protective (89), whereas 
arginine supplementation during the promotion stage stimulated (colorectal) tumor growth (90).  
Arginine or citrulline supplementation 
If a dysfunction or disease is caused by deficiency of arginine, it should be ameliorated or 
reversed by supplementation with arginine or its precursor citrulline. As a practical 
consideration, the efficacy of enteral arginine supplementation is limited by gastrointestinal 
discomfort following ingestion of large amounts of arginine and by catabolism of a significant 
fraction of ingested arginine due to the huge arginase content of the body (91). The trans-
stimulatory property of CAT transporters can also cause intracellular arginine deficiency if the 
extracellular concentration of ornithine or lysine is high (see earlier and Chapter I). Although 
dietary L-arginine supplementation enhanced the blood flow response to acetylcholine in some 
studies (92), it did not lead to significant improvements of endothelium-dependent vasodilation 
and blood flow in others (93). In most studies arginine supplementation increased plasma 
arginine concentrations, but functionally had no beneficial effects (94, 95). These disperse 
findings with respect to the functional benefits made arginine supplementation highly 
controversial (96-99). 
For these reasons, citrulline has been advanced as an indirect source of arginine. Supple-
mentation with citrulline efficiently increases the circulating and tissue arginine concentration, 
and mediates functional effects, such as NO production, without (thus far) side effects (95, 100, 
101). 
Arginase enzyme inhibitors or siRNAs that inhibit expression arginase or its transcription factors 
(102) represent a potential alternative for treatment of arginine deficiency, but side effects, such 
as inhibition of arginase function, require selective uptake in target cells and for that reason 
clearly limit its applicability.  
Conclusion 
Arginine deficiency is detrimental to many cell functions and tends to activate the powerful 
integrated stress-response pathway. The high sensitivity to catabolism by arginase and the 
peculiar characteristics of arginine transport across the cell membrane limit the applicability of 
arginine supplementation. Presently, citrulline supplementation appears to be a more promising 
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strategy. These findings show that intensive-care and pediatric physicians should have a basic, 
but up-to-date knowledge of arginine metabolism and transport.  
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NEDERLANDSTALIGE SAMENVATTING 
In dit proefschrift komen verschillende aspecten van het arginine metabolisme aan de orde. De 
rol van arginine en arginase in de synthese van ureum mag als bekend worden verondersteld. 
Echter, arginine en arginase spelen ook een zeer belangrijke rol in de fysiologie van macrofagen 
(hoofdstuk 1). Macrofagen zijn een heterogene groep cellen die ingedeeld worden op basis van 
hun weefselverdeling, activiteit, en oppervlaktemarkers. In navolging van de TH1/TH2 
naamgeving worden ze vaak ingedeeld als klassiek (M1) of alternatief (M2) geactiveerde 
macrofagen. M1 macrofagen zouden vooral verantwoordelijk zijn voor het opruimen van 
tumorcellen en micro-organismen, terwijl M2 macrofagen betrokken zijn bij wondgenezing, 
doden van parasieten en immuun regulering. Omdat de weefseldistributie en het fenotype snel 
kunnen veranderen in reactie op omgevingsfactoren en vergelijkbare functies teweeggebracht 
kunnen worden door verschillende factoren, past een classificering op grond van functies beter. 
De verschillende typen macrofagen verschillen in hun gebruik van arginine voor stikstofoxide 
(NO via NO synthases) en ornithine synthese (via arginase). NOS2 is de belangrijkste NOS 
isoform in macrofagen die tumorcellen en micro-organismen opruimen, terwijl arginase1 m.n. in 
macrofagen wordt aangetroffen die betrokken zijn bij wondgenezing, het opruimen van 
parasieten en de immuun regulering. In muizenmacrofagen wordt de expressie van arginase sterk 
gestimuleerd door de TH2-type cytokines IL4, IL10, IL13 en TGFβ, terwijl arginase in humane 
macrofagen alleen door eencellige parasieten wordt geïnduceerd. Om de betekenis van arginine 
voor het functioneren van macrofagen beter te begrijpen hebben wij genetisch gemodificeerde 
muismodellen gemaakt waarin arginase tot overexpressie komt of waarin arginase of 
argininosuccinaat synthetase weefselspecifiek kan worden geïnactiveerd (hoofdstukken 2,3,5, en 
6).  
De ontwikkeling van technieken om de nucleotidenvolgorde van een gen in embryonale 
stamcellen te modificeren stelt ons in staat om de expressie van deze genen in levende 
organismen, meestal muizen, te veranderen. Vooral uitschakeling (knock-out) of vervanging 
(knock-in) van genen is een krachtig instrument gebleken. In hoofdstuk 2 bespreken we daarom 
onze ervaringen met het maken van 3 zogenaamde conditionele knock-out muizen. Uitschakeling 
van de expressie van een gen in slechts één weefsel is nodig als deletie in alle cellen niet met het 
leven verenigbaar is. Daarnaast is een dergelijke muis beter geschikt om de functie van het 
betreffende gen in één type weefsel of op een bepaald moment in het leven te onderzoeken. Het 
maken van een conditionele knock-out muis vergt ten minste 2 jaar en bestaat uit een relatief 
groot aantal opeenvolgende stappen die elk voor zich “haken en ogen” hebben. Dit hoofdstuk 
beschrijft onze ervaring met de constructie van de vectoren welke nodig zijn voor het wijzigen 
van de nucleotidenvolgorde van een gen en de protocollen om het relatief geringe aantal 
embryonale stamcellen dat per “targeting” op de juiste wijze gewijzigd is op te sporen en te 
vermeerderen. Door de komst van de “CRISPR” (clustered regularly interspaced short 
palindromic repeats, een gen editerend systeem) en “TALENs” (transcription activator-like 
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effector nucleases, een soort restrictie-enzymen) is de opzet van targeting vectoren sterk 
veranderd. De daarop volgende selectie en vermeerdering van de juiste stamcel is nog 
grotendeels hetzelfde als toen dit overzicht werd samengesteld. 
 
In hoofdstuk 3 wordt de eerste toepassing van de door mij vervaardigde conditionele arginase1 
knock-out muis beschreven. Astma is een chronische ontsteking van de kleine luchtwegen, vaak 
als gevolg van overgevoeligheid voor een bepaald allergeen. De expressie van arginase1 in 
macrofagen is vrijwel afwezig in de long van controle muizen en zeer sterk verhoogd in de 
longmacrofagen van muizen waarin door sensibilisering tegen het kippeneiwit ovalbumine astma 
is opgewekt. Met behulp van een stabiele variant van acetylcholine kan de reactiviteit van de 
luchtwegen getest worden. In deze studie hebben we de expressie van arginase1 in macrofagen 
uitgeschakeld met zogenaamde Tie2Cre (uitschakeling in alle hematopoietische cellen) en 
LysMCre (uitschakeling in allen de macrofagen) transgenen. Helaas bleek LysMCre slechts in 
~60% van de macrofagen voldoende actief om arginase1 te elimineren, terwijl dat 96-98% was 
voor Tie2Cre. De studie rapporteert alleen de effecten in mannelijke muizen waarvan het 
arginase1 gen met Tie2Cre is uitgeschakeld. Longfunctie werd met de “Flexivent” gemeten. 
Uitschakeling van arginase1 in macrofagen veranderde de allergische reactie op ovalbumine 
sensibilisering en de weerstand in de grotere luchtwegen niet, maar verbeterde wel de functie van 
de kleinere luchtwegen. Voorts was de expressie van andere arginine-verbruikende enzymen en 
van arginine transporters, van de chemokines Ccl2 en Ccl11, van de pro-inflammatoire cytokines 
Tnfa en Ifng, en van de epitheliale markers Ccla3 en Muc5ac verminderd. De expressie van de 
voor astma typische genen Il4, Il5, en Il13 was echter niet veranderd. Analyse van de correlaties 
tussen de verschillende parameters liet duidelijk zien dat arginase deficiëntie in macrofagen de 
coördinatie van de reactie op ovalbumine sensibilisering verminderde. De verwachte 
vermindering van de ontstekingsreactie werd dus niet waargenomen. 
 
Moedermelk bevat relatief weinig arginine, maar aminozuren waaruit arginine gemaakt kan 
worden, zoals proline en glutamine, zijn rijkelijk aanwezig. De dunne darm van knaagdieren en 
varkens produceert arginine uit proline in de zoogperiode. Voorts lijden parenteraal gevoede 
zuigelingen vaak aan een te lage concentratie arginine (en daardoor een te hoge concentratie 
ammoniak) in hun bloed. Dit deed ons de vraag stellen of de dunne darm van de mens ook 
arginine zou kunnen maken. Om dit aannemelijk te maken beschrijven we in hoofdstuk 4 
metingen aan darmdoorsneden van 89 kinderen en volwassenen die semi-kwantitatief 
aangekleurd zijn op de aanwezigheid van de cruciale enzymen carbamoylfosfaat synthetase 
(CPS), ornithine aminotransferase (OAT), argininosuccinaat synthetase (ASS), arginase-1 en -2 
(ARG1 en ARG2), en NO synthases (NOS1, -2, en -3). De CPS en ASS concentraties waren 
hoog tussen 23 weken zwangerschap en 3 jaar na de geboorte en daalden in de volgende 2 jaar 
tot het volwassen niveau. De OAT concentratie daalde ook, maar meer geleidelijk, terwijl ARG1 
niet aantoonbaar was en ARG2 in de neonatale periode tot het volwassen niveau steeg. De 
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neuronen van de enterische plexus brachten ASS, OAT, NOS1 en ARG2 tot expressie, terwijl de 
zenuwen in de muscularis propria alleen ASS en NOS1 tot expressie brachten. Het endotheel van 
de arteriolen bracht ASS en NOS3 tot expressie en de gladde spierlaag eromheen OAT en 
ARG2. Op grond van deze bevindingen hebben we geconcludeerd dat de dunne darm van de 
mens ook de capaciteit heeft om arginine te maken. De expressie van ASS verdwijnt, net als die 
van lactase, geheel tussen 3 en 5 jaar na de geboorte, wat suggereert dat dat de normale speentijd 
van de mens als soort is.  
 
Omdat alle tot nu toe bestudeerde zoogdieren, zoals in het vorige hoofdstuk is beschreven, in hun 
zuigelingenperiode alle enzymen die nodig zijn om arginine te maken in de enterocyten van de 
dunne darm tot expressie brengen, hebben we het enzym argininosuccinaat synthetase met 
behulp van het VillinCre transgen specifiek in deze enterocyten uitgeschakeld (hoofdstuk 5). De 
volledigheid van de uitschakeling in de enterocyten is vervolgens immunohistochemisch 
aangetoond (er wordt ook argininosuccinaat synthetase in de zenuwen van de darm tot expressie 
gebracht; zie vorige hoofdstuk). Onverwacht bleken deze muizen echter geen tekort aan arginine 
in hun bloed te hebben. We hebben daarom de flux van aminozuren in de darm en de lever 
bepaald. Hiervoor werd ook de arteriële bloedstroom naar de darm, de lever, en de nieren 
gemeten in 14-dagen oude muizen (respectievelijk 86%, 14% en 33% van de totale bloedstroom 
door de lever). Door de deletie van Ass in de enterocyten verdween de netto arginine synthese in 
de darm, terwijl de citrulline synthese verdubbelde. Voorts nam de arginine productie in de lever 
af of veranderde zelfs in een opname. Deze veranderingen in de lever vinden normaliter pas na 
het spenen plaats, als de darm niet langer arginine produceert. In overeenstemming met deze 
waarnemingen nam de expressie van enzymen die betrokken zijn bij de stofwisseling of het 
transport over de levercelmembraan toe, terwijl (behalve uitschakeling van Ass) geen 
veranderingen in gen expressie in de enterocyten werden gevonden. Deze waarnemingen wijzen 
er dus op dat de voortijdige (genetische) verwijdering van arginine biosynthese uit de 
enterocyten leidt tot een premature inductie van het patroon van aminozuurstofwisseling in de 
lever dat normaliter pas na het spenen wordt gezien.  
 
In hoofdstuk 6 is gezocht naar een mechanisme dat het fenotype van “F/A2” muizen verklaart. 
Deze transgene muizen brengen arginase1 tot overexpressie in de enterocyten van de dunne darm 
en hebben een fenotype dat lijkt enigermate lijkt op een deficiëntie van het groeihormoon IGF1 
(insulin-like growth factor-1; te laag plasma arginine gehalte, verminderde haargroei, en 
onvolledige rijping van B-cellen). Lage arginine concentraties bleken de secretie van 
groeihormoon (GH) in hypofysecellen te remmen en de concentratie van Igf1 mRNA in de lever 
en het plasma IGF1 gehalte te verlagen, maar niet dat in de atrofische spieren. GH suppletie van 
de muizen deed weliswaar het Igf1 mRNA gehalte in de lever toenemen, maar niet de groei van 
de F/A2 muizen. Arginine depletie in het kweekmedium van de C2C12 spiercellijn activeerde 
voorts GCN2 signalering, maar liet dat van mTORC1 ongemoeid. GCN2 signalering, een 
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endoplasmatisch reticulum stress response, wordt geactiveerd door deficiëntie van belangrijke 
aminozuren. In homozygote F/A2 neonaten bedragen de plasma en weefsel concentraties van 
arginine slechts ~25% van de wild-type waarden. Gcn2-deficiente F/A2 muizen sterven kort na 
de geboorte door hypoglycemie, zodat activering van GCN2 kennelijk essentieel is voor het 
overleven van F/A2 neonaten. Omdat “downstream” effecten van andere stress kinases (eIF2α 
fosforylering, Chop expressie) niet verhoogd waren in Gcn2-deficiente F/A2 muizen, konden de 
effecten van arginine deficiëntie aan GCN2 signalering worden toegeschreven.  
 
In hoofdstuk 7 ten slotte worden pro’s en con’s van arginine en citrulline suppletie om een 
arginine deficiëntie te bestrijden besproken. 
 

 

ACKNOWLEDGEMENTS  
Behind every exhaustive thesis are a million things that help shape it. Apart from all the mice 
and bacteria that have helped me, I would like to thank those people who have been an amazing 
support in achieving this significant milestone.  
I would like to acknowledge Wout and Leo for being present from Day 1. Thank you Wout for 
encouraging me into authorship and for all the support you’ve given over the years. Leo has been 
my rock during the storms of my journey in Maastricht with clear and crisp advice. Thank you 
Leo, I’ve learnt a lot about composure from you. 
In a high octane world of research and hectic schedules, I found friends that made the intensity 
fun. Vincent, thank you for all the laughs and making Netherlands so memorable for me. Thank 
you Rinus for being such a great person to be around. Chiel, for all the technics up your sleeve, 
and your kindness in sharing those invaluable technics. My gratitude to everybody in the lab for 
helping me give life to this thesis. 
7000 miles away from home, my friends were as supportive and special as when they had been 
closer. Thank you Gowthamee for being you and having courage enough for the two of us. 
Sandeep Rajan Nair and Sejal Naik for introducing me to some of the best times of my life. 
Jerlin, for being present and patient with me throughout my journey. 
Thank you Mr. M.R.Anantha Padmanaban  for the timely help and motivation during the last 
stages of my thesis. Until recently I was unaware of how operative his motivations were. Prof. 
Chellam Balasundram for all the recommendations/guidance. He has been a critical resource 
without which the struggle would have been real. Prof. Emmanuvel Rajan, my thesis guide 
during the last stages, for making a great impact in my outlook about work. I would also like to 
extend my gratitude to Dr. Palani, Chairman of Alpha group of schools. Ms. Raji 
Ramakrishnan and Ms. Manju Varrier, also of Alpha group, for helping me cement my 
communication with the authority. I also thank Ms. Brinda and Ms.Sundaravalli whose support 
enabled me to spare time for finishing my thesis.  
 Although the deep gratitude and love I feel for my family cannot be bound by words, I need to 
make a note of how very imperative they have been in my journey. My parents, for bringing me 
to this world and making this world beautiful with their kindness and lessons. Dr. V. 
Arunachalam, for being the effervescent guiding light. Rajendran athaan and Meena akka for 
being the most dependable humans I have been lucky enough to know. Athaan has been one of 
my primary motivations to go beyond my comfort zone and achieve larger than life goals. Kanna 
annan and Koki for being there in my heart. My love and thanks to all the Shrees of the house for 
making me understand the vastness of motherhood and the bundle of happiness which comes 
along. My little girls add the spice, which fuels my life. A special thanks to my little niece 
Mahashree for loving me and understanding me and helping at all times of need.  

I am grateful to all those who have wished and blessed me with all the good things in my world 
because in the words of John Whittier- “No longer forward nor behind I look in hope or fear; but, 
grateful, take the good I find, the best of now and here.” 
        -SelvakumariSankaranarayanan 
 



CURRICULUM VITAE 
SELVAKUMARI SANKARANARAYANAN 
Born 20th of November, 1976 in Tirunelveli, Tamil Nadu, India 
 
E: selvima@yahoo.com•M: +91-9962223110  
A: Sanjeevie Nagar Ext, Airport, Tiruchirappalli - 620007, Tamil Nadu, India. 
 
 
EDUCATION 
 
- Ph.D. Thesis            2015 
Maastricht University, the Netherlands 
 
- M.Sc.in Life Sciences, Specialization in Biotechnology 1996-2001 
Bharathidasan Universtity, Tamil Nadu, India 
 
 
 
WORK EXPERIENCE 
 
• Science coordinator at an International School, Trichy, Tamil Nadu since Jan 2014.  
• Business Process Lead, Tata Consultancy Services, Chennai, Tamil Nadu, India. Nov 2012- 
Jan 2014 
• Customer Care Executive, Teknicon Enterprises, Mumbai. Oct 2011-Nov-2012.  
• Guest Lecturer, Department of Biotechnology, Bharathidasan University, Tiruchirappalli, 
Tamil Nadu, India. Sept 2009 - Dec 2009.  
• Lecturer, Department of Biotechnology, St. Joseph’s College, Tiruchirappalli, Tamil Nadu, 
India. June 2007 - April 2008.  
• PhD student, Department of Anatomy and Embryology, Maastricht University, The 
Netherlands. Feb 2003 - Dec 2007. “Role of arginine in chronic inflammatory diseases”  
• Scientific assistant, Department of Gastroenterology, Universitätsklinikum Essen, Essen, 
Germany. Aug 2002 - Feb 2003.  
• Research Assistant, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India. 
May 2001- August 2002. Project: “Establishment of a transformation method on Vigna 
mungo for stress tolerance”.  
• Graduate Student, School of Life Sciences, Bharathidasan University, Tiruchirappalli, Tamil 
Nadu, India. Jan 2001 – May 2001. Project: “Regeneration and somatic embryogenesis in 
Cajanus cajan”. 
 
  



PUBLICATIONS 
 
1. Cloots, R. H., Sankaranarayanan, S., de Theije, C. C., Poynter, M. E., Terwindt, E., van 
Dijk, P., Hakvoort, T. B., Lamers, W. H., and Kohler, S. E. (2013) Ablation of Arg1 in 
hematopoietic cells improves respiratory function of lung parenchyma, but not that of 
larger airways or inflammation in asthmatic mice. American journal of physiology. Lung 
cellular and molecular physiology 305, L364-376 
2. Marion, V., Sankaranarayanan, S., de Theije, C., van Dijk, P., Hakvoort, T. B., Lamers, 
W. H., and Kohler, E. S. (2013) Hepatic adaptation compensates inactivation of intestinal 
arginine biosynthesis in suckling mice. PloS one 8, e67021 
3. Marion, V., Sankaranarayanan, S., de Theije, C., van Dijk, P., Lindsey, P., Lamers, M. 
C., Harding, H. P., Ron, D., Lamers, W. H., and Kohler, S. E. (2011) Arginine deficiency 
causes runting in the suckling period by selectively activating the stress kinase GCN2. The 
Journal of biological chemistry 286, 8866-8874 
4. Kohler, E. S., Sankaranarayanan, S., van Ginneken, C. J., van Dijk, P., Vermeulen, J. L., 
Ruijter, J. M., Lamers, W. H., and Bruder, E. (2008) The human neonatal small intestine 
has the potential for arginine synthesis; developmental changes in the expression of 
arginine-synthesizing and -catabolizing enzymes. BMC developmental biology 8, 107 
5. Elke Cario, Meenakshi Rani, S. Sankaranarayanan, Carsten J. Kirschning, Guido Gerken, 
Daniel K. Podolsky. (2003). Characterization of a novel toll-like receptor 2-dependent 
pathway regulating intestinal epithelial barrier function via protein kinase C. 
Gastroenterology 124(4): A26 
6. Cloots, R. H., Sankaranarayanan, S., Poynter, M. E., Terwindt, E., van Dijk, P., 
Hakvoort, T. B., Lamers, W. H., and Kohler, S. E. Effect of Arg1 deletion in myeloid cells 
on allergic asthma in female mice. Manuscript in preparation 
 
 
PROFESSIONAL ACTIVITIES 
 
• Course on Laboratory Animal Science, Department of Laboratory Animal Science, Utrecht 
University, The Netherlands, 2003 
 
• Course on Radiological protection, Maastricht University, The Netherlands, 2005  
 
• Capita Selecta, parts I and II, Graduate Program Metabolism and Nutrition, 2004-2005 
 
• Metabolomics course, VLAG, Wageningen University, The Netherlands ,2005 
 
• Advanced Microscopy and Vital Imaging, Department of Molecular Cell Biology, CARIM 
Maastricht University, The Netherlands, 2005 


